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ABSTRACT 
The aim of this thesis was to investigate the prevalence and impact of age-related 
macular degeneration (AMD) causing visual impairment in people aged 75 years and 
above in the UK. A secondary objective was to investigate a small number of potential 
risk factors for AMD. This was an add-on study to the MRC Trial of the Assessment 
and Management of Older People in the Community. 
The prevalence of AMD causing visual impairment was estimated at 3.7% (95% 
confidence interval 3.2% to 4.2%) in people aged 75 years and above. This prevalence 
increased sharply with age. There was a higher risk of AMD causing visual impairment 
in women. There were estimated to be approximately 192,000 people aged 75 years and 
above in the UK living in the community with visual impairment due to AMD (95% 
confidence interval 144,000 to 239,000) of whom 60,000 are aged 90 years or above. 
The prevalence of AMD causing visual impairment did not vary by socio-economic 
group or region. 
After controlling for appropriate confounding factors, compared to people not visually 
impaired, people visually impaired due to AMD were more likely to have functional 
difficulties, report poor health and be depressed. They were more likely to be in the 
worst quintile for the home management and mobility dimensions of the Sickness 
Impact Profile (SIP). After controlling for appropriate confounding factors including 
binocular acuity score, compared to people visually impaired due to other causes, 
people visually impaired due to AMD were more likely to have functional difficulties 
and report poor health and less likely to be in the worst quintile for SIP body care and 
movement dimension or die. 
There was an association between smoking status and risk of being visually impaired 
due to AMD. This effect was particularly strong in people aged 75-79 years of age. In 
these people there was a dose-response relationship between pack years of smoking and 
risk of AMD causing visual impairment. There were no statistically significant 
associations between alcohol consumption, cardiovascular disease and reproductive 
factors (in women) and AMD causing visual impairment. 
2 
ACKNOWLEDGEMENTS 
I am greatly indebted to my supervisor, Professor Astrid Fletcher. The work in this 
thesis is a small patch of icing on the large cake that is the MRC Trial of Assessment 
and Management of Older People in the Community. Astrid and the study team have 
put in huge amounts of work to ensure the successful completion of the MRC Trial. 
This thesis would not have happened without it. Thank you Astrid and co-investigators 
(Professor Chris Bulpitt, Dr Dee Jones and Dr Alistair Tulloch) for allowing me to use 
data from the trial. Astrid has also provided much needed guidance for the add-on study 
reported here and direction for this thesis as a whole. Thank you. 
The MRC Trial was undertaken by a large team of people (see Appendix A). I would 
particularly like to thank Susan Stirling, Elizabeth Breeze, Liam Smeeth, Edmond Ng 
and Gill Price at the London School of Hygiene and Tropical Medicine; Nicky Fasey at 
the MRC GPRF; and all the nurses and ophthalmologists who completed forms for me. 
Thank you too to Rakhi Kabiwala, Janbibi Mazar and Sue Prior for clerical assistance. 
Richard Wormald was a co-investigator on the add-on study reported here and kindly 
read and commented on this manuscript. Thank you for your support. 
Thanks to my family for being there. "Nana", "Grandad" and "Uncle Moo" provided 
timely and enthusiastic childcare. Most of all, thank you, Dave, Rosa and Sam for 
putting up with me while I finally finished this off. 
The MRC Trial of the Assessment and Management of Older People in the Community 
was funded by the United Kingdom Medical Research Council, the Department of 
Health and the Scottish Office. Collection of data on causes of visual impairment was 
funded by the Gift of Thomas Pocklington. 
3 
GLOSSARY OF TERMS AND ABBREVIATIONS 
Study acronyms 
ARIC Atherosclerosis Risk in Communities 
NHANES National Health and Nutrition Examination Survey 
SEE Salisbury Eye Evaluation study 
Epidemiological terms and abbreviations for instruments or scales 
ADL Activities of Daily Living 
ADVS Activities of Daily Vision Scale 
BMI Body mass index 
GDS Geriatric Depression Scale 
MMSE Mini Mental State Examination 
PGMS Philadelphia Geriatric Morale Scale 
SIP Sickness Impact Profile 
SMR Standardised mortality ratio 
WARMGS Wisconsin Age-related Maculopathy Grading System 
Agencies 
MRC Medical Research Council 
GPRF MRC General Practice Research Framework 
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CHAPTER ONE BACKGROUND 
1.1 Introduction 
1.2 Prevalence 
1.3 Impact 
1.4 Aetiology 
1.5 Aims and Objectives 
Tables and figures 
1.1 INTRODUCTION 
The population of the UK is ageing rapidly. By 2040, the numbers of people aged 75 
years and above are projected to increase by 90% and the numbers of people aged 90 
years and above by 160%. * Age-related diseases will assume increasing importance in 
the public health of the nation. Age-related macular degeneration (AMD) is one such 
disease. It is the most commonly occurring cause of prevalent visual loss in the UK. The 
aim of this chapter is to review the literature on the prevalence, impact and aetiology of 
AMD. 
Most of the data presented in this thesis refer to analyses of the prevalence and impact 
of AMD causing visual impairment in a cohort of people aged 75 years and above 
taking part in the MRC trial of the assessment and management of older people in the 
community. There were limited data on risk factors in this cohort. In the literature 
review, I will give most emphasis to the areas covered in the thesis, i. e., prevalence, 
impact and risk factors such as smoking and alcohol consumption. For completeness, I 
will review briefly those areas not covered in this thesis, i. e. the role of nutrition, light 
exposure and genetics in the aetiology of AMD. 
1.1.1 Clinical signs and definitions 
AMD is a disease involving typical lesions in the macula in older people that cannot be 
attributed to infectious or inflammatory causes. There are two types of AMD - 
geographic atrophy and neovascular AMD. In geographic atrophy the retinal pigment 
epithelium and overlying receptors degenerate. In cases of neovascular AMD, new 
* http"-'r c. ad. gov. uk, `population, '. Accessed December 2002. 
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vessels grow from the choroidal circulation, leading to the destruction of the retinal 
pigment epithelium. If the vessels leak, the resulting haemorrhage results in further 
scarring and visual loss. 
AMD is associated with "drusen" (yellow spots clinically observable on the retina) and 
pigmentary abnormalities such as hyper- and hypo-pigmentation. Drusen are commonly 
seen in older people, not all of whom will go onto develop visually impairing AMD. 
People with large, ill-defined "soft" drusen are more likely to develop AMD. 
The investigators from several of the largest prevalence studies in Australia, Europe and 
North America have agreed a common classification for AMD in epidemiological 
studies. This classification is set out in table 1.1 (Bird et al. 1995). It is the terminology 
that is used in this thesis. The overall term "age-related maculopathy" (ARM) covers 
early and late stages of the disease. Early ARM refers to signs such as large, soft drusen 
and pigmentary abnormalities that may, or may not develop into late stages of the 
disease. The term "age-related macular degeneration" (AMD) describes geographic 
atrophy and neovascular disease. 
1.1.2 Overview of the epidemiology of AMD 
AMD is the most important cause of visual loss in western industrialised countries. In 
the UK, approximately 30,000 people are registered blind or partially sighted every 
year, half of whom will have macular degeneration(Evans 1995). This pattern in the 
registered population is reflected in Europe, North America and Australia(Bjornsson 
1981; Graf et al. 1999; Hansen 1981; Krumpaszky and Klauss 1992; Chan and Billson 
1991). Cataract is probably more frequent as an incident cause of visual loss but, as 
there is safe and effective surgery for cataract, it is less common as a prevalent cause of 
visual loss. 
AMD increased dramatically as a proportionate cause of registered visual loss in the 
20t" century(Evans and Wormald 1996; Maruo et al. 1991). In 1933, just 6% of the 
registered population in England and Wales had "senile macular degeneration", 
compared to nearly 50% in 1990(Evans and Wormald 1996). Most of this increase can 
be attributed to a combination of ageing population, declining importance of infectious 
causes of visual loss, and increasing effectiveness of ophthalmic surgery. However, age- 
standardised population rates indicate an excess incidence of approximately 30%. This 
may reflect a real increase or simply indicate changes in the detection of this condition 
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in parallel with its increasing importance. In section 1.2, I review the literature on the 
prevalence and incidence of AMD, focussing on what is known about AMD as a cause 
of visual loss in Britain. 
Currently there is no treatment that can restore vision in AMD. There are some 
treatments, for example, laser photocoagulation and photodynamic therapy, that can 
delay the progressive loss of visual function in a small proportion of people with 
neovascular AMD(Fine et al. 2000). As the consequences of the disease are severe 
(visual impairment and blindness) and treatment not available for most people with the 
disease, there is considerable interest in possibilities for preventing AMD developing in 
the first place. The possible role of metabolites of molecular oxygen known as "reactive 
oxygen species" in the biology of ageing and age-related diseases such as AMD has 
provoked considerable interest(Finkel and Holbrook 2000). Increased levels of reactive 
oxygen species may lead to cell death by damage to proteins, lipids and DNA. Interest 
in the role of vascular factors in the development of AMD has lead to investigations of 
cardiovascular disease risk factors. As cardiovascular disease is also a disease of ageing 
the shared common pathway may be oxidative stress. With developments in molecular 
biology and genetic methods, there is increasing potential for discovery of the genetic 
determinants of the pathological mechanisms leading to the development of AMD. The 
evidence for the role of risk factors for AMD is reviewed in section 1.4. 
Most research on AMD has investigated the biological, clinical and therapeutic aspects 
of the disease. More recently, researchers have begun to investigate the impact of the 
disease on the lives of people affected. Section 1.3 summarises the research in this area. 
1.1.3 Identification of studies included in the literature review. 
Over a period of several years, I have developed a database of references on the 
epidemiology of AMD. These were identified using a combination of electronic 
searching, searching reference lists and personal contact. In order to ensure that this 
database was as complete as possible, I conducted the following searches of Medline, 
EMBASE and the Cochrane Register in August 2002. 
The following strategy was used to search MEDLINE and the Cochrane register to end 
May 2002 
#I "MACULAR-DEGENERATION"/ all subheadings 
#2 "RETINAL-DEGENERATION"/ all subheadings 
#3 "NEOVASCULARIZATION, -PATHOLOGIC"/ all subheadings 
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#4 "RETINAL-NEOVASCULARIZATION"/ all subheadings 
#5 "CHOROIDAL-NEOVASCULARIZATION"/ all subheadings 
#6 #1 or #2 or #3 or #4 or #5 
#7 (MACUL* or RETINA* or CHOROID*) near (DEGENER* or NEOVASC*) in 
TI, AB 
#8 MACULOPATHY in TI, AB 
#9 (AGE or AG? ING or AGE? RELATED or SENIL*) in TI, AB 
#10 (#6 or #7 or #8) and #9 
The following strategy was used to search EMBASE to end May 2002. 
#1 explode "RETINA-MACULA-DEGENERATION"/ all subheadings 
#2 "RETINA-DEGENERATION"/ all subheadings 
#3 "NEOVASCULARIZATION- (PATHOLOGY)"/ all subheadings 
#4 "SUBRETINAL-NEOVASCULARIZATION"/ all subheadings 
#5 ((MACUL* or RETINA* or CHOROID*) near (DEGENER* or NEOVASC*)) in 
TI, AB 
#6 MACULOPATHY in TI, AB 
#7 (AGE? RELATED or AGE RELATED OR AG? ING OR SENIL*) IN TI, AB 
#8 (#1 or #2 or #3 or #4 or #5 or #6) and #7 
The major ophthalmic journals were searched online for the period May to August 
2002. These were: American Journal of Ophthalmology, Archives of Ophthalmology, 
British Journal of Ophthalmology, Ophthalmology, Ophthalmic Epidemiology, Survey 
of Ophthalmology. 
Titles and abstract were scanned for articles of relevance to this review. Full text copy 
was obtained of potentially relevant references. The searches were iterative and 
reference lists of all studies were searched by hand. 
1.2 PREVALENCE 
1.2.1 Prevalence studies 
Table 1.2 sets out the details of the prevalence studies on AMD. The majority of 
studies have been undertaken in industrialised countries - Australia/New Zealand (three 
studies), Europe (seven studies), and USA (seven studies). Studies enrolling purely 
volunteer samples or conducted in specific patient groups were excluded(Delcourt et al. 
1998; Cruickshanks et al. 1997). 
There have been two National Health and Nutrition Examination Surveys (NHANES) in 
the USA which have examined eye disease(Klein and Klein 1982; Klein et al. 1995b). 
These are large probability samples of the US noninstitutionalized civilian population. 
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The first survey was conducted in the early seventies, the third in the late 80's. They 
have been a particularly good source of information on racial differences in ARM. The 
Framingham Eye Study, which took place at around the same time as the first 
NHANES-I, was a pioneering study in the development of methods and definitions in 
eye disease surveys(Kahn et al. 1977a; Kini et al. 1978). Eye examinations were 
performed on nearly 2,500 surviving members of the Framingham Heart Study cohort, 
which has been examined biennially since 1948 for the purpose of identifying factors 
that affect the risk of cardiovascular disease. A number of subsequent population-based 
studies - in rural Iceland, Melton Mowbray, England and three areas in China - followed 
the definitions developed in the Framingham Eye Study(Jonasson and Thordarson 1987; 
Gibson et al. 1985; Wu 1987). The Copenhagen City Study was another add-on eye 
examination to a heart study cohort(Vinding 1995; Vinding 1990). Similar definitions to 
Framingham were used. 
In the second half of the 1980's came the development of grading systems for 
classification of the disease from colour fundus photographs. Two systems were 
developed in the States, the Wisconsin Age-Related Maculopathy Grading System 
(WARMGS) which was used in the Beaver Dam Eye Study(Klein et al. 1991 a) and the 
Chesapeake Bay grading system(Bressler et al. 1989). The Beaver Dam Eye Study was 
a survey of the population aged over 43 years in the community of Beaver Dam, 
Wisconsin(Klein et al. 1992a). The Chesapeake Bay study was conducted among the 
watermen residing in Somerset County, Maryland(Bressler et al. 1989). The 
WARMGS was taken up by investigators in a number of countries and has been used in 
surveys in the Netherlands(Vingerling et al. 1995b), Finland(Laatikainen and Hirvela 
1995), Australia(Mitchell et al. 1995; VanNewkirk et al. 2000a), Barbados(Schachat et 
al. 1995), UK(Dickinson et al. 1997) and the third NHANES(Klein et al. 1995b; Klein 
et al. 1999c). It forms the basis for the International System for grading ARM (table 
1.1)(Bird et al. 1995). 
1.2.2 Methodological issues 
Table 1.2 shows the response rates achieved in these prevalence studies. Response rates 
ranged from 46%(Klein et al. 1999a)to 95%(Vinding 1989). In general, response rates 
were higher in the studies where assessment of AMD was "clinical". When 
photographic grading was used, some of the people taking part did not have gradable 
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photographs. A couple of studies did not report response rates. In the case of the study 
in China, there was no discussion of a sampling frame, so it may well be that the sample 
was a volunteer sample(Wu 1987). 
These prevalence studies can be considered in the following categories: national 
probability samples, probability samples of a defined area, samples drawn from general 
practitioner registers, samples drawn from cohorts set up for other purposes and study 
of an occupational cohort. 
NHANES I& III in the USA were national probability samples(Klein and Klein 1982; 
Klein et al. 1995b; Klein et al. 1999c). The aim of the NHANES is to provide periodic 
national statistics on the health and nutritional status of the civilian noninstitutionalised 
population through household interviews and standardised physical examinations. These 
samples are complex multistage area probability samples carefully designed to provide 
an unbiased sample of the US population. 
The most usual study design was a population-based study in one region, town or 
district using municipal registers or census records to identify everyone in eligible in the 
chosen area. Depending on the size of the area either everyone in the specified age 
range was invited to participate or a probability sample selected. In the Beaver Dam Eye 
Study a private census of the population of Beaver Dam, Wisconsin was used to identify 
eligible people who were all invited to take part in the study(Klein et al. 1992a). In the 
Rotterdam Study names and addresses of residents in one suburb of Rotterdam were 
drawn from the municipal register(Vingerling et al. 1995b). Eligible people in randomly 
selected clusters were invited to take part. The Oulu County Study examined everyone 
aged 70 years and above in three communities in Oulu County, Finland(Laatikainen and 
Hirvela 1995). The Barbados Eye Study selected a random sample of Barbados-born 
citizens, aged 40 to 84 years(Schachat et al. 1995). In the Blue Mountains Eye Study, 
the sample was identified by door-to-door census of two postcode areas west of Sydney, 
Australia(Mitchell et al. 1995). Similarly, in the Melbourne Visual Impairment Study, 
door-to-door census identified all eligible people in nine randomly selected pairs of 
adjacent census collector districts in urban Melbourne and four pairs of randomly 
selected adjacent census collector districts in four rural communities in 
Victoria(VanNewkirk et al. 2000a). The Melbourne Study also considered 
institutionalised residents of 13 randomly selected nursing homes and hostels with 5 km 
of the urban test sites. The Atherosclerosis Risk in Communities Study (ARIC) 
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comprised a probability sample of men and women aged 45 to 64 years of age in four 
US communities(Klein et al. 1999a). 
For the studies conducted in the UK, the samples used were drawn from the registers of 
family doctors serving a particular area. In the case of Melton Mowbray, it was argued 
that everyone in a defined geographic area was served by one general 
practitioner(Gibson et al. 1985). In the North London Study, seven general practices 
were randomly selected from 17 practices in six electoral wards(Reidy et al. 1998). A 
simple random sample of people aged 65 years and above in each practice was drawn 
subsequently. In the Leicester Study, random samples of people aged 40 years and 
above were drawn from lists of patients registered with two neighbouring inner-city 
practices(Das et al. 1994). 
Several studies consisted of examination of cohorts set up for other purposes. In the 
Framingham Eye Study, the Framingham cohort, which had originally been set up for 
the study of heart disease, was undergoing its twelfth biennial cycle when eye 
examinations began in 1973(Kahn et al. 1977a). Therefore only people surviving in the 
cohort were eligible to take part in the study. Similarly, the Copenhagen City Study 
was a random sample of people taking part in the Copenhagen Heart Study which had 
been going to five years when the eye examinations took place. 
There was one occupational cohort study. In the Chesapeake Bay Study, a survey of 
watermen identified from fisherman licensing records at the Maryland State Department 
and residing in two communities in Maryland was conducted(Bressler et al. 1989). 
In three studies, the sampling frame was not clearly described although the implication 
was that everyone eligible in a particular area was invited for examination(Wu 1987; 
Martinez et al. 1982; Pagliarini et al. 1997). 
The study design providing the best national estimates is clearly the national probability 
samples such as the NHANES. However, given the size and national distribution these 
studies are more complex to undertake and are more likely to suffer poorer response 
rates. In addition, less eye-specific extra information, such as data collection on relevant 
risk factors can be undertaken. The problem with the studies conducted in one area or 
cluster is that between cluster variation is unknown. The smaller the area or cluster the 
more of a problem this will be. In the UK, particular use has been of general practice 
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registers to identify samples. However, these can be unreliable and not everyone in a 
particular locality will be registered with a general practitioner. 
1.2.3 Prevalence estimates 
Figures 1.1-1.3 present the results of these surveys. 
The prevalence of ARM, detected by grading of retinal photographs with no visual 
acuity cutoff included in the definition of the disease, increases from a prevalence of 
between 0 and 10% at age 50 to almost 100% at age 90 (figure 1.1). If visual function 
is included in the definition of the disease, the observed prevalence is lower (figure 1.2). 
It increases from less than 10% in the 50-59 age-group to a prevalence of somewhere 
between 20 and 50% at ages 85 and older. In general, similar age-specific rates have 
been found in the different studies with the exception of the Gisborne study in New 
Zealand which found lower rates. Using one age-group as an example, the Melton 
Mowbray study in England found a rate twice as high in the age group 85 years and 
above as was observed in Gisborne in the 90 years and above age group(Gibson et al. 
1985; Martinez et al. 1982). Calculating confidence intervals around these estimates 
suggest that the true prevalence for Gisborne lies somewhere between 17% and 37% 
whereas for Melton Mowbray it lies between 37% and 64%. The large difference 
between these two estimates may be due to sampling error. 
AMD is less common (figure 1.3). Approximately 10% of people over 75 years have 
AMD. Barbados has a lower prevalence of AMD; this is discussed below in section 
1.2.6. 
Smith et al pooled data from three large population-based prevalence studies that had 
used similar classification methods(Smith et al. 2001). AMD diagnosis was made from 
masked grading of stereo macular photographs. Table 1.3 shows the results of this 
analysis. Overall, AMD was present in 1.63% of the combined population of 14,752 
participants. The prevalence rose from 0.2% in people aged 55 to 64 years to 13% of the 
population older than 85 years. Neovascular AMD increased from 0.17% among 
subjects aged 55 to 64 years to 5.76% of those aged 85 years and above. Geographic 
atrophy increased from 0.04% to 4.22% for those age groups. It must be noted that, in 
this analysis, all the data were pooled together without taking into the account the fact 
that they came from different centres nor examining the data for heterogeneity. 
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Owen et al pooled data from six studies in order to estimate the prevalence of visual 
loss caused by AMD(Owen et al. 2002). In this analysis, correct meta-analysis 
techniques were used. Table 1.4 shows the prevalence of binocular visual impairment 
caused by AMD (in this case visual impairment was defined as 6/18 or less, rather than 
the more usual less than 6/18 Snellen acuity). The prevalence of visual impairment due 
to AMD rose from 0 in people less than 65 years of age to 15.3% (7.6% to 27.4%)* in 
people aged 90 years and above. 
1.2.4 Gender 
Women tend to live longer and people who live longer are at greater risk of AMD. The 
investigation as to whether there is a gender imbalance in risk of the disease must be 
studied bearing this fact in mind. As there may be differences between the sexes in 
health-seeking behaviour it is important only to consider data from population-based 
studies. 
Figure 1.4 shows results from all the population-based studies of AMD as to the risk of 
the disease in men and women. The results are presented in terms of the relative risk of 
AMD in women compared to men. In order to take into account of the effect of age, the 
results have been stratified into three age-groups - 65-74,75-84 and 85 years and 
above. Confidence intervals around each relative risk are plotted and an overall 
summary relative risk calculated for each age-group and for all studies. 
It is commonly believed that women are at increased risk of developing AMD, however, 
the figure shows that there have been few studies that have demonstrated this increased 
risk unequivocally. Overall, it would appear that women are at slightly increased risk, 
however, we cannot be confident that we have completely excluded age effects from 
this estimate. Other authors have pooled data from the major population-based studies 
and similarly found only a small increased risk for women that could possibly be 
attributed to age effects(Smith et al. 1997; Owen et al. 2002). 
*I will use the following convention regarding confidence intervals. 95% confidence 
intervals will be quoted unless indicated otherwise. The confidence intervals will be the 
form "lower to upper" confidence interval, in brackets after the estimate. If the estimate 
is in brackets already, the confidence intervals will come after a comma. 
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1.2.5 Socio-economic status 
There is limited information about the social class of people with AMD. There was little 
relationship between education, income and employment status and ARM in the cross- 
sectional Beaver Dam Eye Study(Klein et al. 1994c). Follow-up of the cohort five years 
later showed that lower educational status, and being in a service-related occupation 
compared with a white collar professional occupation, was associated with the incidence 
of early ARM(Klein et al. 2001c). This association appeared to be independent of age, 
sex, smoking and vitamin supplement use. Other studies have examined the relationship 
between AMD and social class and education and found no relationship. In NHANES I 
and the Eye Disease Case-Control Study Group there was a reduced risk of AMD with 
increasing number of years of education. These associations were much attenuated 
when other factors were included in the model, such as smoking(Goldberg et al. 1988a; 
Eye Disease Case-Control Study Group 1992). 
1.2.6 Ethnic group 
The study of disease in different ethnic groups is controversial and difficult. The risk 
factor being studied is often unclear - is it a different genetic profile, or differences in 
lifestyle? For example, there are many genetic and cultural differences between people 
from different parts of Africa, however, in studies of ethnic group they are often 
grouped together as "black". 
It is commonly believed that AMD occurs less frequently in people of African 
Caribbean origin or in pigmented races generally. This view has come from the clinical 
impression that black people form a small proportion of people presenting with the 
condition at hospitals. For example, only 0.08% of people enrolled in a trial of laser 
photocoagulation for AMD in the USA were black compared to 5-15% in other eye 
trials (Diabetic Retinopathy and Corneal Transplant studies) in that country(Jampol and 
Tielsch 1992). In the Baltimore Eye Survey, black people had twice the age-adjusted 
legal blindness than whites but no cases of bilateral blindness in blacks were due to 
AMD in contrast to 30% of blindness in whites. 
Population-based studies such as NHANES-III show that early signs of ARM are 
common in black people(Klein et al. 1999c). The population-based study in Barbados, 
which largely comprised black people, found rates of early ARM which were similar to 
those found in studies of white people but lower rates of neovascular disease(Schachat 
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et al. 1995). It may be that later stages of the disease, particularly neovascular disease, 
are less common in African people. 
The prevalence of AMD in different populations has been reviewed recently(Klein et al. 
1999b). The authors concluded that the prevalence of ARM and AMD varies 
considerably in different places and in different ethnic groups. This variation could be 
due to variation in genetic and other risk factors differences, but differences in 
classification between studies cannot be excluded. 
1.2.7 Non-industrialised countries 
There is very little information on the prevalence of AMD in non-industrialised 
countries. The Barbados Eye Study results have been discussed above. The study in 
China, which used Framingham definitions, found prevalence rates of the same order of 
magnitude as USA studies, however it is not clear if the sample of people included in 
the study were population-based(Wu 1987). 
In general, macular degeneration is not an important cause of blindness in national 
surveys conducted in non-industrialised countries, for example, Nepal and Gambia. 
However, not only do such countries have a younger population, but also they have an 
excess of avoidable blindness due to corneal disease and cataract, which may mask the 
existence of AMD, both physically and proportionately. 
1.2.8 Incidence 
Follow-up of the Beaver Dam Eye Study indicated that, in people aged 75 years and 
above, approximately 17% developed features of ARM such as large, soft drusen over 
five years(Klein et al. 1997b). Approximately 13% developed retinal pigment 
abnormalities. Late stage disease occurred in nearly 2% and occurred more commonly 
in people with soft drusen and retinal pigment abnormalities (7%). Similar findings 
were observed in the Blue Mountains Eye Study(Mitchell et al. 2002). 17.8% of people 
aged 70 years and above developed early ARM and 2.9% developed AMD over five 
years. 
1.2.9 Summary 
There are few population-based data on the prevalence of visual impairment and AMD 
in the British population. Estimates of the size of the problem have come from pooling 
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studies from other countries and continents. However, there are many difficulties with 
this as there are substantial differences between countries that make extrapolation of 
results difficult. 
Current research on AMD has focussed on the prevalence of the condition and there is 
less information on AMD as a cause of visual loss. In part, this has occurred because 
population-based eye surveys are expensive and logistically difficult to undertake. This 
means that there is real constraint on eventual sample size. Most of the large population- 
based studies have had relatively few cases of advanced AMD causing visual loss and 
have investigated earlier signs of the disease. 
The prevalence of AMD increases dramatically with increasing age; people aged 75 
years and above bear a disproportionate part of the burden of the disease. However, 
there is a lack of data on older people. Out of approximately 55,000 people taking part 
in the main population-based studies approximately 7,000 have been aged 75 years and 
above and approximately 700 were 90 years and above (table 1.5). These figures are a 
little rough and ready because the published reports do not always present data 
disaggregated for older ages. However, it does indicate a lack of reliable information on 
AMD as a cause of visual loss in the older age-groups. 
The distribution of AMD within different groups in the population is not well- 
established. Whether or not women are at increased risk of the disease is uncertain and 
whether there is a difference in AMD as a cause of visual loss between the two sexes 
has not been addressed. There appears to be little relation with socio-economic status, 
however, few studies have addressed this question adequately. Measures of socio- 
economic status have relied on educational status and the number of cases of late-stage 
disease has been small. No studies have been done in the British population. 
1.3 IMPACT 
1.3.1 Measures of the impact of disease 
The aim of this section is to consider the impact of being visually impaired due to AMD 
on the lives of people affected. There are many potential measures of the impact of 
disease or the outcome of treatment. Mortality and morbidity are commonly used. The 
impact of disease in terms of requirements or use of services has also been measured. 
There are many different measurement scales aimed to measure more complex aspects 
25 
of a person's health such as functioning and well-being. The terminology in this area is 
not well-defined with the terms "quality of life" and "well-being" used in different ways 
by different researchers. I will use the conceptual framework as set out in "Measuring 
Health: a review of quality of life measurement scales" which is summarised 
below(Bowling 1997). 
There are several ways of considering health status. One of the most commonly used 
methods is describing people's ability to perform tasks of daily living, that is, their 
functional ability. There are a number of methodological techniques for measuring 
function: direct physical tests of function, direct observation of behaviours and/or 
interviews with the person or their proxy. Most measures of functional ability or 
disability are self-report methods. In many studies of disability, single-item questions 
such as ability to read newsprint or to see faces across the road are used. One of the best 
known and oldest of the multi-item disability scales is the Activities of Daily Living 
(ADL) index developed to describe the states of elderly persons(Katz et al. 1963). It has 
been modified specifically for people with AMD(Dahlin-Ivanoff et al. 2001). 
Measures of functional ability specific to people with vision impairment have also been 
developed, for example, the Activities of Daily Vision Scale (ADVS)(Mangione et al. 
1992). This scale consists of 21 multiple-response items representing common visual 
activities categorised into five subscales: night driving, daytime driving, distance vision 
activities that do not require driving, near vision activities, and activities subject to 
glare. Additionally, the subscales can be combined into an overall visual function score. 
All scale scores range from 0 to 100, where 100 represents no difficulty and 0 means the 
activities are no longer performed because of visual impairment. If a person indicates 
that an activity is difficult because of limitations not caused by vision, the item does not 
contribute to the scale score. The ADVS was originally developed to evaluate the 
outcome of care after cataract surgery but has been used in people with a range of vision 
problems including glaucoma and diabetic retinopathy, and in population-based studies. 
Broader measures of health status generally focus on people's perceptions of their 
health and are sometimes referred to as health-related quality of life. A popular single- 
item measure consists of asking respondents to rate their health as "excellent, good, fair 
or poor" in relation to other people of their age. This measure is linked to mortality, 
admission to hospital and use of health services. In some cases poor mental health will 
distort perceptions of health and well-being and poor physical health can also lead to 
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poor mental health and well-being. This can lead to difficulties in interpreting results. 
There are many multi-item measures reported in the literature, some of which are 
general, e. g., the Sickness Impact Profile (SIP)(Bergner et al. 1981), Nottingham Health 
Profile(Hunt 1984), or specific, e. g. the VF-14 aims to measure health of people with 
vision impairment and/or eye disease(Steinberg et al. 1994). There is some overlap 
between measures of functional ability and broader measures of health status. For 
example, the SIP assesses the impact of sickness on daily activities and behaviour 
covering the following different dimensions: work, recreation, emotion, affect, home 
life, sleep, rest, eating, ambulation, mobility, communication and social interaction. 
There are a number of instruments designed to assess psychological well-being 
including those aimed specifically to detect psychiatric disorder such as depression, 
anxiety, dementia and cognitive impairment. In general these consist of a checklist of 
statements asking respondents to compare their recent experience to their usual state, 
with the answer graded according to severity. One the most commonly used in the UK 
is Goldberg's General Health questionnaire and in older people the Geriatric Depression 
Scale(Sheik and Yesavage 1986). The Mini-Mental State Examination (MMSE) is the 
most commonly used scale aiming to assess cognitive impairment and includes tasks 
such as arithmetic, memory and reading(Folstein et al. 1975). Again there is some 
overlap between measures of psychological well being and broader measures of health 
status, which may include components designed to assess psychological well being. 
The last type of measure to be considered is measures of emotional well being, i. e. life 
satisfaction and morale. The first population survey of emotional well being asked the 
question "... would you say you're very happy, pretty happy or not too happy these 
days? " Happiness implies an affective mood or state, however, life satisfaction 
suggests a cognitive process and, in general, is defined as an overall assessment of one's 
life. It has been observed that older people often report lower levels of happiness but 
higher levels of life satisfaction than younger people do. This could reflect the fact that 
happiness reflects emotions but life satisfaction is a more cognitive concept. Morale 
has been less well defined but is probably best reflected as a basic sense of satisfaction 
with oneself. Many of the major scales of well-being correlate well, which suggests 
that they are directed at measuring a common underlying construct. The most 
commonly used scales have been LifeSatisfaction A, Bradburn Affect-Balance Scales 
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and Philadelphia Geriatric Center Morale Scale (PGMS)(Lawton 1975), as well as 
global items of happiness and life satisfaction. 
To summarise, the following measures of the impact of visual impairment due to AMD 
will be assessed in this review: 
9 Morbidity 
" Mortality 
9 Measures of functional ability 
9 Measures of perceived health status (health-related quality of life) 
" Measures of psychological well-being 
9 Measures of emotional well-being (life satisfaction and morale) 
As the condition "visual impairment due to AMD" consists of two parameters, having 
AMD and being visually impaired, I shall also consider the literature on the impact of 
visual impairment per se. 
Table 1.6 summarises the studies identified. 
1.3.2 Morbidity 
The main type of morbidity addressed in the literature in relation to visual impairment 
has been that of hip fractures occurring as a result of falls. 
Two studies were identified that investigated the association between visual impairment 
and falls in older adults. Jack et al investigated 200 consecutive patients aged 65 years 
and above admitted via accident and emergency to an acute geriatric medical unit (Jack 
et al. 1995). Patients admitted with falls had a higher prevalence of visual impairment 
(76%) than those admitted for other reasons (45%). In the cross-sectional Blue 
Mountains Eye Study, people with a visual acuity worse than 20/30 were twice as likely 
to report two or more falls(Ivers et al. 1998). 
Four studies were identified that examined the relationship between visual impairment 
and hip fractures. In the Beaver Dam Eye Study, people with best-corrected acuity 
20/25 or worse were twice as likely to have had two or more falls and nearly four times 
as likely to report having had a hip fracture(Klein et al. 1998a). These relationships 
also were found when visual function was measured by near visual acuity and current 
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binocular acuity. Contrast sensitivity was not associated with falls and hip fractures. In 
the Auckland Hip Fracture Study, having a binocular acuity worse than 20/60 was 
associated with increased risk of hip fracture (odds ratio 1.5,1.1 to 2.0) with no depth 
perception being a marked risk factor for hip fractures (odds ratio 6.0,3.2 to 11.1). 
Similar estimates of effect were seen in the Framingham Study and EPIDOS. In the 
Framingham Study, 2,633 people were followed up for 10 years after the eye 
examination and 110 had a hip fracture (Felson et al. 1989). There was a "dose- 
response" relationship with people with good vision (20/25 or better) experiencing less 
hip fractures (3%) than those with moderate visual impairment (20/30 to 20/80) (8.5%) 
and those with poor vision (20/100 or worse) (11.3%). They also found evidence that 
people with different visual function in the two eyes were more likely to sustain a hip 
fracture. In the EPIDOS study, 7,575 women aged 75 years or older were followed up 
for an average of 1.9 years, 154 women experienced a first hip fracture. Reduced visual 
acuity (<2/10) was associated with an increased risk of hip fracture (relative risk 2.0,1.1 
to 3.7)(Dargent-Molina et al. 1996). 
No studies were found that investigated the different causes of visual impairment or the 
impact of macular degeneration on the risk of falling and hip fractures. 
1.3.3 Mortality 
The association between mortality and vision impairment or age-related eye disease has 
been examined in the Melton Mowbray Study(Thompson et al. 1989), Melbourne 
Visual Impairment Project (McCarty et al. 2001b; Taylor et al. 2000), the Beaver Dam 
Eye Study (Klein et al. 1995a), the Blue Mountains Eye Study (Wang et al. 2001), the 
North London Study (Reidy et al. 2002), and the National Health Interview Survey 
(Lee et al. 2002). Four of the studies were cross-sectional with repeat examination five 
years later at which time the number of people who had died since the first examination 
was assessed. In the North London Study and National Health Interview Survey 
participants were flagged for mortality with the relevant government agencies. In all 
studies, visual impairment was associated with an increased risk of death, after 
controlling for relevant confounding factors, such as age, sex, socio-economic status 
and cigarette smoking. In the Melton Mowbray study people with moderate visual 
impairment had a two-fold increased risk of mortality (Thompson et al. 1989). 
However, people who were blind did not. In the Blue Mountains Study the relative risk 
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of dying associated with visual impairment was 1.7 (1.2 to 2.3) (Wang et al. 2001). In 
the Visual Impairment Project, best corrected visual acuity of less than 6/12 was 
associated with a increased risk of death five years later (odds ratio 2.34) (McCarty et 
al. 2001 b). In the Beaver Dam Eye Study, people with impaired vision were found to 
have a poorer five-year age and sex adjusted survival (87.5%) compared with those 
whose vision was not impaired (91.8%)(Klein et al. 1995a). In the North London Study 
and National Health Interview Survey, mortality was only associated with cataract in 
women (Reidy et al. 2002). 
Appollonio et al followed up 1140 non-institutionalised elderly subjects aged 70-75 
years and found that hearing impairment but not vision impairment was associated with 
a significant increased mortality risk in men only (Appollonio et al. 1995). 
The Beaver Dam Eye Study was the only study to examine AMD and survival. After 
controlling for age and sex, ARM was not associated with survival (Klein et al. 1995a). 
1.3.4 Functional ability 
Four studies were identified which examined the relationship between visual 
impairment and functional ability. Three studies were cross-sectional population-based 
studies (Established Populations for the Epidemiologic Studies of the Elderly (Salive et 
al. 1994), Salisbury Eye Evaluation (SEE) study (Rubin et al. 1997), Blue Mountains 
Eye Study (Ivers et al. 2000)) and one study was conducted in nursing home residents 
(Marx et al. 1992). In addition, one qualitative study on the impact of vision 
impairment on functioning was identified (Keeffe et al. 1998). 
Salive et al examined the association of visual impairment with mobility and physical 
function in a population-based study of older adults (Salive et al. 1994). Limitations in 
mobility, activities of daily living and physical performance were associated with worse 
visual function. 
The SEE study was specifically designed to determine the impact of age-related eye 
disease and visual impairment on functional status in an elderly population and to 
determine the role of visual impairment on a variety of adverse outcomes, such as 
admission to nursing homes and falls. Salisbury is a semirural, stable community and 
nearly 18% of people aged 65 years and above are black. Physical function was 
assessed using Activities of Daily Living (ADL), which determines difficulty in the 
basic areas of self-care (dressing, bathing, toileting, feeding and mobility) (Katz et al. 
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1963) and the Instrumental Activities of Daily Living (IADL), which determines 
difficulty in more complex tasks necessary for independent living (Lawton 1975). These 
tasks include activities such as housework, paying bills, and shopping. The third 
dimension they addressed was general physical abilities and mobility, such as walking 
defined distances and climbing stairs. The ADL, IADL and physical mobility questions 
contain a five-part response scale ranging from "no difficulty" to "cannot do for health 
or physical reasons". To determine the level of function specific for visually orientated 
tasks, the ADVS questionnaire was administered. Several vision tests were performed. 
These included visual acuity, contrast sensitivity, glare testing, visual fields and stereo 
acuity. Visual impairment was defined as presenting binocular acuity worse than 20/40. 
The final sample for the SEE project was 2,520 participants aged 65 years to 84 years. 
Visual impairment was significantly associated with all the measures of functional 
status assessed, i. e. ADL, IADL and ADVS. After controlling for age, sex and race, 
visually impaired people were more likely to report difficult with any ADL (odds ratio 
1.82,1.18 to 2.83) and with any IADL (odds ratio 2.45,1.77 to 3.40). The mean ADVS 
coefficient was significantly lower in visually impaired people. For every increase in 
visual acuity logMAR score of 0.3 (equivalent to doubling of visual angle), there was an 
odds ratio of 2.39 (1.77 to 3.23) associated with being low versus high functioning as 
measured by the ADVS. Other measures of visual function such as contrast sensitivity, 
glare sensitivity, visual field and stereoacuity were independently significantly 
associated with ADVS score. However, the ADVS was developed for use with cataract 
patients in the hospital setting. In the SEE project, these associations were found to 
apply only to the ADVS subscales on far vision, near vision and night driving only. The 
day driving and glare subscales did not provide appropriate summaries in the 
population-based SEE project because they were limited by items not widely 
participated in and have weak within-subscale associations. 
The Blue Mountains Eye Study was a cross-sectional census-based survey of eye 
disease in two postcode areas in the Blue Mountains, west of Sydney, Australia. The 
final sample consisted of 3,654 people. Visual acuity, contrast sensitivity, disability 
glare and visual fields were measured. A questionnaire on perception of visual disability 
was administered by an interviewer (Ivers et al. 2000). This included questions on 
trouble driving at night, difficulty recognising a friend across the street, reading a 
newspaper or recognising detail on television. Visual acuity and contrast sensitivity 
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were significantly associated with all self-reported measures of visual disability. Visual 
field was less strongly associated with visual disability. 
Marx et al studied 103 nursing home residents (mean age 85 years) (Marx et al. 1992). 
Half of the participants were visually impaired (best corrected acuity of less than 20/70). 
For each resident, the degree of assistance needed to perform seven activities of daily 
living was assessed by the resident's charge nurse using the Maryland Appraisal of 
Patient Progress. The activities were toileting, transferring from bed to chair, bathing or 
showering, washing hands or face, dressing the upper body, dressing the lower body, 
and whether the resident was wheelchair-dependent. These items were rated as 1- 
independent/needs some assistance or 2- completely dependent. In all the items 
studied, visually impaired people were more likely to be classified as completely 
dependent. However, these differences only reached statistical significance for toileting, 
transferring, washing face/hands and dressing upper body. 
Keeffe et al conducted a qualitative study to investigate the impact of vision loss on 
people with impaired vision (Keeffe et al. 1998). Focus groups were formed that took 
into account the factors that can affect the impact of vision loss: age, gender, age of 
onset, cause and degree of vision loss. The following domains were explored: mobility, 
household and personal care, consumer and social interactions and leisure, employment 
and education. A fifth domain "reaction to vision loss" was added subsequently. Other 
issues raised were that multiple impairment, such as hearing loss, complicates matters 
and that men and women differ in the ways of coping with vision impairment. 
Two studies were identified that specifically looked at the impact of AMD on functional 
ability. Both of these studies were hospital-based. 
Williams et al identified 86 adults (average age 79 years, range 63 to 91) with AMD 
who were legally blind in at least one eye (Williams et al. 1998). The age, racial and 
gender mix of the sample was typical of people at risk for AMD. They used the IADL 
focussing on domains of managing medications, shopping for necessities, managing 
finances, using the telephone, maintaining a household and preparing meals. Responses 
were scored from 1 to 3 with 1 representing complete independence in these activities 
and 3 indicating inability to carry out any of the tasks. A composite score was created 
by averaging the responses to 12 items. They also used the Quality of Well-being 
(QWB) Scale. The QWB Scale includes functional scales for mobility, physical activity 
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and social activity. The scoring system applies estimates of quality of life to 
combinations of functioning and symptoms. The quality estimates are obtained from an 
independent panel of judges. The scoring system places each case on a continuum 
ranging form 0.0 (dead) to 1.0 (optimum function with no symptoms). The study did 
not have a control group but the authors compared the mean QWB score with other 
populations. People with macular degeneration in the sample had a mean QWB score of 
0.581. This compared with 0.770 for elderly adults of a similar age. More study 
participants reported difficulty in carrying out instrumental activities of daily living than 
did a national sample of non-institutionalised adults aged 65 years and older; this 
applied to all the domains studied. 
Mangione et al recruited 201 people with various stages of ARM from the 
Massachusetts Eye and Ear Infirmary (average age 71 years)(Mangione et al. 1999). 
Median corrected visual acuity for this sample was 20/25 in the better eye with all 
subjects having 20/200 or better in at least one eye. All participants completed an 
interview that included the ADVS. Although there was no control group, the authors 
evaluated the association between ADVS and clinical severity of AMD. There was a 
statistically significant linear trend across ARM severity categories for four unadjusted 
ADVS scores: the overall score, near vision, disability glare and daytime driving scales. 
Analyses were adjusted for age, sex, medical co-morbidity and presence of other eye 
disease. Including visual acuity in the model suggested that most, if not all, of this 
variation could be explained by visual acuity rather than severity of AMD per se. 
1.3.5 Broader measures of health status (health-related quality of life) 
Two cross-sectional population-based studies and one hospital-based study examined 
the relationship between visual impairment and health-related quality of life. Two 
further hospital-based studies examined patients with AMD. 
Scott et al compared 86 patients with visual impairment to 51 controls and used the 
following questionnaires: Sickness Impact Profile, the vision-specific Sickness Impact 
Profile, the Community Disability Scale and the General Health Questionnaire (Scott et 
al. 1994). They found that scores of all four questionnaires and their subscales were 
significantly associated with visual acuity. 
Wang et al examined the association between visual impairment and a single-item 
question on self-rated health in the population-based Blue Mountains Eye Study (Wang 
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et al. 2000). The question was "For someone of your age, how would you rate your 
overall health? Excellent, good, fair or poor". Response to this question was strongly 
related to visual impairment. After adjustment for potential confounding factors, for 
each 5 letter reduction in best-corrected visual acuity, there was a 20% increased 
likelihood of low self-rated health. However, this association applied only to people less 
than 80 years of age. In people aged 80 years and above, reduced vision had no impact 
on global health rating. 
In the SEE project, two questions from the social interaction scales from the Sickness 
Impact Profile were used because the authors had identified in previous work that these 
were highly correlated with degree of visual impairment in a clinic-based population. 
People with visual impairment were more likely to report no social or religious 
activities compared to people without visual impairment (odds ratio 1.67,1.17 to 2.37 
for no social activities and 1.96,1.41 to 2.74 for no religious activities), controlled for 
age, sex and race. 
Williams et al investigated 86 elderly adults (average age 79 years) with AMD who 
were legally blind in at least one eye (Williams et al. 1998). A single-item global 
measure of health was used with participants being asked to rate their overall health as 
excellent, very good, good, fair or poor. These categories were scored from 1 (excellent) 
to 5 (poor). The average score was 2.5. In the absence of a comparison group it is 
difficult to interpret this figure and the authors did not identify another population group 
for comparison. 
Mangione et al studied the Short Form-36 Health survey which is a generic measure of 
multidimensional health-related quality of life in a hospital-based sample of 201 people 
with various types of ARM (Mangione et al. 1999). There was no control group for the 
study but the authors found that, in contrast to the ADVS (see section 1.3.4 above), the 
SF-36 Health Survey scale was not correlated with severity of AMD. However, the 
sample had a good average visual acuity and few participants with severe bilateral 
AMD. 
1.3.6 Psychological well-being 
In a population-based study in northern Italy, Carabellese et al measured visual acuity in 
1,191 people aged 70 to 75 years (Carabellese et al. 1993). Visual acuity was 
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significantly associated with an increased risk for clinical depression (odds ratio 2.3,1.5 
to 3.4). 
Brody et al studied 151 adults aged 60 years and above with advanced macular 
degeneration and vision 20/60 or worse in the better eye (Brody et al. 2001). They 
found that depression, as assessed using a structured clinical interview for DSM-IV, 
was common - occurring in 32.5% of the sample. This was estimated to be 
approximately twice that in other studies of community dwelling adults, although the 
authors themselves had only studied people with macular degeneration. 
In a hospital-based case-control study, 87 cases aged 65 years and above with mild-to- 
moderate Alzheimers disease were compared to 87 non-demented controls matched to 
the cases by age, sex and education(Uhlmann et al. 1991). The prevalence of visual 
impairment was higher in cases than in controls: unadjusted odds ratio for near-vision 
impairment 2.7,1.4 to 5.2; unadjusted odds ratio for far-vision impairment 2.1,1.02 to 
4.3). 
1.3.7 Emotional well-being (life satisfaction and morale) 
One study was identified which examined life satisfaction, daily hassles, social support 
and self-esteem in 30 cases of AMD compared to age and sex-matched controls (Davis 
et al. 1995). Life satisfaction was measured using the Life Satisfaction Index of Well- 
being. This was scored on a five-point Likert scale. Higher summed scores on this scale 
indicated greater life satisfaction. Social support was measured using the Social Support 
Scale. Self-esteem was measured using the Revised Feelings of Inadequacy Scale. Daily 
hassles were measured using a revised version of the Hassles Scale. People with AMD 
reported significantly poorer life satisfaction and greater stress, perhaps as a result of 
poor social support. 
Williams et al examined the Profile of Mood States which is a 65-item, self-report 
symptom inventory designed to assess mood state in the past week (Williams et al. 
1998). The participants respond to each item on a five-point Likert scale, ranging from 
"not at all" to "extremely". There are six subscales (tension/anxiety, 
depression/dejection, vigour/activity, confusion/bewilderment, fatigue/inertia, and 
anger/hostility) and a total score. In general people with AMD had higher scores 
indicating more severe distress, compared with a similar aged sample. 
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1.3.8 Summary 
There is an increasing body of literature on the impact of visual impairment on 
functional ability, health-related quality of life, psychological and emotional well-being. 
It has been shown to have a deleterious impact on many of these aspects of daily life 
and an increased risk of mortality and morbidity (falls and hip fractures). There is little 
information on the impact of AMD and nothing on the impact of AMD as a cause of 
visual loss in the community. Most studies in this area have been conducted in the USA 
and Australia; there is no information on the impact of this disease in the British 
population. There is also little information on older age-groups as studies have been 
under-powered at older ages, however, some researchers have suggested that the effect 
of visual impairment is different at older ages. 
1.4 RISK FACTORS 
1.4.1 Hypotheses 
There are two main hypotheses for the development of AMD. 
(1) Oxidative mechanisms are thought to be important in the pathogenesis of AMD 
(Beatty et al. 2000). Oxidative stress is the name given to the damage caused by 
metabolites of molecular oxygen known as "reactive oxygen species" (ROS). 
Tobacco smoking and exposure to UV and visible light increase levels of oxidative 
stress. Factors that reduce the level of oxidative stress include antioxidant 
micronutrients in the diet and blood and exposure to endogenous and exogenous 
oestrogen. 
(2) Vascular problems leading to deficiencies in the circulation supplying the retina or 
increased haemodynamic resistance may lead to degeneration of the retinal pigment 
epithelium, either because of lack of oxygen or build up of waste products 
(Friedman 1997). This hypothesis has lead to the investigation of the association of 
cardiovascular disease and its risk factors (smoking, alcohol consumption, high 
blood pressure, obesity, diabetes and oestrogen levels in women) with AMD(Snow 
and Seddon 1999). 
In practice it is difficult to disentangle these two hypotheses as oxidative stress is also a 
proposed mechanism in the pathogenesis of cardiovascular disease, another ageing 
disease. 
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The risk factors considered in this review are: smoking, cardiovascular disease, other 
shared risk factors for cardiovascular disease (high blood pressure, alcohol 
consumption, dietary fat intake, obesity and diabetes), antioxidant micronutrients, light 
exposure and oestrogen levels in women. I will conclude this section on aetiology with 
a brief overview of current research on the genetics of AMD. 
1.4.2 Assessment of study quality 
Three types of study design were considered in this review - cross-sectional studies, 
cohort studies and case-control studies. Table 1.7 gives an overview of study design 
types. There are two broad types of cohort studies: studies where the exposure is 
randomly allocated (randomised controlled trials) and studies where it is not 
(observational studies). Case-control studies can be either population or hospital-based. 
Population-based studies often compare the prevalence of exposure in people with 
AMD versus people without i. e. all the people taking part in the cross-sectional study 
are included in the analysis (analytic cross-sectional studies). 
The following aspects of the design and execution of randomised controlled trials have 
been demonstrated to minimise bias in empirical studies (Juni et al. 2001). The 
allocation of treatment should be generated using a random process and concealed from 
people enrolling participants; the assessment of outcome should be masked to treatment 
status; withdrawals and dropouts should be unrelated to treatment status and an 
intention to treat analysis conducted. There has been less empirical research on quality 
of observational studies. However, two main aspects are likely to be important: 
ascertainment of exposure should be independent of outcome (and vice versa) and 
potential confounding variables should be taken into account in the analysis(Hennekens 
and Buring 1987). In practice, good response rates, assessment of exposure status prior 
to the occurrence of outcome and masking of observers to exposure / outcome status 
will help to reduce the occurrence of the former. Hospital-based case-control studies can 
be difficult to interpret because of the difficulties inherent in selecting a control group. 
Potential confounding variables need to be considered, measured properly and analysed 
appropriately. 
When evaluating epidemiological evidence, it is important to take into account negative 
findings. Publication bias, whereby studies with statistically significant findings, are 
published preferentially, has been shown to be a significant problem in randomised 
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controlled trials (Simes 1986), and is likely to be more of a problem for observational 
studies. This can make obtaining an unbiased estimate of effect difficult. Authors may 
only report statistically significant results when presenting the results of observational 
studies where large numbers of exposures have been investigated. Indicators of good 
practice in this area are statements regarding primary and secondary outcomes and 
reference to a prior analysis plan. 
1.4.3 Studies on risk factors for AMD 
Many of the cross-sectional studies set out in table 1.8 have investigated risk factors for 
AMD. The usual approach has been to compare the prevalence of exposure in people 
with AMD compared to those people without AMD. In general these studies have been 
underpowered to investigate risk factors for late stage AMD with numbers of cases 
ranging from 9 in the Chesapeake Bay Study to 77 in the Beaver Dam Eye Study (table 
1.8) (West et al. 1989; Klein et al. 1992a). The table also shows aspects of the quality of 
these studies with respect to investigation of risk factors. The major deficiency in these 
studies has been a lack of a clear analysis plan, distinguishing a priori and post hoc 
analyses and no clear strategy for analysis of potential confounding variables. 
Table 1.9 shows the case-control studies on AMD (Maltzman et al. 1979; Delaney and 
Oates 1982; Hyman et al. 1983; Weiter et al. 1985; Blumenkranz et al. 1986; Eye 
Disease Case-Control Study Group 1992; Eye Disease Case-Control Study Group 1993; 
Sanders et al. 1993; Chaine et al. 1998; Hyman et al. 2001; AREDS 2000). The table 
includes some parameters of quality in the studies, for example, whether or not the 
assessment of exposure was masked to case status and whether appropriate confounding 
variables were included in the analysis. 
The studies have varied in size from 26 cases (Blumenkranz et al. 1986) to 1844 cases 
in a case-control study in France (Chaine et al. 1998). Of the 10 case-control studies, 
four had sample sizes less than 100 people. 
As for cross-sectional studies, a major deficiency in the case-control studies was a lack 
of discussion of prior analysis plans. A problem specific to case-control studies is the 
difficulties inherent in selecting a control group. In four studies, this problem was 
approached systematically with attention to avoiding bias (Eye Disease Case-Control 
Study Group 1992; Sanders et al. 1993; Hyman et al. 2001; AREDS 2000). In the 
others this issue was not adequately addressed. Similarly, not all studies specifically 
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stated that assessment of exposure was masked to case-control status. Most of the 
studies attempted to control for confounding factors other than age and sex. 
Table 1.10 shows the cohort studies on AMD. There have been two types of cohort 
study. Examination for AMD has been added onto pre-existing cohorts, for example, the 
Baltimore Longitudinal Study of Aging (West et al. 1994a)the Physicians' Health Study 
(Christen et al. 1996) and the Nurses' Health Study (Seddon et al. 1996). 
The second type of cohort study has been the re-examination of some of the large cross- 
sectional population-based surveys such as the Beaver Dam Eye Study, Rotterdam 
Study and the Blue Mountains Eye Study (Bressler et al. 1995; Cruickshanks et al. 
2001; Klaver et al. 2001; Klein et al. 2000; Klein et al. 1997a; Klein et al. 1997b; 
Mitchell et al. 2002). 
The advantage of the add-on studies is that, in general, the original cohort study or trial 
is large. For example, 22,071 male physicians were enrolled in the Physicians' Health 
Study and 31,843 registered nurses in the Nurses' Health Study. This is much larger 
than eye surveys which, in general, have of the order of 5,000 participants. The result is 
that more incident cases of AMD can be identified - 268 in the Physicians' Health 
Study compared to 25 in the Blue Mountains Eye Study. However, because of the size 
of such cohorts, a pragmatic approach has had to be taken to the assessment of AMD. In 
the Physicians' Health Study and Women's Health Study AMD outcome was assessed 
by a combination of self-report and medical record review. 
Re-examination of some of the larger cross-sectional eye studies has enabled 
measurement of the incidence and progression of early signs of ARM such as drusen 
and pigmentary abnormalities. However, the number of cases of late-stage disease is 
very low and hence such studies lack power to investigate risk factors for visually 
impairing AMD. 
1.4.4 Smoking 
Smoking cigarettes has been established to be a major risk factor in the development of 
cardiovascular disease and many cancers. It is a major source of oxidative stress. 
Tobacco smoke contains, amongst other ingredients, nicotine, carbon monoxide and 
hydrogen cyanide. Nicotine is an alkaloid from the tobacco plant (Nicotiana) and is 
highly toxic. It is a vasoconstrictor that reduces blood flow and increases platelet 
adhesiveness. It is also implicated in the reduction of levels of serum antioxidants. 
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There are two potential mechanisms by which smoking may lead to an increased risk of 
macular degeneration. It may have direct effects on the choroidal circulation or it may 
increase the levels of oxidative stress and decrease blood plasma levels of antioxidant 
micronutrients. 
Table 1.11 summarises the results of epidemiological studies investigating the 
relationship between smoking and AMD. This relationship has been investigated in 
eight cross-sectional studies (West et al. 1989; Klein et al. 1993b; Smith et al. 1996; 
Delcourt et al. 1998; Vingerling et al. 1996; Klaver et al. 1997; Hirvela et al. 1996; 
Vinding et al. 1992; McCarty et al. 2001 a), three cohort studies (Christen et al. 1996; 
Seddon et al. 1996; Klein et al. 1998b), and six case-control studies (Eye Disease Case- 
Control Study Group 1992; Blumenkranz et al. 1986; Chaine et al. 1998; Hyman et al. 
1983; Tamakoshi et al. 1997; AREDS 2000). The majority of studies have found a 
statistically significant association between smoking and development of AMD. Most 
studies found a risk of the order of 2 to 3 (range 1.6 to 4.9). Three studies did not find 
an association between smoking and AMD (West et al. 1989; Hirvela et al. 1996; 
Chaine et al. 1998). The French study is particularly puzzling because they had 1844 
cases of AMD and found no evidence of effect with an odds ratio= 1.06 (Chaine et al. 
1998). There are several possible explanations of this: either there was some problem in 
the study design or execution either in the classification of smoking or AMD or in the 
selection of controls; the other studies may have some common bias which was 
somehow avoided in this study; or the effect of smoking on AMD does not apply in the 
French population. It has been observed in some studies that the effect of smoking is 
more apparent in neovascular disease (Klein et al. 1993b; Vingerling et al. 1996), 
however, this has not always been the case. In the Blue Mountains Eye Study, people 
who smoked were nearly 5 times as likely to have dry AMD compared to those who had 
never smoked (odds ratio for geographic atrophy in current vs. never smokers 4.94,1.29 
to 18.82) (Smith et al. 1996). However, this analysis included only 11 cases of disease 
therefore wide confidence intervals are consistent with a more moderate risk. In the 
Physicians Health Study the relative risk of neovascular disease with smoking was 
slightly lower than the relative risk for all types of AMD (Christen et al. 1996) and the 
Nurses' Health Study also found similar risks for dry and wet disease (Seddon et al. 
1996). 
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More persuasive evidence for the role of smoking in the aetiology of AMD has come 
from the demonstration of a dose response effect. In the Physicians' Health Study, men 
who smoked more than 20 cigarettes a day were at increased risk compared to those 
who smoked less than 20 cigarettes a day (odds ratio of 2.46 versus an odds ratio of 
1.26) (Christen et al. 1996). There was also a strong trend of increased risk with 
increased number of pack-years of smoking (p<O. 001). In the Nurses' Health Study, 
there was a strong trend of increased risk with increasing number of cigarettes smoked 
per day (p=0.004) and pack-years (p=0.005) (Seddon et al. 1996). 
The finding that smoking is implicated in the aetiology of AMD is an important one 
because it is a risk factor that is amenable to modification. 
1.4.5 Cardiovascular disease 
History of cardiovascular disease 
The findings for reported history of cardiovascular disease have been inconsistent with 
some studies finding an association(Hyman et al. 1983; Chaine et al. 1998; Goldberg et 
al. 1988a) and others not (Maltzman et al. 1979; Delaney and Oates 1982; Vinding et 
al. 1992; Eye Disease Case-Control Study Group 1992; Klein et al. 1993a; Smith et al. 
1998a; Delcourt et al. 2001). Table 1.12 summarises the results of those studies that 
have provided data in a form that can be extracted. 
Atherosclerosis 
The association between carotid atherosclerosis and AMD (geographic atrophy and 
neovascular disease) was investigated in the Rotterdam Study(Vingerling et al. 1995a). 
Atherosclerosis was assessed using ultrasonography with images being stored on 
videotape. Atherosclerotic lesions were defined as focal widening relative to adjacent 
segments, with protrusion into the lumen. People with plaques in the carotid bifurcation 
were at increased risk of AMD (odds ratio 4.5,1.9 to 10.7). This finding has not been 
studied again but a study in Finland examined the relationship between retinal 
arteriosclerosis (defined as marked generalized narrowing of the arterioles) and 
AMD(Hirvela et al. 1996). They found that people with retinal arteriosclerosis had a 
higher prevalence of AMD. However, as only two people in the age group studied did 
not have retinal arteriosclerosis this finding cannot be considered robust. There was a 
higher prevalence of ARM in people with retinal arteriosclerosis but this was not 
statistically significant. 
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1.4.6 Other shared risk factors for cardiovascular disease 
Blood pressure 
Table 1.13 shows the results of studies that have investigated the relationship between 
blood pressure and AMD. Data from the Framingham Eye Study were analysed in two 
different ways. The mean blood pressure in people with AMD and vision of <_ 20/30 
was compared to those people without AMD (Kahn et al. 1977b). The data on blood 
pressure were collected during the Framingham Heart Study, prior to the collection of 
data on AMD. Only statistically significant results were reported in the paper. People 
with AMD in selected age-groups had a higher mean diastolic blood pressure. The 
Framingham Eye Study was analysed again some years later. In the repeat analysis, 
there were more cases of macular degeneration as vision was no longer included in the 
definition of the disease(Sperduto and Hiller 1986). Detailed information on 
hypertension, including its duration over 20 years prior to the eye examination was 
used. This showed that people with hypertension were more likely to have AMD and 
that this was related to the duration of hypertension. People who had had hypertension 
for longer had an increased risk of AMD. These results have been found in two other 
studies (Goldberg et al. 1988a; Chaine et al. 1998), but have not been replicated in a 
number of other studies (Maltzman et al. 1979; Eye Disease Case-Control Study Group 
1992; Klein et al. 1993a; Hirvela et al. 1996; Smith et al. 1998a). 
If there is a moderate increased risk of AMD with increasing blood pressure, large 
numbers of cases of disease will be required to detect this. This might be the reason why 
in some studies no statistically significant relationships were found. It is interesting to 
note that in most studies non-statistically significant increased odds ratios were found. 
However, some studies, such as the Eye Disease Case-Control Study group have been 
large (421 cases of neovascular disease) and have still failed to find an effect that could 
not be attributed to other confounding factors. In some of the cross-sectional studies, the 
number of cases of late stage disease has been small. However, these studies have had 
large numbers of early cases, and if raised blood pressure affected the incidence of the 
disease, it might be expected to increase the risk of early signs. 
It is unlikely that raised blood pressure has a strong direct effect on the development of 
AMD, although there is some evidence that people with prolonged hypertension may be 
at increased risk of the disease. 
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Alcohol consumption 
Alcohol has both harmful and beneficial effects on the circulation and physiology. It 
may increase oxidative stress or adversely affect the mechanisms that protect against 
oxidative damage(Cederbaum 1989). Its benefits may occur because it increases high 
density lipoprotein cholesterol(Gaziano et al. 1993) and decreases platelet 
aggregation(Renaud et al. 1992), and serum fibrinogen(Meade et al. 1979). All these 
changes may decrease the risk of cardiovascular disease in moderate drinkers. In 
coronary heart disease, it is thought that there is a J-shaped curve such that people who 
drink moderate amounts of alcohol are at reduced risk of the disease compared to those 
who drink none or large amounts. There have been few studies of the role of alcohol 
consumption in the development of AMD and these have produced conflicting results. 
In NHANES 1, in an analysis of 184 individuals with AMD, moderate alcohol 
consumption reduced the risk of developing the disease (odds ratio 0.86,0.73 to 
0.99)(Obisesan et al. 1998). The authors concluded that the majority of this effect was 
attributable to wine consumption. 
In the Copenhagen study, there was a non-significant trend of increased risk with 
increasing daily alcohol intake(Vinding et al. 1992). There was some suggestion of a J- 
shaped curve, with individuals consuming moderate amounts (1-2 alcoholic drinks a 
day) having a marginally reduced risk compared to those who drank none. 
The Beaver Dam study found neither wine nor liquor consumption was related to early 
or late ARM. However, consumption of beer in the past year was related to a greater 
odds of neovascular macular degeneration (odds ratio 1.41,1.05 to 1.88)(Ritter et al. 
1995). In the longitudinal Beaver Dam Study, they found a higher 5-year age-adjusted 
incidence of various early signs of ARM in men who drank beer(Moss et al. 1998). 
In the Eye Disease Case-Control Study, no association between alcohol consumption 
and risk of neovascular AMD was found(Eye Disease Case-Control Study Group 1992). 
In the Blue Mountains Eye Study neither alcohol intake nor intake of beer was 
associated with ARM, however, they did find an association between consumption of 
spirits and early stages of the disease(Smith and Mitchell 1996). 
In the Physicians' Health Study there was no statistically significant associations but 
some indication of a J-shaped curve(Ajani et al. 1999). After adjusting for age, 
treatment assignment, and other potential risk factors, the relative risk for those 
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reporting alcohol consumption of <1 drink/week, 1 drink/week, 2-4 drinks/week, 5-6 
drinks/week, and >= 1 drink/day were 1.00 (referent), 1.00 (0.65 to 1.55), 0.68 (0.44 to 
1.04), 1.32 (0.89 to 1.95), and 1.27 (0.93 to 1.73), respectively. 
Cho et al analysed data from the Nurses' Health Study and the Health Professionals 
Follow-up Study (111,238 men and women)(Cho et al. 2000). ARM with vision loss of 
20/30 or worse was diagnosed in 298 women (697,498 years of follow-up) and 153 men 
(229,180 years of follow-up). After controlling for age, smoking, high blood pressure, 
total energy intake, lutein/zeaxanthin intake, body mass intake, post menopausal 
oestrogen use and vigorous exercise, the relative risk for AMD compared with 
nondrinkers were 1.0 (0.7 to 1.2) for drinkers who consumed 0.1 to 4.9 g/day of 
alcohol; 0.9 (0.6 to 1.4) for 5 to 14.9 g/day; 1.1 (0.7 to 1.7) for 15 to 29.. 9 g/day; and 
1.3 (0.9 to 1.8) for 30 g/day or more. They found some evidence that wine at higher 
levels of consumption (> two drinks per day) increased the risk of developing AMD 
(odds ratio 1.87,1.17 to 3.00). 
In summary, there are conflicting reports of the effect of alcohol intake on development 
of AMD. Some studies have reported an increased risk whereas others have found a 
decreased risk. There is no clear pattern as to which type of alcohol is important. This 
may reflect the consumption patterns of the communities studied, for example, beer 
drinking is very common in Beaver Dam but other types of alcohol are rarely 
consumed. This may explain why associations were only found with beer consumption 
in that study. In two studies, the Copenhagen Study and the Physicians' Health Study, 
there was some indication of a J-shaped curve but this relationship was not statistically 
significant. 
Dietary fat intake 
Dietary fat intake may influence the risk of developing AMD by two 
mechanisms(Mares-Perlman et al. 1995b). Raised levels of cholesterol in the 
bloodstream increase the risk of atherosclerosis which may have adverse effects on the 
choroidal circulation. Alternatively there may be increased deposition of fat in Bruchs 
membrane that would adversely affect flow supply of nutrients and removal of waste 
products from the retinal pigment epithelium. 
Table 1.14 shows the relationship between dietary intake of fat and AMD. In the Beaver 
Dam Eye Study, data on the intake of food and supplements was collected using a 
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modification of the Health Habits and History Questionnaire developed by 
Block(Mares-Perlman et al. 1995b). There were 314 cases of early ARM and 30 cases 
of AMD. People with intakes of saturated fat and cholesterol in the highest quintile had 
a greater risk of early ARM. Similar estimates were found for AMD but these were not 
statistically significant due to the low number of cases. 
In NHANES-III there was a non-significant association between total fat intake 
(expressed as a percentage of total energy intake) and ARM. After adjustment for age, 
race, eye colour and sedentary lifestyle, the odds ratio for early ARM was 1.4 (0.9 to 
2.2) and AMD was 0.7 (0.2 to 2.6) comparing the highest against the lowest 
quintiles(Heuberger et al. 2001). 
In the Eye Disease Case-Control Study, higher intakes of specific types of fat, i. e. 
vegetable, monounsaturated and polyunsaturated fats, rather than total fat intake was 
found to be associated with a greater risk of neovascular AMD(Seddon et al. 2001). 
Diets high in w-3 fatty acids and fish were inversely associated with risk for AMD when 
intake of linoleic acid was low. 
Cho et al reported data from the Nurses' Health Study and the Health Professionals 
Follow-up study. They identified prospectively 567 patients with ARM and visual loss 
of 20/30 or more. They found that total fat intake was associated with an increased risk 
of ARM. The relative risk for the highest compared with the lowest quintile of total fat 
intake was 1.54 (1.17 to 2.01). However, they suggest that this may have been due to 
intakes of individual fatty acids, such as linolenic acid rather than total intake per se. 
Docosahexaenoic acid had a modest inverse relation with ARM; four servings of fish 
per week was associated with a 35% lower risk of ARM compared with three or less 
servings per month (relative risk 0.65,0.46 to 0.91). 
The findings for biochemical markers of dietary fat have been inconsistent (table 1.15). 
Three studies have investigated this. In the Eye Disease Case-Control Study, people 
with high serum cholesterol (> 6.749 mmol/L) were at increased risk of neovascular 
disease compared to people with low values of serum cholesterol (<_ 4.888 mmol/L) 
(Eye Disease Case-Control Study Group 1992). However, this finding was not repeated 
in two other studies. In NHANES 1, people with high cholesterol (>300 mg/100ml) 
were less likely to develop AMD compared to people with low cholesterol (<200 
mg/I00mml) (odds ratio 0.51,0.26 to 1.00)(Goldberg et al. 1988a). Conversely, other 
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authors reported no association between AMD and cholesterol in NHANES-1(Klein and 
Klein 1982). 
Body mass index 
Table 1.16 shows the results of studies on body mass index. 
Several studies have found that high body mass index is a risk factor for development of 
AMD. In the POLA study, people with a body mass index of 30 or more were at 
increased risk of AMD(Delcourt et al. 2001). In the AREDS case-control study, people 
in the top quintile for body mass index (> 31) were at increased risk of neovascular 
AMD compared to those in the lowest quintile (<23.6)(AREDS 2000). This was also 
seen in the Eye Disease Case-Control Study Group, however, this relationship was no 
longer significant once other confounders were taken into account(Eye Disease Case- 
Control Study Group 1992). In the Oulu County Study, high body mass index (> 27.5) 
was found to be associated with ARM in men only(Hirvela et al. 1996). 
A couple of the larger studies have found some evidence of a J-shaped curve. In the 
prospective Physicians Health Study, a J-shaped relationship was found such that 
people with normal body mass index (in this case defined as 22.0 to 24.9) were at the 
lowest risk of developing ARM causing visual loss(Schaumberg et al. 2001). A similar 
finding was seen in the Blue Mountains Study(Smith et al. 1998a). This was significant 
for early ARM and non-significant for AMD due to lower number of cases. 
In the cross-sectional Beaver Dam Eye Study, waist-to-hip ratio was more strongly 
associated with risk of developing early ARM and AMD than body mass index(Klein et 
al. 2001a). 
Diabetes 
Hyperglycemia may affect the normal functioning and structure of the choroidal 
circulation, the retinal pigment epithelium or Bruch's membrane. In the cross-sectional 
Beaver Dam study, diabetes in men 75 years of age and older was associated with an 
increased risk of neovascular AMD (odds ratio 10.2,2.4 to 43.7)(Klein et al. 1992b). 
There was little evidence for a relationship in women (odds ratio 1.1,0.4 to 3.0 
However this finding has not been repeated in any of the many studies that have 
examined this association(Eye Disease Case-Control Study Group 1992; Delcourt et al. 
200 1; Smith et al. 1998a; Hirvela et al. 1996; AREDS 2000). 
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1.4.7 Antioxidant micronutrients 
There is much interest in the role of antioxidant micronutrients, largely because this, 
like smoking, is a potentially modifiable risk factor. If we all ate enough fruit and 
vegetables or took a multi-vitamin pill every day, could we avoid developing AMD in 
later life? 
The two major antioxidant micronutrients in the retina are the carotenoids lutein and 
zeaxanthin. The most plausible hypothesis would be that increased levels of macular 
pigment would decrease the risk of AMD through its ability to reduce the effect of light 
induced retinal damage from the photodynamic production of free radicals(Beatty et al. 
1999). 
Unlike many of the other risk factors discussed in this paper, this is one area where 
there is the potential to undertake randomised controlled trials. Randomised controlled 
trials are considered a better source of evidence than observational studies, because the 
investigator, using the process of adequately concealed random allocation, can create 
two groups which are comparable apart from the intervention under study. I have 
conducted a Cochrane systematic review evaluating the effect of antioxidant vitamin 
and mineral supplementation on the progression of AMD(Evans 2001 a). This review 
includes seven trials which randomised 4119 people with signs of AMD. The majority 
of people (88%) were randomised in one trial that was conducted in a relatively well- 
nourished American population. This trial found a modest beneficial effect of 
antioxidant and zinc supplementation on progression to advanced AMD (odds ratio 
0.72,99% confidence interval 0.52 to 0.98). People supplemented with antioxidants and 
zinc were less likely to lose 15 or more letters of visual acuity (equivalent to a doubling 
of the visual angle) (odds ratio 0.79,99% confidence interval 0.60 to 1.04). The other 
six trials in this review were small and the results were inconsistent. 
There is no evidence at present that people with early signs of the disease should take 
supplementation, however, current studies are underpowered to answer that question. 
The generalisability of these findings to other populations with different nutritional 
status is not known. 
Randomised controlled trials of simple vitamin supplements may not assess the correct 
exposure. It may be that a few chemical supplements do not substitute for a diet rich in 
antioxidants. There are a number of observational studies that have examined the 
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association between antioxidant micronutrients in the diet and AMD(Eye Disease Case- 
Control Study Group 1993; Goldberg et al. 1988b; Mares-Perlman et al. 1995a; Mares- 
Perlman et al. 1996; Sanders et al. 1993; Seddon et al. 1994; VandenLangenberg et al. 
1998; West et al. 1994b). Observational studies are not such a good source of evidence 
as to the benefits of dietary intake of antioxidant micronutrients. People who have a diet 
rich in antioxidant vitamins and minerals or who choose to take supplements regularly, 
are different in many ways from those who do not; these differences may not be 
adequately controlled by statistical analysis. Inconsistent results have been found(Evans 
2001b). As I will not present data on antioxidant micronutrients in this thesis I will not 
discuss these observational studies further. 
1.4.8 Light 
Photoreceptors in the retina are subject to oxidative stress throughout life due to 
combined exposures to light and oxygen(Young 1988). The action of light on the 
photoreceptors generates free radicals. These are short-lived molecular fragments that 
have an unpaired electron in the outer orbital. This unstable structure is highly reactive 
and toxic. It attacks other molecules, particularly polyunsaturated fatty acids, which are 
an essential component of biological membranes. 
It is thought that AMD might occur in individuals that have received excess light 
stimulation, particularly at vulnerable times, or who do not have enough protective 
antioxidant micronutrients in the serum or retina. 
Most ultraviolet radiation (wavelength 200-400 nanometers) is absorbed by the lens and 
cornea. It is largely visible light (wavelength 400 to 780 nanometers) that reaches the 
retina. Animal studies and case reports in humans show that excessive exposure to 
bright light, from solar or other sources, can damage the retina. There is also some 
evidence that intense bright sunlight causes changes in the retinal pigment epithelium 
similar to those seen in ARM. Whether or not exposure to sunlight or artificial light 
sources is an important cause of AMD in human populations is not clear. It is difficult 
to measure lifetime light exposure in human populations. There is also uncertainty about 
when light exposure is important. Some authors have suggested that the period of 
exposure of interest may well be in childhood at which time the ocular media transmit 
more blue light and ultraviolet radiation than those of adults(Simons 1993). There is 
increasing absorption of short wavelength light by the lens with increasing age, 
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however, this is counteracted by the greater proportion of people who have cataract 
surgery at older ages. It has been shown that increased ambient light increases the 
antioxidant capability of the retina. This raises the question as to whether it is chronic 
high ambient light levels that are harmful or rather increases in the level of light to 
which the eye is accustomed that could be problematic. 
It is difficult to measure lifetime light exposure directly. A number of investigators have 
tried to estimate the average annual exposure. They have done this by asking study 
participants about their activities in relation to time spent out of doors and use of hats 
and sunglasses and relating this to records of ambient light exposure in the region of the 
study. They have combined the two measures using mathematical formulae that adjust 
the maximum potential light exposure according to attenuating factors such as time 
spent indoors, use of hats and glasses. The estimates of the effects of these attenuating 
factors is crude as the questionnaires attempt to measure lifetime exposures, however, 
minute by minute exposures can vary enormously depending on the angle of the sun, the 
position of the head, use of hats, buildings, trees, reflective surfaces and so on. 
However, although such measures are necessarily crude they may be good enough to 
distinguish groups of people with very different exposures. In the case of cataract such 
instruments have been sufficient to detect an effect of ultraviolet light exposure on 
cortical cataract(McCarty and Taylor 2002). 
There have been a number of studies that have examined the role of ultraviolet and 
visible light on the development of AMD(Hyman et al. 1983; Blumenkranz et al. 1986; 
Taylor 1989; West et al. 1989; Taylor et al. 1990; Eye Disease Case-Control Study 
Group 1992; Cruickshanks et al. 1993; Darzins et al. 1997; Mitchell et al. 1998; 
Cruickshanks et al. 2001). 
In both the Chesapeake Bay study and Beaver Dam Eye Study no association was found 
with lifetime exposure to ultraviolet light(West et al. 1989; Cruickshanks et al. 1993). 
However, in a subsequent re-analysis, the Chesapeake Bay study found a borderline 
association with visible light(Taylor et al. 1990). The authors of the Beaver Dam Eye 
Study also argued that some of their measures indicated that visible, rather than 
ultraviolet, light might be the problem(Cruickshanks et al. 1993). Other studies have 
found no association with proxy measures of lifetime exposure such as time spent out 
doors(Darzins et al. 1997; Eye Disease Case-Control Study Group 1992). 
Hcf 
49 
1.4.9 Oestrogen 
Oestrogens are female sex hormones that have well documented favourable effects on 
blood lipids and clotting factors and may protect against peroxidative damage of 
membrane lipids and low density lipoproteins. Many case-control and prospective 
studies have reported less coronary heart disease in women using oestrogen. 
Randomised controlled trials of hormone therapy have failed to confirm these beneficial 
effects on cardiovascular disease(Barrett-Connor and Stuenkel 1999). The role of 
oestrogens in the development of AMD has been investigated in several studies(Eye 
Disease Case-Control Study Group 1992; Vingerling et al. 1995c; Klein et al. 1994a; 
Smith et al. 1997). 
The Eye Disease Case-Control Study Group was the first study to report on 
oestrogens(Eye Disease Case-Control Study Group 1992). They found that women 
currently taking oestrogen replacement were at a reduced risk of neovascular AMD 
compared to women who had never taken replacement therapy (odds ratio 0.3,0.1-0.8). 
Women reporting former use were at an intermediate risk (odds ratio 0.6,0.3-0.98). 
This association remained after controlling for smoking, education, physical activity, 
antioxidant intake and plasma lipids. 
In the Rotterdam Study, 59 women with AMD were each matched with five controls 
born in the same year who did not have macular degeneration (295 controls)(Vingerling 
et al. 1995c). Women with early menopause after removal of one or both ovaries had an 
increased risk of macular degeneration compared to women who had their menopause at 
45 years or later (relative risk 3.8,1.1-12.6). The only confounder adjusted for in these 
analyses was age. 
Conflicting results were produced in the Beaver Dam Study which investigated three 
measures of premenopausal oestrogen exposure (age at menarche, the number of years 
of having menstrual cycles and number of pregnancies) and two measures of exposure 
to exogenous oestrogens (birth control pills and oestrogen replacement therapy)(Klein 
et al. 1994a). Analysis of the relationship between these measures and various signs of 
early and late AMD revealed little evidence to support the hypothesis that female sex 
hormones are important protective factors in the development of AMD. The analyses 
were repeated with incidence data and similar findings obtained(Klein et al. 2000). 
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Similar findings were obtained in the Blue Mountains study(Smith et al. 1997). 
Analysis of a variety of measures of oestrogen exposure with early and late ARM only 
revealed one statistically significant association - women with increased time from 
menarche to menopause had a reduced risk of early ARM (odds ratio 0.97,0.95-0.99). 
The role of oestrogens in the development of AMD clearly warrants further study. Two 
studies have found effects of oestrogen replacement and early surgical menopause but 
two large cross-sectional studies have failed to find any strong evidence of effects with 
a number of factors indicating premenopausal and postmenopausal oestrogen exposure. 
1.4.10 Genetic factors 
Work on the genetic determinants of AMD has been slow to develop for two reasons. 
Firstly, as AMD is a disease of old age, surviving parents and well-established family 
trees are rare. Secondly, it is likely to be a complex trait, that is, its inheritance is 
probably controlled by more than one gene. The study of complex traits has been a 
relatively recent development. 
The extent of heritability and the number of genes involved in AMD is unknown at 
present(Gorin et al. 1999). However, there is considerable evidence from the occurrence 
of AMD in families and populations to suggest that there is a genetic basis for this 
condition. 
Several studies have shown that people reporting a family history of AMD are at 
increased risk of the disease(Hyman et al. 1983; Smith and Mitchell 1998). A number 
of twin studies have shown a higher concordance rate between monozygotic than 
dizygotic twins in features of the disease(Gottfredsdottir et al. 1999; Grizzard and Beck 
1994; Klein et al. 1994b; Melrose et al. 1985; Dosso and Bovet 1992). Family-based 
studies, comparing siblings rather than twins, also provide evidence for a genetic basis 
for the condition(Piguet et al. 1993; Seddon et al. 1997; de Jong et al. 1997; Klein et al. 
2001 b). It has been estimated that siblings of an affected person have nearly a 20 times 
higher risk of developing the disease compared to the general population(Silvestri et al. 
1994). Segregation analysis of siblings enrolled in the Beaver Dam Eye Study found 
results consistent with a major gene effect accounting 
for 62% and 59% of the 
expression of ARM in the right and left eyes respectively(Heiba et al. 1994). 
One approach to examining the genetics of AMD has been to study the genetics of 
hereditary retinal dystrophies that share similar phenotypic characteristics to AMD. To 
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date there have been a number of autosomal genes identified for hereditary retinal 
dystrophies (http: //www. sph. uth. tmc. edu/retnet/). Study of the biology and genetics of 
photoreceptor degeneration is likely to further understanding of the pathophysiology of 
AMD (Zack et al. 1999). 
1.4.11 Summary 
The main risk factor for AMD, apart from age and genetic factors, is smoking. This has 
been demonstrated in numerous studies of different design to be associated with an 
increased risk of AMD. The other risk factors studied such as oestrogen use, light 
exposure, cardiovascular disease and its risk factors and alcohol consumption have 
produced conflicting results. Antioxidant vitamin and mineral supplementation has been 
found to be associated with reduced risk of disease progression in one large trial but 
observational studies have produced conflicting results. 
1.5 AIMS AND OBJECTIVES 
The review of the literature has shown a lack of information on AMD as a cause of 
visual loss, no information on AMD as a cause of visual loss in Britain, and limited 
information for people aged 75 years and above. 
Population-based studies have been limited by the numbers of people with advanced 
disease detected. Hospital-based studies have been limited by lack of suitable control 
groups and uncertainty about the representativeness of the AMD cases. There has been 
a lack of heterogeneity in vision status and severity of AMD. 
Although people aged 75 years and above bear the burden of this disease 
disproportionately, previous research has not focussed on the differing needs of this 
group, particularly with respect to increasing age. People aged 90 years and above may 
have very needs compared to people aged 75-79. 
The aims and objectives of this thesis are as follows: 
(1) To estimate the prevalence of AMD causing visual impairment in people aged 75 
years and above in UK, and to investigate how this varies by age, sex, socio-economic 
status and region. 
(2) To investigate the impact of AMD causing visual impairment on the lives of people 
aged 75 years and above in the UK: specifically, its impact on: 
52 
" mortality 
" morbidity 
" functional ability 
" health-related quality of life 
" psychological well-being 
" emotional well-being (life satisfaction and morale) 
To investigate whether the impact of AMD causing visual impairment varies in 
different age and sex groups. 
(3) To investigate the aetiology of visually impairing AMD in people aged 75 years and 
above in UK, that is, to test the following hypotheses: 
" that smoking cigarettes and drinking alcohol are associated with an increased 
risk of visually impairing AMD; 
" that factors indicating increased oestrogen exposure in women are protective for 
developing visually impairing AMD; 
0 that people with evidence of cardiovascular disease are at increased risk of 
developing visually impairing AMD. 
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TABLES AND FIGURES 
Table 1.1 Classification of AMD 
Age-group: 50 years and above Visual acuity: No cutoff 
Detection: Grading of colour fundus transparencies 
Overall term: Age-related maculopathy (ARM) 
The following signs in the absence of other diseases* which may cause these lesions. 
Early ARM 
" Soft drusen >=63 microns 
" Areas of increased pigment or hyperpigmentation (in the outer retina or choroid) 
associated with drusen 
" Areas of depigmentation or hypopigmentation of the RPE, most often more sharply 
demarcated than drusen, without any visibility of choroidal vessels, associated with 
drusen. 
Late ARM = AMD 
Geographic atrophy 
("dry" AMD): 
" any sharply delineated roughly round or oval area of hypopigmentation or 
depigmentation or apparent absence of the RPE in which choroidal vessels are more 
visible than in surrounding areas that must be at least 175 microns in diameter. 
Neovascular AMD 
("disciform", "exudative" or "wet" AMD): 
" RPE detachment (s) which may be associated with neurosensory retinal detachment, 
associated with other forms of ARM 
" subretinal or sub-RPE neovascular membrane (s) 
" epiretinal (with exclusion of idiopathic puckers), intraretinal, subretinal, or sub- 
pigment epithelial scar/glial tissue or fibrin-like deposits 
" subretinal haemorrhages that may be nearly black, bright red, or whitish-yellow and 
that are not related to other retinal vascular disease 
" hard exudates (lipids) within the macular area related to any of the above and not 
related to other retinal vascular disease. 
*Other diseases: 
ocular trauma, retinal detachment, high myopia, chorioretinal infection or inflammation, 
choroidal dystrophy 
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Table 1.3 Prevalence (%) of AMD from pooled analysis of three population-based 
studies* 
Age N 
Geographic 
atrophy alone 
Neovascular 
AMD alone 
Geographic 
atrophy and 
neovascular 
AMD 
Geographic atrophy 
or neovascular 
AMD 
55-64 4797 0.04 0.17 0 0.21 
65-74 4799 0.29 0.54 0.02 0.85 
75-84 2656 1.54 2.52 0.53 4.59 
85+ 521 4.22 5.76 3.07 13.05 
All 
ages 14752 0.54 0.89 0.21 1.63 
* Beaver Dam Eye Study (USA), Rotterdam Study (Netherlands), Blue Mountains Eye 
Study (Australia) From pooled analysis by Smith et al(Smith et al. 2001) 
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Table 1.4 Prevalence (%) of AMD causing visual impairment (binocular acuity 
6/18 or less) from pooled analysis of six population-based studies 
95% confidence 
Age group Number Prevalence % intervals 
65-69 3787 0.13 0.04 to 0.51 
70-74 3288 0.33 0.11 to 0.88 
75-79 2527 1.55 0.86 to 2.61 
80-84 1422 3.58 2.13 to 5.69 
85-89 570 8.07 4.74 to 12.99 
90+ 196 15.3 7.61 to 27.37 
Beaver Dam Eye Study (USA), Blue Mountains Eye Study (Australia), Copenhagen 
City Study (Denmark), North London Eye Study (UK), Rotterdam Study (Netherlands), 
Melbourne Visual Impairment Study (Australia). From pooled analysis by Owen et 
al(Owen et al. 2002) 
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Table 1.5 Number of participants assessed for AMD in prevalence studies 
Study Age 
range 
Total number 
examined 
Number 
aged 75 
years and 
above 
Number aged 
90 years and 
above 
NHANES I 45-75 3056 0 0 
Framingham Eye Study 52-85 2477 392 0 
Gisborne 65+ 481 433 56 
Melton Mowbray Study 76+ 484 484 92** 
Chesapeake Bay Study 30+ 777 119* NK 
Copenhagen City Study 60-80 924 242 0 
Baltimore Eye Study 40+ 5308 ? ? 
Beaver Dam Eye Study 43-84 4771 676 0 
NHANES III 40+ 4007 NK NK 
Rotterdam Study 55-98 6251 1570 326** 
Leicester 40+ 377 92* NK 
Oulu County Study 70+ 478 478* NK 
Salandra Study 60-89 366 73 0 
Barbados Eye Study 40-84 3444 780* 0 
Blue Mountains Eye 49+ 3654 788 135** 
Study 
Melbourne VIP Study 40-98 4345 NK 27 
ARIC Study 48-72 11532 0 0 
North London Eye Study 65+ 1547 743 NK 
Hisayama Study 50+ 1486 ? 
Total 55765 6870 636 
* 70 years and above ** 85 years and above 
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Table 1.7 Overview of study designs 
Type of Useful for Advantages Limitations 
study 
Cross- Evaluating 
sectional effect of 
study exposures by 
comparing 
prevalence 
ratios (relative 
risk) between 
different 
Exposure often measured retrospectively 
Knowledge of disease status may change 
measurement of risk factor 
Effects of confounders can be difficult to 
assess 
groups defined 
by exposure 
Cohort Evaluating Random Can only study exposures where 
study effect of allocation ethical/practical to randomise 
randomised exposures/inter removes Needs to be large 
controlled 
trial 
ventions/ 
treatments 
effects of 
known/unknow 
n confounding 
variables 
Cohort Estimating Exposure 
study incidence status 
observation Evaluating measured 
al study effect of before disease 
Relevant confounding variables need to be 
measured accurately and analysed 
appropriately 
Needs to be large 
exposures occurs 
Population- Estimating Selection of Can be harder to obtain large case group 
based case- effect of control group Relevant confounding variables need to be 
control exposure reasonably measured accurately and analysed 
study (relative risk) straightforward appropriately 
Exposure often measured retrospectively 
Knowledge of disease status may change 
measurement of exposure 
Hospital- Estimating Easier to Selection of control group can be 
based case- effect of obtain problematic 
control exposure reasonably Relevant confounding variables need to be 
study (relative risk) large case measured accurately and analysed 
group appropriately 
Exposure often measured retrospectively 
Knowledge of disease status may change 
measurement of exposure 
Relative risk estimated by odds ratio which 
can be problematic if rare disease assumption 
does not apply 
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Figure 1.1: Prevalence of ARM by age: 
studies using grading of photographs 
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Figure 1.2: Prevalence of ARM by age: 
studies using clinical examination with 
visual acuity cutoff 
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Figure 1.3: Prevalence of AMD by age: 
studies using grading of photographs 
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Figure 1.4: Prevalence of AMD in women compared to men, stratifying by age 
Figure 4: Prevalence of age-related macular degeneration in women compared to men, stratifying by age 
Study 
Females 
n/N 
Males 
n/N 
RR Weight 
5%CI Fixed) % 
RR 
5%CI Fixee 
01 Ages 65-74 
Framingham Eye Study 681538 33 / 371 8.0 1.42[0.96,2.111 
NHANES 1 451654 59 / 612 12.5 0.71(0.49,1 . 04] 
Melton Mowbray 1141260 491132 13.3 1.18[0.91,1 . 53] 
Copenhagen Study 251237 16 / 226 3.3 1.49[0.82,2.72] 
Beaver Dam Eye Study 91722 6/ 527 1.4 1.09[0.39,3.06] 
NHANES III 4/ 582 71608 1.4 0.60[0.18,2.03] 
Rotterdam Study 811280 91977 2.1 0.68[0.26,1.75] 
Blue Mountains Eye S 6/ 682 3/ 527 0.7 1.55[0.39,6.15] 
ARIC 108/1152 100/1191 20.1 1.12[0.86,1.45] 
Subtotal(95%CI) 38716107 282/5171 62.7 1.09[0.94,1.25] 
Chi-square 10.44 (df=8) P: 0.24 Z=1 . 14 P: <0.00001 
02 Ages 75-84 
Framingham Eye Study 94 / 313 421174 11.0 1 . 24[0.91,1 . 70] 
Melton Mowbray 51 177 9/15 3.1 1.10[0.71,1.72] 
Copenhagen Study 321123 341119 7.1 0.91 [0.60,1.37] 
Beaver Dam Eye Study 351451 15 /266 3.9 1.38[0.77,2.47] 
Rotterdam Study 301788 16 / 456 4.1 1.09[0.60,1.97] 
Blue Mountains Eye S 23 / 374 121279 2.8 1.43[0.72,2.82] 
Subtotal(95%CI) 265/2126 128/1309 1 , 1111- 32.0 1.17[0.97,1.41 1 
Chi-square 2.35 (df=5) P: 0.80 Z=1 . 60 P: 
0.02 
03 Ages 85+ 
Rotterdam Study 291253 7173 2.2 1.20[0.55.2.621 
Blue Mountains Eye S 27/407 131299 3.1 1.5310.80,2.911 
Subtotal(95%CI) 56/660 20/372 5.3 1.39[0.84,2.28] 
Chi-square 0.86 (df=1) P: 0.35 Z=1 . 29 P: 0.4 
Total(95%CI) 70818893 430/6852 100.0 1.13[l. 01.1.261 
Chi-square 13.65 (df=16) P: 0.62 Z=2.1 3 P: <0.00001 
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Tables and figures 
2.1 MRC TRIAL OF THE ASSESSMENT AND MANAGEMENT OF OLDER 
PEOPLE IN THE COMMUNITY 
2.1.1 Background to the MRC Trial 
The study of visual impairment and macular degeneration reported in this thesis is an 
add-on study to the MRC trial of the assessment and management of older people in the 
community. The MRC trial is a large community-based randomised trial taking place in 
England, Wales and Scotland (Britain). Participating practices belong to the MRC 
General Practice Research Framework (GPRF) which is a network of practices 
interested in research, co-ordinated by the MRC GPRF Co-ordinating Centre, now 
based at the Clinical Trials Unit, University College, London. 
The MRC Trial was undertaken because surveys in the UK population indicated that 
many older people have health problems that are undetected, including visual 
impairment. However, there was little evidence as to whether assessment of people aged 
75 years and above in general practice would be effective in reducing the risk of 
mortality, hospital and institutional admissions, or whether it would have measurable 
benefits on quality of life. Despite the lack of evidence, the Department of Health 
Contract of Service with General Practitioners 1990 required that general practitioners 
should invite all patients aged 75 and over to a consultation. It was required that 
assessment should include sensory function, mobility, mental condition, physical 
condition including continence, use of medicines and social environment. There was 
little direction as to exactly what form the assessment should take or the best way of 
managing the problems identified. Different methods of initial assessment can be used - 
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such as postal, lay person or nurse - and screening can be universal, i. e. comprehensive, 
or targeted. Whether health problems identified should be dealt with by primary care 
professionals or using specialist geriatric assessment was also unclear. 
2.1.2 Overview of MRC Trial study design 
The aim of the MRC Trial was to determine the best method of assessing and managing 
people aged 75 years and above in primary care within the context of the 1990 
Contract(Fletcher et al. 2002). The principal investigators were Professor Astrid 
Fletcher, Dr Dee Jones, Professor Chris Bulpitt and Dr Alastair Tulloch. Details of the 
study team are shown in Appendix A. 
The study compared two different types of assessments ("targeted" versus "universal") 
and two different management models ("primary care team" versus "multidisciplinary 
geriatric evaluation team"). Figure 2.1 shows the design of the study. 
General practices recruited through the GPRF were randomly allocated to the two 
different types of assessment. In the "targeted" arm, patients were given a brief 
questionnaire followed up by a detailed examination by a practice nurse if any 
(predetermined) responses indicated potential problems, i. e. if they "triggered". The 
triggers were set to allow an approximate 20% referral rate for detailed assessment. 
Table 2.1 shows the details of the brief assessment questionnaire questions. It covers all 
areas covered in the GP contract with a few extra questions on alcohol consumption, 
cigarette smoking and physical activity. 
In the "universal arm" all patients were given both a brief assessment and a detailed 
examination. The detailed examination covered all the same health issues as the brief 
assessment but included objective measures as well. For example, in the brief 
assessment participants were asked "Do you have a problem reading newsprint even 
while wearing glasses? " while in the detailed examination they were given a visual 
acuity test. Other objective tests in the detailed examination included whispered voice 
test for hearing, Mini Mental State Examination (MMSE) for cognitive impairment and 
the Geriatric Depression Scale (GDS). Physiological measurements e. g. blood pressure, 
heart rate and a full biochemical screen were undertaken, with additional laboratory 
investigations in response to appropriate abnormal findings e. g. faecal occult testing for 
a positive response to blood in the stools. Functional ability and social difficulties were 
also assessed. 
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Two different methods of assessment were tested: administering a brief questionnaire 
versus giving a detailed examination by a nurse, with very different cost implications. 
Within each arm of the trial, the practices were randomly allocated to three different 
ways of administering the brief questionnaire: postal, lay or nurse. 
In the detailed examination the practice nurse followed a standard protocol to refer the 
patient onto a "management team", other medical services or agencies and emergency 
referrals to the general practitioner. In the case of vision, if a participant had a pinhole 
corrected 1ogMAR visual acuity score of 0.5 or more (equivalent to less than 6/18 
Snellen acuity) in either eye the nurse was required to refer them to an ophthalmologist, 
if the problem had not been previously identified. If uncorrected acuity of 0.5 or more 
corrected to less than 0.5 with a pinhole the participant was advised to see an optician. 
Each practice was randomly allocated to two different types of "management team" - 
the primary care team or the local hospital geriatric multidisciplinary team. As the 
details of this stage of the trial are not relevant to the causes of visual impairment add- 
on study, it is not discussed further. 
In the add-on study reported here, data from the 53 practices in the "universal arm" only 
were used as everyone had a visual acuity test in these practices. 
2.1.3 MRC Trial study population 
The recruitment of practices was by invitation letter to all the practices in the GPRF. 
Practices then volunteered to take part. For practices who agreed, in principle, to take 
part the "local" geriatrician was then approached and invited to participate (with a view 
to the second stage randomisation). The aim of the study was to recruit practices which 
were representative of the UK population. In order to ensure a good distribution of 
practices from different socio-economic areas and different health states of population, 
the practices were recruited according to indicators of deprivation (Jarman score 
(Jarman 1983)) and health (standardised mortality ratio (SMR)). The Jarman score is 
derived from ward percentages of the following census variables: elderly people living 
alone; households with children under 5 years; one parent families; unskilled manual 
workers; unemployed people; overcrowded households; residents who have changed 
address in the previous year; and head of household born in the new commonwealth. A 
higher score indicates more relative deprivation. 
82 
A total of 106 practices were recruited with 43,219 people aged 75 years and above 
eligible to take part in the study. Table 2.2 shows the distribution of the practices 
according to tertiles of Jarman score and SMR. Table 2.3 shows the random allocation. 
All patients aged 75 years or over on the general practitioner list were included in the 
study, unless they were in long stay hospital or nursing homes, or were terminally ill at 
the time of the study. 
2.1.4 Outcome measures in the MRC Trial 
The main outcome measures for the trial were mortality, hospital admissions and length 
of stay and institutional admissions including long stay hospitals, (geriatric, or 
psychogeriatric), local authority residential and nursing homes and private nursing 
homes. Quality of life was also an outcome measure and was assessed in a randomly 
selected subset of practices (n=23). 
Follow-up for mortality was undertaken by the Office of National Statistics, Southport, 
who notified the trial co-ordinators when a trial participant had died. They provided data 
on the date and cause of death which was coded according to International 
Classification of Disease Revisions 9 and 10(WHO 1977; World Health Organization 
1992). 
The practice nurse collected information on hospital admissions for each participant by 
hospital discharge letters contained in the participant's GP medical notes. Hospital 
admissions were recorded for two years after recruitment into the trial. Institutional 
admissions were collected on an ongoing basis for each patient, up until October 2000. 
Quality of life interviews took place before the trial assessments (baseline) and 18 
months and 36 months following the baseline interview. Quality of life was measured 
using three instruments - the Sickness Impact Profile(Bergner et al. 1981), the 
Philadelphia Geriatric Centre Morale Scale(Lawton 1975) and the SF-36 health survey 
questionnaire. The interviews were undertaken by research fieldworkers who were 
independent of the practice nurses. 
Use of services was ascertained by cross sectional and longitudinal sampling throughout 
the study in order to provide a full economic evaluation. 
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2.1.5 Ethics approval 
The MRC Trial was approved by all the relevant local research ethics committees. 
2.1.6 Date of data collection 
Data collection began in April 1994 and finished in November 1999, however, the 
majority of assessments (99.7%) were done between 1995 and 1998. 
2.2 MEASUREMENT OF VISUAL IMPAIRMENT 
2.2.1 Measurement of visual acuity at the detailed assessment 
Visual acuity was measured at 3 metres with a Glasgow Acuity Chart which measures 
the minimal angle of resolution on a logarithmic scale (LogMAR)(McGraw and Winn 
1993). This chart was originally developed for use in children but has been shown to 
give equivalent measurements to the Bailey-Lovie chart in adults(McGraw et al. 2000), 
and has been used in other surveys in the elderly(van der Pols et al. 2000). This chart 
was chosen because it met the requirements for a simple visual screening test to be 
conducted in general practice and as part of the over 75s health check. As well as 
applying modern scientific principles to the measurement of visual acuity, it was cheap 
and portable. The nurses also could use the chart on home visits. 
Binocular vision was measured first, followed by vision in the right and left eyes. 
People with a logMAR vision of 0.5 or more in either eye (equivalent to less than 6/18 
Snellen acuity) were tested again using a pinhole occluder. Everyone with a pinhole 
vision of 0.5 or more in either eye was referred to an ophthalmologist by the general 
practitioner. People whose vision improved from 0.5 or more to less than 0.5 were 
advised to see an optician. All vision measurements were conducted while wearing 
usual spectacle correction; participants were asked to bring their glasses with them. All 
patients were also asked about their vision and whether they were on the blind or partial 
sight register. 
Study nurses attended a two day training session in the trial protocol which included a 
training session run by myself on how to use the chart. This included ensuring the 
measurement was taken as far as possible under standardised conditions at the correct 
distance and with optimum lighting. All nurses received regular quality control visits 
from a regional trainer who checked their performance against a checklist. In addition, I 
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reviewed the data periodically and gave feedback to the nurses at annual workshops and 
in newsletters. Sections of the training manual relating to vision screening and the 
regional trainer checklist are shown in Appendix B which also includes a comparison of 
the Snellen notation and logMAR acuity score. 
2.2.2 Definitions of visual impairment and blindness 
Visual acuity is measured on a continuous spectrum. There is considerable variation in 
the cutpoints and terminology used. The International Classification of Diseases 10th 
edition (ICD10)* defines low vision as a visual acuity of less than 6/18, but equal to or 
better than 3/60 in the better eye with best possible correction and blindness as visual 
acuity of less than 3/60 or corresponding visual field loss in the better eye with best 
possible correction. In this study, binocular presenting vision is used to describe the 
level of vision that the person uses in everyday life with usual spectacle correction. 
Although not reporting best corrected vision, the terminology of ICD 10 and the same 
cut points for visual acuity to describe binocular low vision and blindness are used. The 
term visual impairment includes both low vision and blindness. 
Visual impairment overall was defined as a binocular acuity of <6/18 Snellen acuity 
(logMAR score of 0.5 or more), low vision as a binocular acuity of <6/18 to 3/60 
Snellen acuity (logMAR score 0.5-1.375) and blindness as <3/60 Snellen acuity 
(logMAR score of 1.4 or more, that is, could not read the Glasgow acuity chart at one 
metre). Visual acuity for the better eye was used if binocular visual acuity data were not 
available. 
Some people already registered as blind or partially sighted were not given a visual 
acuity test. This may be because the participant was reluctant to have a test that they 
knew could not confer any benefit. People who reported that they were on the blind 
register were counted as blind. People who reported that they were on the partial sight 
register were counted as low vision. Registration status was cross-checked with the 
general practitioner medical notes. 
http: /%'Nk , N"%'v Who. 
illtim topicsiblindness en%iridex. htrnl [accessed October 2"d 2001] 
85 
2.3 CAUSES OF VISUAL IMPAIRMENT ADD-ON STUDY 
2.3.1 Procedures 
All of the 53 practices taking part in the universal arm of the MRC trial were 
approached to take part in the causes of visual impairment study; 49 practices agreed to 
take part. For those who agreed to take part the following procedures took place. 
First, a list of visually impaired people was compiled. For the purposes of this study, 
visual impairment was defined as presenting binocular acuity of less than 6/18. Overall, 
there were 1,742 (12.5%) people binocularly visually impaired in the 49 practices taking 
part. Of these, 450 (26%) achieved a pinhole acuity in either eye of 6/18 or better. In 
these people, the principal reason for visual loss was considered to be refractive error. 
There were, therefore, 1,292 people in 49 practices for whom a cause of visual loss was 
sought. 
Each study nurse was sent a list of people with visual impairment for their practice. 
Each person was identified only by a unique number that enabled the study nurse to 
locate the general practice notes. The study nurse abstracted diagnostic information 
from the general practitioner notes. This diagnostic information was obtained from 
correspondence between the hospital ophthalmologist and general practitioner. The 
nurse used a form that included: date of correspondence, source of correspondence, 
results of any visual acuity test, diagnosis, treatment (see appendix C). The nurse also 
recorded the name and hospital of the last ophthalmologist seen. All correspondence 
relating to eye disease was abstracted, in addition to the correspondence resulting from 
the MRC Trial examination. Each form was completed at least six months after the 
detailed assessment in order to give time for the results of any referrals to come 
through. If any participant had died in the interim, their notes were obtained by the 
practice nurse from the appropriate Family Health Services Authority. 
In order to validate the causes of visual loss derived from coding the diagnostic 
information obtained from the general practitioner notes, a one-page questionnaire was 
sent to the hospital ophthalmologist who had last seen the patient (see appendix C). This 
questionnaire was in the form of a check-list by eye that covered: age-related macular 
degeneration (exudative, geographic atrophy), cataract (age-related, congenital, other), 
glaucoma (primary open-angle, primary closed-angle, other), 
diabetes (diabetic 
retinopathy, other), myopic degeneration, other (specify). The ophthalmologist was 
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asked to rank, if possible, any conditions ticked in order of their contribution to cause of 
visual loss. In addition, they recorded which eye lost vision last and visual acuity at last 
examination. 
If no reply was received from the ophthalmologist, one reminder letter was sent. Each 
ophthalmologist was offered a small payment (£20 per form) to compensate for the time 
involved. 
2.3.2 Ethics approval 
As this was additional data collection to that originally in the protocol for the MRC 
Trial I obtained approval from all the relevant local research ethics committees. 
2.3.3 Date of data collection 
Data collection took place between 1996 and 2000. 
2.3.4 Coding cause of visual loss 
All forms were returned to myself and coded twice in order to minimise any errors. A 
maximum of three diagnoses was recorded. The aim was to identify the cause of visual 
loss for the person. The main cause of visual impairment was taken to be the cause of 
visual loss in the eye that lost vision last. Appendix D sets out the coding scheme. 
If there were co-existing conditions which made it difficult to assess which was the 
major cause of visual loss then two options were followed. If there was enough 
information then the condition least amenable to intervention was chosen. For example, 
if a person had co-existing cataract and AMD, and the hospital ophthalmologist had 
decided that surgery for cataract was not worthwhile because of the macular 
degeneration, then AMD was coded as the main cause of visual loss because the person 
was unlikely to have vision restored after cataract surgery. If the situation was not so 
clear cut, then both conditions, for example, AMD and cataract were coded as 
contributory causes of visual loss. In effect, there was uncertainty as to which condition 
was most responsible for the visual loss. 
The medical notes provide a longitudinal record of visual deterioration. However, the 
detailed assessment of the MRC Trial was a cross-sectional study. As the ophthalmic 
examinations did not often coincide with the MRC Trial detailed examination the 
following assumptions were made when coding the general practice medical notes: 
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" that chronic causes of visual loss (such as AMD, cataract, glaucoma etc) recorded 
before the detailed examination were present at the detailed examination, unless 
otherwise indicated. 
9 that chronic causes of visual loss recorded within one year after the detailed 
examination were present at the detailed examination, unless otherwise indicated. 
" that if the first recorded ophthalmic examination occurred more than one year after 
the MRC Trial, any chronic causes of visual loss reported at this ophthalmic 
examination was assumed to be the most likely cause of visual loss at the detailed 
examination. 
2.4 CLASSIFICATION OF AMD 
The following coding schema was used for age-related macular degeneration. 
(1) Definite AMD, type unspecified 
The following terms, recorded by a hospital ophthalmologist in correspondence with the 
general practitioner. 
9 Age-related macular degeneration or Senile macular degeneration. 
(2) Definite exudative AMD 
The following terms in conjunction with a diagnosis of age-related macular 
degeneration 
" Neovascular, Exudative, Disciform, Pigment epithelial detachment, Wet 
" Any terms relating to new vessel growth and/or leakage/haemorrhage in the retina 
(3) Definite geographic atrophy 
"A diagnosis of age-related macular degeneration combined with any definite 
statement that the condition was "dry" or that there was no evidence of new 
vessels/leakage on fluoroscein angiography. 
(4) Possible AMD 
" Macular degeneration/disturbance with onset after 50 with no obvious cause but that 
was not directly described by the ophthalmologist as "age-related". This was also 
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subdivided into exudative disease and geographic atrophy according to the 
definitions above. 
" Age-related macular degeneration or macular degeneration described by an optician 
or other health professional. 
2.5 LINKED DATA FROM THE MRC TRIAL 
The aims of the study are set out in chapter one and briefly summarised here: 
(1) To estimate the prevalence of AMD causing visual impairment in people aged 75 
years and above in the United Kingdom, and to investigate how this varies by age, 
sex, socio-economic status and region. 
(2) to investigate the impact of AMD causing visual impairment on the lives of people 
aged 75 years and above in the UK: specifically, its impact on: 
" functional ability 
" health-related quality of life 
9 psychological well-being 
9 emotional well-being (life satisfaction and morale) 
9 mortality 
9 morbidity 
(3) To investigate the aetiology of visually impairing AMD in people aged 75 years and 
above in the UK, that is, to test the following hypotheses: 
" that smoking cigarettes and drinking alcohol are associated with an increased 
risk of visually impairing age-related macular degeneration; 
" that reproductive factors indicating increased oestrogen exposure in women are 
protective for developing visually impairing age-related macular degeneration; 
" that people with evidence of cardiovascular disease are at increased risk of 
developing visually impairing age-related macular degeneration; 
Collection of data on visual acuity (in the MRC Trial) and cause of visual loss (by me) 
are described in sections 2.2 to 2.4. The other data (indicated 
in bold above) were all 
collected during the course of the MRC Trial and are described 
below. All data were 
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collected during the detailed assessment that was done by the MRC Research Nurses as 
part of the MRC Trial, unless otherwise indicated. 
2.5.1 Age, sex and socio-economic status 
Age and sex were derived from the general practice registers. They were checked at the 
time of the detailed assessment and cross-checked with data on cause of death from the 
Office of National Statistics, where available. 
There were several measures of material wealth collected on all participants in the MRC 
Trial. The most important one was housing tenure. This is a commonly used indicator 
of socio-economic status and is particularly appropriate in the elderly as other measures 
depend on classification of occupation. Housing tenure was divided up into "owner 
occupier" and "rented" accommodation. In addition, a proportion of the population aged 
75 years and above live in the MRC Trial were living in "sheltered" accommodation. 
Participants were also asked whether they had central heating, access to an indoor toilet, 
difficulty keeping their home warm and/or difficulty making ends meet. For each of 
these variables, the numbers of people responding "negatively" were small. An overall 
socio-economic status score, including housing tenure, was constructed as follows: 
Question Score 
Housing tenure Home owner=0 
Rented accommodation= I 
Do you have central heating? Yes or missing=O No=1 
Do you have an indoor toilet? Yes or missing=O No=1 
In the last year have you had difficulty keeping your home warm? Yes or missing=l No=O 
Do you ever having difficulty making ends meet, I mean, is it Yes or missing=l No=O 
difficult to find the money to pay your bills? 
The score ranged from 0 to 4 and was set to missing for people who had missing data 
for every question. People who were in sheltered housing were excluded as these 
measures are not meaningful in that context. 
In the randomly selected subset of practices in which quality of life was assessed, 
participants were asked about their occupation, usual for "most of their working life". 
The quality of life interviews were administered by independent interviewers. 
Occupation was coded according to the Registrar General Classification of Social Class 
by clerical officers at LSHTM. This divided the study sample into social class groups. 
For married and widowed women, the husband's occupation was used. This gives a 
measure of socio-economic status during lifetime rather than current status. 
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2.5.2 Impact 
Functional ability 
Two single-item measures of functional ability were used. Participants were asked "Do 
you have difficulty in seeing newsprint, even when you are wearing your glasses? " and 
"Do you have difficulty managing your finances, I mean paying bills, working out 
change etc? " 
One multi-item measure of functional ability was used: the Activities of Daily Living 
(ADL) scale(Katz et al. 1963). In the MRC Trial eight questions were asked regarding 
Activities of Daily Living and Instrumental Activities of Daily Living. Participants are 
required to indicate the level of difficulty (No difficulty/Some difficulty/Unable to do) 
that they have performing basic tasks. The following activities were assessed. 
Activity Coding 
Activities of Daily Living O=No data 
Cut your own toenails 1= No difficulty 
Dress yourself including zips or buttons 2=Some difficulty 
Go up and down stairs and steps (if necessary using a frame, tripod or 3=Unable to do alone 
stick) 
Wash all over (including bathing or showering) 
Walk 50 yards down the road (if necessary using a frame, tripod or 
stick) 
Instrumental Activities of Daily Living 
Cook a hot meal 
Do light housework or simple repairs 
Do shopping 
A composite score was created by adding the scores for each variable. The resultant 
score ranged from 0 to 24. People who scored 0 i. e. had no data for all categories were 
set to missing. People who had some data for each category, some of which indicated 
difficulties were counted as missing. People who had some data, all of which indicated 
no difficulty were included. The score was divided up into quintiles. People in the worst 
quintile for ADL score had some difficulty, or were unable to do alone, the following 
tasks: do shopping (99.9%), cut their own nails (98.6%), go up and down stairs (96.0%), 
do light housework (95.9%), walk 50 yds (93.0%), wash all over (91.0%), cook a hot 
meal (84.3%), dress themselves (66.3%). This pattern of disability reflects that seen in 
longitudinal studies where it has been observed that tasks requiring lower-extremity 
strength such as walking and washing are lost before those requiring upper-extremity 
strength, such as cooking and dressing (Dunlop et al. 1997), (Jagger et al. 2001). 
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Psychological well-being 
Cognitive ability was measured using the MMSE(Folstein et al. 1975). This consists of 
a series of tasks testing recall (remembering three words); mental arithmetic 
(subtracting from 100); spelling backwards; naming everyday objects; repeating a 
sentence; following a 3-stage command; reading a simple instruction and following it 
correctly; writing a sentence; copying a drawing. The resulting score ranges from 0 to 
30 with higher scores indicating better cognitive ability. The score was divided to create 
a dichotomous variable to indicate people with poor cognitive ability. 
There are two sections: a verbal section with a maximum score of 21 and a performance 
section (that involves, for example, copying a drawing) with a maximum score of nine. 
For physical or educational reasons not all people are able to complete the performance 
section. In the MRC Trial this was decided by the nurse administering the questionnaire. 
Separate cut-off points are used depending on whether or not the performance section 
was completed. The cut off points of less than 17 for the whole test or less than 12 if the 
performance section was not completed were used. In order to remove any potential 
effects of poor vision on ability to complete the test, independent of cognitive ability, 
only the verbal section was used. 
Depression was assessed using the GDS- 15. This is a set of 15 short questions (with 
yes/no answers) about feelings over the last week(Sheik and Yesavage 1986; Yesavage 
et al. 1982). The total possible score is 15 with higher scores indicating worse 
depression. The cutoff point used to define depression was <6/6+ as this has been used 
in other studies in the MRC Trial(Osborn et al. 2002). It was chosen for the cutpoint 
because it gives a higher specificity for depression (between 74% and 82%) than other 
thresholds such as <3/3+ and <5/5+ which have been used by other authors. 
Health-related quality of life and morale 
One global item was used: "Compared to other people of your own age would you say 
that your health is generally: excellent, good, fair or poor? " 
Health-related quality of life was also measured using the Sickness Impact Profile (SIP) 
in a randomly selected subset of practices. The quality of life 
interviews were 
administered by independent interviewers. The SIP was 
developed to provide a measure 
of perceived health status, broadly applicable across different 
illnesses(Bergner et al. 
1981). It is similar to the ADL scale in that it aims to measure the actual performance of 
92 
activities, however, it is much broader in scope. In its full form it consists of 136 
statements about health-related function in 12 different areas: sleep and rest, eating , 
work, home management, recreation and pastimes, ambulation, mobility, body care and 
movement, social interaction, alertness behaviour, emotional behaviour and 
communication. In the MRC Trial, four of these areas were assessed: home 
management, mobility, body care and movement and social interaction. A full 
description of the questions asked is in appendix E. 
People could choose one of three responses in the SIP: "yes, and due to health"; "yes, 
and not due to health"; and "no". The scores used in this thesis include any "yes" 
answers, whether due to health or not. The item answers were weighted using British 
weights from the Lambeth Disability Study and the total converted into a percentage of 
the maximum. Higher scores mean lower quality of life. 
Emotional well-being (life satisfaction and morale) was assessed using the Philadelphia 
Geriatric Morale Scale (PGMS). The PGMS is a series of questions, all in a 
dichotomous format, that aim to measure the morale of older people (Lawton 1975). See 
appendix E for the list of questions. The resultant score ranges from 0 to 17 with higher 
scores reflecting a worse morale. 
Other authors have examined the characteristics of people in the worst quintile for 
PGMS score in the MRC Trial cohort (Breeze 2002). People in the worst quintile for 
PGMS score reported that "things kept getting worse as they got older" (91 %), that they 
"took things to heart" (90%), did not have as much energy as they did last year (88%), 
that they felt less useful as they got older (88%), that they were not as happy now as 
when younger (81 %) and got upset easily (80%). 75% reported that as they got older 
things were not better than expected and 73% that "little things bothered them more" 
this year. 
Mortality 
Follow-up for mortality was undertaken by the Office of National Statistics, Southport, 
who notified the trial co-ordinators when a trial participant had died. They provided data 
on the date and cause of death. 
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Morbidity 
The participants were asked "In the last six months, how many falls have you had at 
home? " They were also asked "Has a doctor ever told you that you had a fractured 
hip? `) 
Potential confounding factors 
There were several variables indicating the living circumstances of the participants in 
the MRC Trial, that is, whether they live alone, care for someone else, have access to 
help, and frequency of seeing friends/neighbours or relatives. 
Other sensory impairments include hearing loss. This was measured using the 
"whispered voice test" (Swan and Browning 1985). The nurse stood behind the patient 
at a distance of 15 centimetres and whispered three words, after having exhaled. If the 
participant was unable to repeat these items, the test was done again. In the case of 
people who failed the test twice, the ears were examined for wax and syringed if 
necessary, after which time the test was repeated again. The whispered voice test has 
been found to have sensitivity of between 80% and 100% and specificity of between 80 
and 89% when compared to hearing loss in the range 30 to 40 decibels measured by 
pure tone audiometry (Smeeth et al. 2002b). The test was performed with any hearing 
aids worn at the time of testing, thus testing the participants' everyday hearing. 
Other potentially confounding factors are discussed in the next section. 
2.5.3 Risk factors 
Cigarette smoking 
Smoking history was ascertained using an interviewer-administered questionnaire. The 
questions used came from the Whitehall study (de Mheen et al. 2001). Participants 
were asked whether they smoked currently. For people who responded no, they were 
asked whether they had ever smoked cigarettes. Age smoking started and stopped was 
also elicited and the number of cigarettes (ozs tobacco) smoked a day. One ounce of 
tobacco was assumed to correspond to 30 cigarettes. 
The following variables were created: 
9 Smoking status 1=Never smoked 2=Ex-smoker 3=Current smoker 
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" Pack-years were calculated from the number of years participants had smoked, 
multiplied by the usual daily cigarette-equivalent intake, and divided by 20. This 
gives a measure of the lifetime exposure dose received. 
" The number of years since stopping smoking was calculated from the current age 
minus the age stopped smoking. People who were still smoking had a value of 0; 
people who had never smoked were excluded from this variable. 
Alcohol consumption 
Alcohol consumption was ascertained using an interviewer-administered questionnaire. 
Each participant was asked whether they had had an alcoholic drink during the past 
year. For those responding yes, they were asked to quantify their consumption in the 
past week. The number of drinks of spirits (single), wine (glass) or beer (half pint) was 
recorded. Each of these measures corresponds approximately to one unit of alcohol 
equivalent to 8g of ethanol. The total number of units of alcohol consumed in the 
previous week was calculated. 
In order to assess whether patterns of alcohol consumption had changed, each 
participant was asked whether or not they drank more, less or about the same today 
compared with five years ago. People who were non-drinkers were asked whether they 
had always been a non-drinker, and, if they had stopped drinking why they had stopped. 
Cardiovascular disease 
Participants were also asked about a history of cardiovascular disease. "Has a doctor 
ever told you that you had any of the following? If yes, was that in the last year? " High 
blood pressure and/or heart attack and/or stroke. 
The Rose Chest Pain Questionnaire was used to identify people with definite or 
probable angina (Rose et al. 1977; Bulpitt et al. 1990). 
Systolic blood pressure was measured using a random zero sphygmanometer after the 
participant had rested for at least three minutes. The sitting blood pressure was repeated 
after another three minutes rest, followed by standing blood pressure after three minutes 
rest. It was recorded to the nearest 2mmHg. If the pressure was greater or equal to 
180mmHg, the test was repeated one week later. 
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Body mass index 
Weight and height were measured and body mass index calculated as weight (kg)/height 
(metres)2. Body mass index was grouped into the following groups: less than 20 
(underweight), 20 to less than 25 (normal), 25 to less than 30 (overweight), 30 and 
above (obese). 
Reproductive factors (in women) 
Women were asked about their menstrual history, that is, age at menarche and 
menopause. "How old were you when you had your first menstrual period? " and "How 
old were you when you had your last menstrual period? " and "Did your periods stop 
naturally, because of surgery or for some other reason? " They were also asked about 
number of pregnancies and children. "Have you ever been pregnant (including 
miscarriages and stillbirths)? How many children, including stillbirths, have you had? " 
Years of menstruation was analysed as a continuous measure and also sub-divided into 
quartiles. A cut-off point to define the 10 % of women with early menopause (40 years 
or less) was also used. In order to compare with previous studies, women with 
menopause at less than 45 years due to surgery were identified. 
2.6 STATISTICAL METHODS 
2.6.1 Data entry and cleaning 
The data from the main MRC Trial were collected on specially designed forms that 
were scanned directly onto computer. Range checks were conducted by Edmond Ng and 
Elizabeth Breeze and clerical officers (see Appendix A for details of MRC study team). 
For the visual acuity data, I did further range checks and basic consistency checks (for 
example, checking that visual acuity scores were compatible with the distance at which 
the measurement was done). Clerical officers at LSHTM checked any odd values by 
looking at the original data forms. 
The data from the cause of visual impairment questionnaire and hospital 
ophthalmologist form were entered onto a customised Access 
database with range and 
consistency checks built into the program. Both sets of data were entered twice and 
errors checked. Prior to analysis, range and consistency checks were 
done and raw data 
checked. 
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2.6.2 Variable format 
Some variables were in a binary format e. g., reported fractured hip/not reported 
fracture hip; many were in the form of a score or scale. The distribution of the scale was 
examined. If it was normally distributed, or could be transformed to a normal 
distribution, it was analysed as a continuous variable. If it was skewed it was divided up 
into quintiles, and a binary variable derived whereby 0=not in worst quintile 1= in 
worst quintile ("worst" quintile indicates most severely affected or poorest outcome). 
In some cases an a priori cutpoint was used as identified in the literature review, e. g., 
for the Geriatric Depression Scale a score of 6+ was used to define depression (Sheik 
and Yesavage 1986). 
2.6.3 Taking into account the cluster design of the study 
Classical statistical techniques and regression models share a common assumption that 
individual observations are statistically independent of each other. In the MRC Trial, 
treatments were assigned at the general practice level, therefore general practices, rather 
than individual patients, were selected to take part in the study. Observations on 
individuals within the same general practice may be correlated. Therefore, the 
assumption of statistical independence does not hold for the data presented in this 
thesis. Ignoring the extra variation introduced by clustering may lead to an incorrect 
interpretation as confidence intervals, in general, will be narrower and p-values smaller 
than they should be (Skinner et al. 1989). 
A simple way round this problem is to calculate a single summary measure for each 
cluster (i. e. each practice). This would be feasible for simple analyses, for example, in 
presenting the overall prevalence of visual impairment, however, it is difficult to take 
into account the effects of factors that occur at the individual level, such as age and sex, 
using this method. 
There are three possible options for analysing clustered data at the individual level. 
Calculating "robust" standard errors, using population average models (generalised 
estimating equations) or random effects models (multilevel models). Random effects 
models are theoretically preferable because they specify a full probability model, 
however, they have problems when dealing with binary outcomes, as is the case for 
most of the analyses in this thesis. All regression analyses took account of the cluster 
design of the study using the "svy" commands in Stata (StataCorp 2001). These 
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commands calculate semi-robust confidence intervals, allowing for clustering within 
practices (Eltinge and Sribney 1996). 
Associations between categorical variables were tested using the chi-square test 
adjusted for the clustered design of the study (Rao and Thomas 1989). 
All data were analysed at the individual person level or the practice level. There was 
therefore no need to take into account correlation between eyes. 
All analyses were done using Stata version 7.0. 
2.6.4 Analysis strategy 
The majority of the data reported in this thesis are cross-sectional, i. e. outcomes and 
exposures were collected at the same point in time. 
The analysis strategy varied according to the different research questions. 
(1) Prevalence study (chapter three). 
The overall strategy for analysis was to estimate the prevalence of AMD causing visual 
impairment, including confidence intervals taking into account the cluster design (see 
above). The prevalence of AMD was estimated in different socio-economic groups and 
by region. Age and sex were considered as potential confounding factors. The main 
methodological issues were the possible effects of missing data on the prevalence 
estimates. 
The effect of missing data (non-response) 
In this study of AMD causing visual impairment, there were two steps. Firstly, I 
estimated the prevalence of visual impairment. Secondly, I considered how much of the 
visual impairment identified was due to AMD. 
The prevalence of visual impairment in people who were eligible to take part in the 
study, but who were not examined for whatever reason, is unknown. The implicit 
assumption in the figures presented in this chapter is that the prevalence of visual 
impairment in non-responders was similar to that in people examined. I calculated the 
prevalence of visual impairment as n/N where n=number of people visually impaired 
and N=number of people with data on vision in the MRC Trial. 
I investigated the cause of visual loss for everyone who was visually impaired in the 
MRC Trial. For some of these people, I could not find out why they had a measured 
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binocular acuity of less than 6/18 at the detailed examination in the MRC Trial. A 
conventional approach would be to assume (as for visual impairment above) that 
missing data were similar to the non-missing data. However, during data collection I 
was aware that the people for whom I could not identify the cause were likely to be 
different to those for whom I could. For example, the medical notes of people who had 
died since the detailed examination were less likely to be available as they leave the 
practice and were not always returned upon request. People who had a longstanding 
eye complaint and who had been registered blind or partially sighted were more likely 
to have data on cause of visual loss in their medical notes. I therefore felt it unwise to 
make any assumptions about people for whom I could not identify the cause of visual 
loss. I calculated the prevalence of AMD causing visual impairment as follows: na/N 
where na number of people visually impaired due to AMD and N=number of people 
with data on vision in the MRC Trial. This assumes that none of the people whom I 
knew to be visually impaired but for whom I could not find out the cause of the visual 
loss were visually impaired due to AMD. In section 3.4 I also present alternative 
prevalence figures calculated with less conservative assumptions. 
Coding cause of visual loss 
In this study, the aim was to identify the cause of visual loss for the person. For each 
person identified as visually impaired the cause of visual loss in the last eye to lose sight 
was identified, where possible. If there were co-existing conditions which made it 
difficult to assess which was the major cause of visual loss then two options were 
followed. If there was enough information then the condition least amenable to 
intervention was chosen. For example, if a person had co-existing cataract and AMD, 
and the hospital ophthalmologist had decided that surgery for cataract was not 
worthwhile because of the macular degeneration, then AMD was coded as the main 
cause of visual loss because the person was unlikely to have vision restored after 
cataract surgery. If the situation was not so clear cut, then both conditions, for example, 
AMD and cataract were coded as contributory causes of visual loss. In effect, there was 
uncertainty as to which condition was most responsible for the visual loss. 
The medical notes provide a longitudinal record of visual deterioration. However, the 
detailed assessment of the MRC Trial was a cross-sectional study. As the ophthalmic 
examinations did not often coincide with the MRC Trial detailed examination the 
following assumptions were made when coding the general practice medical notes: 
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" that chronic causes of visual loss (such as AMD, cataract, glaucoma etc) recorded 
before the detailed examination were present at the detailed examination, unless 
otherwise indicated. 
" that chronic causes of visual loss recorded within one year after the detailed 
examination were present at the detailed examination, unless otherwise indicated. 
" that if the first recorded ophthalmic examination occurred more than one year after 
the MRC Trial, any chronic cause of visual loss reported at this ophthalmic 
examination was assumed to be the most likely cause of visual loss at the detailed 
examination. 
Choice of a comparison group when investigating associations with age, sex, socio- 
economic status and region 
Most of the analyses in this chapter are simple presentations of prevalence figures. 
However, when investigating the independent effects of age, sex and socio-economic 
status, I constructed logistic regression models. These require a dependant variable in 
the format 0=comparison group 1=AMD causing visual impairment. There were several 
options for a comparison group: (i) people with good vision only, (ii) people not 
visually impaired, (iii) people not visually impaired or visually impaired due to other 
causes. I chose (iii) because this model most closely corresponds to the prevalence 
figures with all the population included in the analyses. 
Analysis strategy 
The overall strategy for analysis was to estimate the prevalence of AMD causing visual 
impairment, including confidence intervals taking into account the cluster design (see 
section 2.6.3). 
This prevalence was estimated for the population as a whole, and within different 
subgroups in the population defined by age (four groups, 75-79,80-84,85-89 and 90+) 
and sex. In order to assess the independent effects of age and sex, a logistic regression 
model was developed with AMD causing visual impairment as the outcome (binary 
0=not visually impaired/visually impaired due to other causes, 1=AMD causing visual 
impairment), and terms for age and sex. 
The prevalence of AMD causing visual impairment was estimated in the different socio- 
economic groups. There were three different measures of socio-economic status (see 
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section 2.5.1): housing tenure (owner occupier, rented, sheltered accommodation), 
socio-economic status score which included housing tenure (score=O, score=1 and 
score>2); and social class as indicated by lifetime occupation (five groups). The latter 
measure was available in a sub-sample of 11 practices only. Housing tenure and socio- 
economic score are current measures of socio-economic status. People in sheltered 
accommodation were excluded from the socio-economic status score as measures such 
as having an indoor toilet or keeping the house warm do not apply to people in sheltered 
housing. Social class assessed from occupation is a lifetime measure. 
Age and sex were considered as potential confounding variables, using logistic 
regression models as described above. 
Regional variation was assessed by grouping the 53 practices according to area: 
Scotland, North, Midlands and South. The one Welsh practice was included in the 
Midlands group. 
(2) Cross-sectional analytical study investigating the association between visual 
impairment and AMD and functioning and quality of life and longitudinal analyses of 
the association between visual impairment and mortality (chapter four) 
In these analyses, the variables on functioning, quality of life, morbidity and mortality 
were considered as "outcome" variables with visual impairment due to AMD as the 
"exposure". Possible confounding factors associated both with the outcome and 
exposure were identified and controlled for in logistic regression models. For the 
mortality analyses, Cox proportional hazards models were used. 
The condition "AMD causing visual impairment" has two parameters that might have 
an impact on people's lives: "AMD" and "visual impairment". For that reason the 
analysis consisted of three stages: firstly, visually impaired people were compared to 
non-visually impaired people; secondly, people visually impaired due to AMD, and 
people visually impaired due to other causes were compared to non-visually impaired 
people; lastly, people visually impaired due to AMD were compared directly to people 
visually impaired due to other causes, and binocular acuity score included in the model. 
Interactions by age and sex were investigated. 
AMD and visual impairment 
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The condition "AMD causing visual impairment" has two parameters that might have 
an impact on the lives of people affected: "AMD" and "visual impairment". People with 
AMD had worse acuity than people visually impaired due to other causes (see chapter 
three section 3.4). Controlling for the effects of visual acuity is problematic because 
non-visually impaired people all have binocular acuity 6/18 or better and visually 
impaired people all have acuity of less than 6/18. When considering the effects of visual 
acuity, only visually impaired people were examined. 
"Impact" variables 
Data on impact were drawn from three sources. (1) Data on most of the variables were 
collected by the practice nurse at the time of the brief assessment or detailed 
examination. These were available on almost all the study population. These variables 
were: self-reported health and physical activity, self-reported difficulties seeing, 
activities of daily living, difficulty managing finances, depression, cognitive function, 
falls and hip fractures. (2) More detailed information on health-related quality of life - 
Sickness Impact Profile (SIP) - and morale - Philadelphia Geriatric Morale Scale 
(PGMS) - were collected by independent fieldworkers in a randomly selected subset of 
11 practices only. (3) Data on mortality was collected prospectively by flagging the 
records with the Office of National Statistics. 
The variables indicating "impact" were considered to be the outcome or dependent 
variables. These variables were in different formats. Some were in a binary format e. g., 
reported fractured hip/did not reported fracture hip; many were in the form of a score 
or scale. The distribution of the scale was examined. If it was normally distributed, or 
could be transformed to a normal distribution, it was analysed as a continuous variable. 
If it was skewed it was divided up into quintiles, and a binary variable derived whereby 
0=not in worst quintile 1= in worst quintile ("worst" quintile indicates most severely 
affected or poorest outcome). In some cases an a priori cutpoint was used as identified 
in the literature review, e. g., for the Geriatric Depression Scale a score of 6+ was used 
to define depression (Sheik and Yesavage 1986). 
Identification of potential confounding factors 
Confounding factors were considered to have the following attributes: (Rothman 1986). 
(i) A confounding variable must be a risk factor for the disease (ii) a confounding 
variable must be associated with the exposure under study in the population from which 
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the cases derive (iii) a confounding variable must not be an intermediate step in the 
causal path between the exposure and the disease. 
Potential confounding factors were identified from review of the literature, (see section 
1.4) (Rubin et al. 2001; Rubin et al. 1997; Valbuena et al. 1999; Ivers et al. 1998; Ivers 
et al. 2000; Wang et al. 2001; Wang et al. 2000; Appollonio et al. 1996; Appollonio et 
al. 1995; Carabellese et al. 1993; Brody et al. 2001; Williams et al. 1998; Keeffe et al. 
1998), and previous analyses of the MRC Trial(Osborn et al. 2002; Breeze et al. 2001). 
They were as follows: 
Socio-economic and demographic factors 
" Age and sex 
" Socio-economic status 
" Social support 
Lifestyle factors 
" Smoking and alcohol consumption 
" Body mass index (BMI) 
Other diseases and impairments 
" Hearing impairment 
" History of arthritis 
" History of asthma 
" History of cardiovascular disease 
" Angina 
" Diabetes 
" Urinary incontinence 
" Lower legs swollen in morning 
" Severe shortness of breath 
" Three or more prescribed medicines 
In addition, the following "impact" outcomes could possibly be considered as 
confounders for others. 
" Depression 
" Falls and hip fractures 
" Cognitive impairment 
However, as these confounders are considered as an effect of visual impairment, they 
might be considered to be on the "causal pathway". The analyses were done with, and 
without, these variables as recommended by Rothman (see figures 4.1 to 4.4)(Rothman 
1986). 
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Analysis strategy 
The overall analysis strategy was to determine which of the confounding factors were 
likely to be important by examining whether they were associated with the outcome 
("impact") and with the exposure ("visual impairment by cause"). The association 
between exposure and outcome controlling for confounding variables was assessed 
using logistic (or Cox proportional hazard) models. Having identified which 
confounders were likely to be important, three sets of analyses were done for each 
outcome. Firstly, visually impaired people were compared to non-visually impaired 
people; secondly, visually impaired people were separated into those visually impaired 
due to AMD and those visually impaired due to other causes and the analyses repeated. 
Thirdly, direct comparison was made between people visually impaired due to other 
causes and those visually impaired due to AMD, controlling for visual acuity. 
The following steps were taken in the analysis of each "impact" variable. 
" Potential confounding factors were identified from the literature review (see above). 
Only variables that were significantly associated with visual impairment by cause 
(not visually impaired, visually impaired due to other causes, visually impaired due 
to AMD) (design-based x2 test, p<0.05), were considered further as potentially 
confounding factors. These factors were: housing tenure, smoking, drinking, BMI 
less than 20, hearing impairment, reported stroke, reported diabetes, urinary 
incontinence, lower legs swollen in morning, severe shortness of breath and three or 
more prescribed medicines. 
" The following "outcomes" were also considered as potentially confounding factors 
for other outcomes: depression, cognitive impairment, falls and hip fractures. As 
these could theoretically be considered to be on the causal pathway, analyses were 
done with, and without, these factors. 
" The association between the potential confounding factor and the "impact" variable 
was assessed by constructing a series of logistic regression models with the 
"impact" variable as the outcome and including terms for age (75-79,80-84,85- 
89,90+) sex and the confounding factor. Only confounding factors significantly 
associated with the "impact" variable in question were included 
in further models of 
that variable (see table 4.1). 
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" Estimates of odds ratios and confidence intervals of visual impairment associated 
with outcome, controlled for appropriate confounding factors, were derived from 
separate models for each "impact" variable. These models included terms for age, 
sex and potential confounding factors. 
" In order to control for the effects of differing levels of visual impairment, further 
models were constructed including only visually impaired people, including a term 
for distance visual acuity - binocular acuity score grouped into five equal groups 
(quintiles) and comparing people visually impaired due to AMD with people 
visually impaired due to other causes (referent group). 
" In order to assess whether the effect of visual impairment on outcome was different 
between men and women and at different ages, interaction terms for age*"visual 
impairment" and sex*"visual impairment" were entered into each of the above 
models. The significance of these terms was assessed using the adjusted Wald test. 
Interactions with other potential confounding factors were assessed if there was an a 
priori reason to do so. 
" For the two measures collected on a subset of practices only (SIP and PGMS) as 
numbers of people over 90 years of age was small, age was grouped in three groups 
(75-79,80-84 and 85 years and above). In addition, analyses of these outcomes 
required a different strategy as the data were derived from only 11 practices. It was 
impossible to include all potential confounding factors in the model at the same 
time. The strategy was as follows: each potential confounding factor was introduced 
into a model with age, sex and visual impairment by cause only. If the factor 
changed the effect estimate by 10% or more it was retained as a confounder. 
Otherwise it was dropped. 
" Mortality data were collected prospectively. The incidence rate (number died/person 
years at risk) of mortality was calculated. The person years at risk was estimated 
from the start date of the MRC Trial as that was the date of diagnosis of visual 
impairment for the purposes of this study. The 31St of December 2001 was taken as 
the censoring date if still alive. Analyses were similar as for other "impact" 
variables however the data were modelled using Cox proportional 
hazard model. 
Log-log plots were examined to verify that the proportional hazard rule applied 
(Cox 1972). 
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9 All hypothesis tests and models took into account the cluster design of the MRC 
Trial (see section 2.6.3). 
(3) Case-control study investigating possible risk factors for AMD, including smoking, 
alcohol consumption, reproductive factors and cardiovascular disease (chapter five). 
In this chapter, the outcome under study was case/control status with cases being people 
with AMD causing visual impairment and controls being people with good vision 
(binocular acuity of 6/6 or better). The risk factors (exposures) studied were smoking, 
alcohol consumption, cardiovascular disease and reproductive factors. Logistic 
regression models were used to control for potential confounding factors and 
interactions by age and sex investigated. 
Control selection 
People with AMD causing visual impairment were considered as "cases" and compared 
to a "control" group. There were two different options for selection of the control group. 
Firstly, to compare people visually impaired due to AMD with the rest of the MRC 
Trial study population. This control group would include people visually impaired due 
to other causes and people not visually impaired. The second option considered was to 
compare people visually impaired due to AMD with people with good vision (i. e. visual 
acuity of 6/6 or better). 
The signs and symptoms of AMD form a continuous spectrum. Dichotomising the 
disease, as in many other conditions, is essentially arbitrary. In this study, relatively 
severe AMD cases were selected because a cut-point of visual acuity worse than 6/18 
was used to identify them. It is likely that a small proportion of people with vision 
worse than 6/6 and better than, or equal to, 6/18 will have AMD and a larger proportion 
will have early age-related maculopathy (ARM) i. e. drusen and pigmentary changes 
putting them at increased risk of developing AMD(Bird et al. 1995). 
For this reason, in 
order to minimise the number of controls who have AMD or ARM, a control group of 
people with good vision, i. e. binocular visual acuity of 6/6 or 
better, was selected. 
Controlling for the effects of age 
Visual acuity decreases with increasing age. The control group of people with good 
vision will have a different age structure to the visually 
impaired cases. Table 5.1 shows 
the number of cases and controls by age and sex. 
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Age is likely to be an important confounding factor in many analyses. There are two 
ways of dealing with this different age structure, either in the design, by matching cases 
to controls based on age, or in the analysis. As matching makes the analysis more 
complicated (requiring conditional logistic regression) I decided to control for the 
effects of age (and sex) in the analysis using logistic regression models. 
Concurrent versus historical data 
In common with all case-control studies there are differences in strength of evidence in 
concurrent data versus historical data. For example, there were two different measures 
of hypertension in the MRC Trial. Participants were asked whether a doctor had ever 
told them that they had high blood pressure. Blood pressure was also measured at the 
detailed examination. The latter measure is not a good indicator of cardiovascular 
disease in older people as many people take anti-hypertensive medication. In addition, 
as the measurement of outcome and exposure are concurrent, it is not clear which came 
first. 
Identification of potential confounding factors 
Confounding factors were considered to have the following attributes: (Rothman 1986). 
(i) A confounding variable must be a risk factor for the disease (ii) a confounding 
variable must be associated with the exposure under study in the population from which 
the cases derive (iii) a confounding variable must not be an intermediate step in the 
causal path between the exposure and the disease. 
All exposures were considered as potential confounding factors for each other. Other 
potential confounding factors were identified from review of the literature. They were 
as follows: 
" Socio-economic status 
" Antioxidant micro-nutrient intake 
0 Exposure to sunlight 
" Family history of AMD 
" Postmenopausal oestrogen use (in women) 
" Physical activity 
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Data were not available on antioxidant micro-nutrient intake, exposure to sunlight, 
family history of AMD or postmenopausal oestrogen use. Data were available on socio- 
economic status and physical activity and these were considered as possible 
confounders in addition to age, sex and the other exposures under study. 
Power of the study 
The size of the study was set by the size of the MRC Trial. The add-on study on causes 
of visual impairment generated approximately 500 cases of visual impairment due to 
age-related macular degeneration. 
Although post hoc power calculations are not to be encouraged, in this specific 
situation, where the number of cases is fixed by factors outside the control of the 
investigator, it is of interest to know what level of risk is detectable for the different risk 
factors studied. 
Table 5.2 (chapter five) shows the power of the study to detect various odds ratios, 
given the prevalence of exposure in the control group. For most of the risk factors 
examined the study, has good power (>90%) to detect odds ratios of 2 or more. For 
some of the risk factors that occur more commonly in this age-group such as systolic 
blood pressure over 140mmHg and alcohol consumption the study has good power to 
detect odds ratios of 1.5. For none of the risk factors is the study powerful enough to 
detect odds ratios in the order of 1.2. 
For smoking, odds ratios in the order of 2-3 have been reported in the literature (see 
chapter one table 1.11). One study on menopause before 45 years of age due to surgery 
found an odds ratio of 5. In these two cases, the study is adequately powered to test 
these hypotheses. 
Information on the other risk factors is more inconsistent. However, given the 
distribution of exposures in the control group in this study, there is reasonable power for 
most risk factors to detect odds ratios of the order of 2 or more. 
Analysis strategy 
The following steps were undertaken in the analysis. 
" The association between exposure (or confounders) and AMD causing visual 
impairment was assessed using a logistic regression model. This model had 
case/control status as the dependent variable (control=0, case=l) and included terms 
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for age (75-79,80-84,85-89,90+), sex and the variable in question. This was termed 
a "univariate" screen. 
" All variables that were significantly associated (p<0.05) with AMD causing visual 
impairment on the univariate screen were included in a final model. Any variables 
that did not contribute to the fit of the model as assessed using an adjusted Wald test 
(p<0.05) were dropped from the model to produce a final model. 
" Estimates of odds ratios and confidence intervals of exposure associated with 
outcome, controlled for appropriate confounding factors, were derived from this 
model. 
" All models took into account the cluster design of the MRC Trial (see chapter two 
section 2.6.3). 
" Exposures that were significantly associated with AMD causing visual impairment, 
after controlling for potential confounders, were analysed in more detail as follows 
" Effect modification by age and sex was examined. Other potential effect 
modifiers were examined if indicated from literature review or a priori 
hypothesis. To assess effect modifiers, interaction terms of the format 
age *exposure were entered into the model and their significance assessed using 
the adjusted Wald test. 
" Duration or dose of exposure was examined by constructing relevant logistic 
regression models. 
" As reproductive factors only apply to women, they were analysed separately. The 
above analysis steps were repeated. 
2.6.5 Missing data 
Prevalence data: various assumptions were made for the missing data to derive more 
accurate levels of prevalence of AMD. The rates were calculated assuming that the 
prevalence of visual impairment in the 31 % of people who were invited for examination 
but either did not attend, or who attended and did not have vision measured, was similar 
to those that attended and had vision measured/were registered. There was also a group 
of people who were known to be visually impaired but for whom no cause of visual loss 
was established. The prevalence rates assume that none of these people 
had visual loss 
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due to AMD. This gives a conservative measure of prevalence. In order to determine 
how important this assumption was the prevalence rates were recalculated assuming that 
the proportion of people with AMD in cases where no cause of visual loss was 
identified were similar to those were it was. 
In general no other assumptions were made about missing data, other than that any 
associations observed also applied in the people for whom data were missing. 
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TABLES AND FIGURES 
Table 2.1 Brief assessment questionnaire 
Areas specified in the GP Questions 
contract 
Social Environment 
Social support 
Living circumstances 
Carer for someone else at home 
Someone to call on for help 
Frequency of social contacts 
Self care 
Wash all over 
Get dressed 
Cut toe nails 
Cook hot meal 
Do light housework or simple repairs 
Financial problems 
Difficulty keeping home warm 
Problems in making ends meet 
Sensory impairment Difficulty hearing 
Difficulty seeing newsprint 
Mental condition Feeling sad, depressed or miserable 
Problems with everyday memory 
Difficulty managing finances 
Problems remembering medication 
Physical condition Vomited blood 
Coughed up blood 
Severe shortness of breath sitting 
Severe swollen legs 
Unexpected weight loss 
Falls in last six months 
Incontinence Urinary 
Faecal 
Use of medicines Number of prescribed medicines 
Mobility Walk 50 yards 
Go up and down stairs and steps 
Do shopping 
Lifestyle Use of alcohol in previous week 
(not part of GP contract) Current smoker (amount daily) 
Physical activity 
Table 2.2 Distribution of practices according to Jarman score and SMR 
Number of practices Low SMR Medium SMR High SMR Total 
Low Jarman 12 11 12 35 
Medium Jarman 7 13 13 33 
High Jarman 14 11 13 38 
Total 333538 106 
Table 2.3 Allocation of practices in the MRC Trial 
"Targeted" "Universal" 
Detailed examination by Detailed examination by 
Method of administration nurse if indicated by the nurse irrespective of the 
of questionnaire questionnaire results of the questionnaire 
Postal questionnaire 17 19 
Lay person interview 18 17 
Nurse interview 18 17 
Total 53 53 
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CHAPTER THREE PREVALENCE OF VISUAL IMPAIRMENT DUE TO 
AM D 
3.1 Introduction 
3.2 Visual impairment in the MRC Trial 
3.3 Causes of visual impairment 
3.4 AMD as a cause of visual impairment 
3.5 Socio-economic status and AMD causing visual impairment 
3.6 Regional variation in AMD causing visual impairment 
3.7 Key Points 
Tables and figures 
3.1 INTRODUCTION 
3.1.1 Research questions 
There were three main research objectives: 
" To estimate the prevalence of AMD causing visual impairment in people aged 75 
years and above in the UK. 
" To investigate how this varies by age, sex and socio-economic status. 
9 To investigate regional variation in the prevalence of AMD as a cause of visual 
impairment in people aged 75 years and above in the UK. 
In order to set the data on AMD in context, the prevalence of visual impairment is 
described (see section 3.2), followed by analysis of the causes of visual loss (see section 
3.3). Data on the research objectives are presented in the sections 3.4 to 3.6. 
3.1.2 A note on cutpoints 
" People with AMD who were not visually impaired were not counted 
This thesis examined the prevalence of AMD causing visual impairment. There will be 
people with AMD who did not have binocular acuity less than 6/18 (or who improved to 
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6/18 or better with pinhole). This will mean that the prevalence estimates presented in 
this chapter underestimate the prevalence of AMD. The choice of the cutpoint of less 
than 6/18 was dictated by the design of the MRC Trial. People with visual acuity of less 
than 6/18 in either eye were referred for ophthalmic investigation. This point is 
considered in the discussion (see section 6.1.2). 
3.2 VISUAL IMPAIRMENT IN THE MRC TRIAL 
Figure 3.1 shows the location of all the 106 practices taking part in the trial. The 
distribution of the study practices reflects the population density of Britain with the 
majority of practices located in the major conurbations. However, there are a good 
number of rural practices and a spread of practices from north to south and east to west 
of the three countries of Britain 
3.2.1 Response 
Figure 3.2 shows a profile of the study. There were 42,278 eligible people in the 106 
practices enrolled in the study. In the universal arm of the study, there were 21,241 
eligible people in 53 general practices. Of these, 15,126 (71%) had a detailed 
assessment. People taking part in the study were of a similar age (median age 80.3 
interquartile range 77.2-84.2) to those not taking part (median age 81.0 interquartile 
range 77.7-85.2). Women were less likely to take part than men - 68% of the non- 
responders were women, compared to 62% of the responders (p<0.001). 
Not everyone given a detailed assessment participated in a visual acuity test. Out of 
15,126 detailed assessments 699 people did not have a vision test; 173 of these were 
registered blind or partially sighted and are therefore counted in our measure of visual 
impairment. A total of 526 (3.5%) people therefore did not have any information on 
their vision, even though they had been seen by the nurse and had received some of the 
detailed assessment. These people were older (median age 83.3 interquartile range 
79.1-87.9) and were more likely to be women (69% vs. 62%, p<0.001). In addition, 
they were more likely to require a person to help with the interview - 22% of people 
with missing vision required a totally or partly proxy interview compared to 3% of 
people with a visual acuity test (p<0.001). 
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3.2.2 Prevalence of visual impairment and blindness 
Table 3.1 shows the prevalence of visual impairment, low vision and blindness by age 
and sex. A total of 1803 (12.4%) of people were counted as visually impaired. Of these, 
229 people were counted as visually impaired on the basis of self-reported registration 
status alone. The visual status of these people was checked from examining the general 
practitioner notes, hospital consultant form and detailed assessment carried out by the 
nurse: 172 were confirmed to be registered from general practitioner notes; 15 were 
confirmed to be visually impaired from general practitioner notes or from hospital 
questionnaire; 25 had other comments from nurse at the detailed assessment indicating 
that they could not see; 16 reported glaucoma; and one person was unclear but on 
balance was considered to be visually impaired. 
The prevalence of low vision increased sharply between the ages 75-79 and 90 years 
and above. At ages 75-79,5.6% (4.5% to 6.6%)* of the cohort had low vision. At ages 
90 and over, 30.0% (25.8% to 34.1 %) had low vision. Women had a higher prevalence 
of low vision than men in all age groups. 
The prevalence of blindness also showed a dramatic increased risk with increasing age. 
At ages 75-79,0.6% (0.3% to 0.9%) of the cohort was blind. At ages 90 and over 6.6% 
(3.1 % to 10.1 %) were blind. Women had a marginally increased risk at all ages. 
Table 3.2 gives the results of logistic regression models showing the association 
between age, and sex with visual impairment. People in the 90 years and above age- 
group had markedly increased odds of being visually impaired (odds ratio 8.34,6.67 to 
10.43) compared to people aged 75-79. Women were at a 67% increased risk compared 
to men which was only slightly attenuated after controlling for age. In models looking at 
blindness alone, the association with sex was not as marked and no longer remained 
statistically significant after controlling for age. 
* As for chapter one, I will use the following convention regarding confidence 
intervals. 95% confidence 
intervals will be quoted unless indicated otherwise. The confidence intervals will 
be the form "lower to 
upper" confidence interval, in 
brackets after the estimate. If the estimate is in brackets already, the 
confidence intervals will come after a comma. 
116 
3.2.3 Using other definitions of visual impairment 
Figure 3.3 shows the results using three different ways of defining visual impairment. 
(i) visual acuity of less than 6/18 in the better eye pinhole corrected; (ii) binocular visual 
acuity of less than 6/18; and (iii) binocular acuity of less than 6/12. 
The graph shows that the definition of binocular visual acuity less than 6/18 as a 
measure of visual impairment is a conservative one. If we had defined visual 
impairment as binocular visual acuity of less than 6/12, over half of our population in 
the older age-groups would have been visually impaired. 
The MRC Trial protocol required that everyone with visual acuity less than 6/18 receive 
a pinhole test. However, use of the pinhole was not straightforward in this elderly 
population and only 62% of people with visual acuity less than 6/18 in either eye 
completed a pinhole test satisfactorily. The graph shows that using the pinhole removed 
some of the refractive error as a cause of visual impairment in our population. The 
prevalence of pinhole corrected acuity of less than 6/18 in the better eye was 10.2%. 
Using the pinhole resulted therefore in an approximate 18% reduction in prevalence of 
visual impairment (10.2% compared to 12.4%). 
3.3 CAUSES OF VISUAL IMPAIRMENT 
3.3.1 Collecting data on cause of visual loss from the general practice notes 
Response 
I approached all 53 practices in the universal arm of the MRC Trial and asked if they 
wished to take part in the add-on study on the causes of visual impairment. 49 practices 
agreed to take part. These practices had a similar age and sex distribution and 
prevalence of visual impairment compared to the four practices that declined to take 
part (table 3.3). The practices that declined to take part appeared to be smaller in size 
with an average of 181 participants in the MRC Trial compared to 294 in the practices 
that agreed to take part. However, this difference was not statistically significant (ttest 
t=1.395, p=0.183). 
In these 49 practices, there were 1742 people who had a binocular acuity of less than 
6/18. Of these 450 (26%) achieved a pinhole acuity of better than or equal to 6/18 in the 
better eye. In these people the principle cause of visual impairment was considered to be 
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refractive error. For the remainder (n= 1292) 1 tried to find out the cause of visual loss 
using the methods as set out in section 2.3. 
Out of 1292 visually impaired people, I obtained the cause of visual loss for 976 (76%). 
There were 316 people for whom I could not identify the cause of visual loss. The 
reasons why are set out in table 3.4. In 43% of these missing cases the practice nurse 
was unable to locate the medical notes, either because the patient had moved practice or 
died (and the Family Health Services Authority refused to supply the notes), or the 
notes were lost. In a further 42% of cases, the practice nurse was able to obtain the 
medical notes but there was no record of the patient having an eye examination. In 5% it 
was not clear from the notes what the cause of visual loss was. 
People for whom data on the cause of visual loss were available were similar in terms of 
age and sex to those for whom data were not available (table 3.5). However, they had 
worse visual acuity - 25.5% had a visual acuity of less than 3/60 compared to 13.0% of 
people for whom cause of visual loss was not available. 
3.3.2 Verifying the cause of visual loss with the consultant ophthalmologist 
The aim behind collecting data both from the general practice notes and the hospital 
consultant was to verify that the data collection on cause of visual loss from medical 
record review had been reasonably accurate. 
I sent a questionnaire to all consultant ophthalmologists most recently involved in the 
care of the 976 people for whom there was a cause of visual loss identified from the 
general practice medical notes (see Appendix Q. A total of 470 (48%) forms were 
completed by consultant ophthalmologists. Of these, three people appeared to have a 
mistaken identity and were excluded leaving a total of 467 forms. 
The main difference between the two sources of data was that the hospital 
ophthalmologist recorded fewer potential causes of visual loss. In 46% of cases s/he 
recorded only one condition. In the review of the general practice medical records only 
one condition was recorded in 32% of cases. 
In addition to recording fewer potential causes of visual loss, the hospital consultant 
was more likely to attribute a main cause in cases where several conditions co-existed. 
S/he attributed a main cause in 86% of cases where several conditions co-existed, in 
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contrast to review of the general practice medical notes where a main cause was 
attributed in 65% of cases with multiple conditions. 
Table 3.6 compares the results of the hospital questionnaire with the coding of general 
practice correspondence. In 335/467 cases (72%), both the medical record review and 
hospital consultant questionnaire attributed a main cause of visual loss. In 295 (88%) of 
these 335 cases, the two sources of data agreed as to what was the main cause of visual 
loss (kappa = 0.81). 
Taking the table as a whole, the overall agreement is 64%. This corresponds to a kappa 
of 0.51. However, this underestimates the level of agreement for two reasons: firstly, 
cases where joint causes were assigned, such as AMD/Cataract, are taken as being 
"disagreements" when compared to cases where, for example, AMD only was assigned. 
Secondly, kappa is dependent on the number of categories. In a table such as this with 
many categories kappa will be lower irrespective of the actual agreement(Maclure and 
Willett 1987). 
In order to deal with the first problem a weighted kappa was calculated, assuming that 
cases such as AMD/cataract "agreed" with coding of "AMD" or AMD or cataract with 
another cause. This gave a kappa of 0.79. 
For AMD, in a total of 239 cases the hospital and general practice agreed that AMD was 
the main or contributory cause; in 156 cases they agreed that AMD was not a main or 
contributory cause. In 39 cases the general practice notes suggested that AMD was a 
main or contributory cause but the hospital consultant disagreed whereas in 33 cases the 
opposite was true. This gives a percentage agreement of 395/467=85% (kappa = 0.68). 
3.3.3 Causes of visual loss 
Table 3.7 shows the main causes of visual impairment for the 976 people for whom data 
were available. The data are drawn from the hospital questionnaire, where available, 
and from the coding of general practice notes otherwise. "Joint" causes are assumed to 
contribute 50% each to the cause of visual loss. 
The table shows the causes of visual loss in two categories of people: firstly, in people 
with a binocular acuity of less than 6/18; and, secondly, 
in people with a binocular 
acuity of less than 6/18, but excluding people who achieved a pinhole acuity 
in the right 
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of left eye of 6/18 or better. In these people the principal cause of visual loss was 
assumed to be refractive error. 
In addition, the percentages are calculated including and excluding people for whom the 
cause of visual loss was unknown. 
In all cases, the main cause of visual loss was AMD, followed by (refractive error), 
cataract, glaucoma, myopic degeneration, diabetic eye disease and vascular occlusions. 
AMD 
The proportion of binocularly visually impaired people affected by AMD is likely to lie 
somewhere between 27% and 33%. The lower estimate of 27% assumes none of the 
cause unknown had AMD (a conservative assumption), the higher estimate of 33% 
assumes that people whose cause was unknown had a similar prevalence of AMD. If 
people with refractive error are excluded, the proportion of people affected by AMD 
increases and probably lies between 36% and 48%. 
Other causes 
Table 3.8 shows details of the other causes of visual loss. 
The most common "other" cause of visual loss was corneal opacity which affected 17 
people. In seven of these people this was considered the main cause of visual loss, in the 
rest it was a contributory cause with AMD (1 person), cataract (8 people) and retinal 
detachment (1 person). 10 of these 17 people had Fuchs endothelial dystrophy. 15 
people had some form of retinal degeneration. There were three cases of retinitis 
pigmentosa and eight macular holes. 12 people were visually impaired due to disease of 
the visual cortex or optic pathways. In the majority of cases (7) this was optic nerve 
disease. Seven people had retinal detachments. In most of these cases this was 
considered to be the main cause of visual loss. There were a small number of people (5) 
who had visual symptoms such as diplopia or who had systemic disease causing tremor 
which affected their vision. Herpes zoster, uveitis and trauma accounted for a further 
six cases. 
Cataract 
Nearly 30% of visually impaired people had cataract as the main or contributory cause 
of visual loss. Table 3.9 sets out further details of the cataract cases. In the majority of 
cases (281,80%) there was record in the medical notes prior to the 
MRC Trial detailed 
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examination that the person had a cataract. 36 people were on the waiting list and 8 
people were in the process of being referred. 50 people had already had a cataract 
operation in one or both eyes but still failed the visual acuity test at the detailed 
examination. Three of these people took part in the MRC Trial shortly after their 
cataract operation and their vision probably had not settled down; a further 14 had 
record of surgical complications, high astigmatism or posterior subcapsular opacity that 
could account for the visual loss. In most cases, however, there was no obvious reason 
why the person should not have achieved good vision after cataract surgery. 
In 187 people, cataract had been identified prior to the MRC Trial, however, an 
operation had not been performed. 28 of these people had refused the operation and for 
56 there was record that a decision had been taken not to do the operation for health 
reasons. In the remaining 103, the record of ophthalmic examinations prior to the MRC 
Trial had indicated that the lens opacity had been mild. In the majority of these cases no 
further follow-up took place (62). In 31, they were referred again within one year of the 
MRC Trial, and in 10 after one year after the MRC Trial examination. 
Figure 3.4 shows the causes of visual loss by age and sex. In men, AMD was the most 
important cause of visual loss at all ages. In women, at the younger age-groups, 75-79, 
cataract was the most important cause of visual loss. With increasing age, AMD became 
the predominant cause. Figure 3.5 shows the causes of visual loss by binocular visual 
acuity score. This shows that cataract and AMD predominate as causes of moderate 
visual loss but as vision becomes poorer AMD becomes increasingly important. Over 
60% of people with a binocular acuity of less than 3/60 (blind) lost their sight because 
of AMD. Both figures 3.4 and 3.5 emphasise the dominance of AMD and cataract in 
causing visual impairment in this age-group. 
3.4 AMD AS A CAUSE OF VISUAL IMPAIRMENT IN THE MRC TRIAL 
Table 3.10 shows the distribution of AMD. In total there were 976 visually impaired 
people for whom a cause of visual loss was identified. Of these, 516 were identified as 
having AMD as a cause of visual loss. Of these 516 people, 428 (83%) were definite 
AMD and a further 88 people had "possible" AMD (see section 2.4 for definitions of 
definite and possible AMD). 
Table 3.11 shows the different subtypes of AMD identified. In 26% it was not possible 
to identify a subtype. In 34% neovascular AMD was identified and in 40% geographic 
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atrophy was identified. Out of 467 people with a hospital questionnaire returned, 103 
had neovascular disease and 158 had geographic atrophy. This suggests that for every 
two cases of neovascular disease there were three cases of geographic atrophy in this 
visually impaired population. 
Table 3.12 shows the characteristics of people with AMD as a cause of visual loss 
compared to people who had another cause of visual loss. People with AMD as a cause 
of visual loss were older than people with other causes of visual loss (design-based x2 
p<0.001). There was no difference between men and women (p=0.475). They were 
more likely to be registered blind or partially sighted (p<0.001) and to have a worse 
visual acuity (p<0.001). 
Table 3.13 compares people with the different subtypes of the disease. They had a 
similar age-distribution (p=0.424). People with type unspecified were more likely to be 
women but this could have been due to chance (p=0.138). People with neovascular 
disease were more likely to be registered blind or partially sighted, compared to people 
with type unspecified or geographic atrophy (p=0.003) and had a worse visual function 
(p= 0.052). 
Table 3.14 shows the age-specific prevalence rates of AMD causing visual impairment. 
Overall, 3.7% (3.2% to 4.2%) of the population of people aged 75 years and above were 
visually impaired due to AMD. There was a higher rate in women (4.4%) than men 
(2.6%). There was a strong relationship with age, 1.2% of the 75-79 year age-group 
were visually impaired due to AMD compared to 14.4% of people aged 90 years and 
above. Women had a higher rate than men at all ages. Table 3.15 shows the results of 
logistic regression models showing the association between age, and sex with visual 
impairment due to AMD. 
These rates are calculated assuming that the prevalence of visual impairment in the 31 % 
of people who were invited for examination but either did not attend, or who attended 
and did not have vision measured, was similar to those that attended and had vision 
measured/were registered. There was also a group of people who were known to be 
visually impaired but for whom no cause of visual loss was established. I have 
calculated the prevalence rates assuming that none of these people 
had visual loss due to 
AMD. This gives a conservative measure of prevalence. 
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Excluding people with unknown cause of visual loss from the denominator gives an 
estimate of prevalence of AMD causing visual impairment that assumes that the 
proportion of people with cause of visual loss unknown affected by AMD was similar to 
the proportion of people with cause of visual loss known affected by AMD (table 3.14). 
These results give a less conservative estimate of the prevalence of AMD causing visual 
impairment and are shown on the table. These figures indicate that as many as 1 in 5 
women aged 90 years and above may be visually impaired due to AMD. 
Table 3.16 shows the effect of applying these figures to the UK population in 2001. 
There are estimated to be approximately 192,000 people aged 75 years and above 
visually impaired due to AMD (144,000 to 239,000) living in the UK. The majority of 
the burden of visual impairment due to AMD in this age-group is borne by women. Out 
of the estimated 192,000 people visually impaired due to AMD, 146,000 (76%) are 
women. 
3.5 AMD AND SOCIO-ECONOMIC STATUS 
3.5.1 Housing tenure 
In this population of people aged 75 years and above, 64% owned their own homes, 
28% rented their accommodation and 9% lived in sheltered housing. The majority of the 
rental population was council accommodation. Home ownership declined with 
increasing age, especially in women, who had lower levels of home ownership at all 
ages. The proportion of the population in sheltered housing increased with age, 
particularly in the 90 years and above age-group. In each age-group, women are more 
likely to be in sheltered accommodation than men. 
Table 3.17 shows the prevalence of AMD causing visual impairment by housing tenure. 
There was a similar prevalence in people who owned their own homes and people living 
in rented accommodation (3.3% and 3.7% respectively). People living in sheltered 
accommodation had a higher prevalence of AMD causing visual impairment (6.2%). 
Table 3.18 shows the results of a logistic regression model with AMD causing visual 
impairment as the dependent variable (0=not visually impaired/visually impaired due to 
other causes, 1=AMD causing visual impairment) and including terms for housing 
tenure, age and sex. There was no statistically significant association between AMD 
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causing visual impairment and living in sheltered accommodation, after taking into 
account age and sex. 
3.5.2 Socio-economic status 
A socio-economic score was constructed from variables on housing tenure, central 
heating, access to an indoor toilet, difficulty keeping their home warm and/or difficulty 
making ends meet (see section 2.5.1). A higher score indicated a worse socio-economic 
status. People living in sheltered housing were excluded from the score. 
The majority (56%) of the population scored 0 on this variable i. e. they owned their 
own homes, had central heating, an indoor toilet, did not have difficulty keeping their 
home warm and did not report any difficulty making ends meet. A further 34% scored 1 
and 10% scored 2 or more. In general, women had a worse score than men; there was no 
clear pattern with age. 
Table 3.19 shows the prevalence of AMD causing visual impairment by socio-economic 
score and table 3.20 shows the results of a logistic regression model including terms for 
age, sex and socio-economic status score. There was little evidence of any relationship 
between AMD causing visual impairment and socio-economic score. 
3.5.3 Social class from lifetime occupation 
Social class was graded from lifetime occupation using the Registrar General's 
Classification of Occupation (see section 2.5.1). For married or widowed women, the 
husband's occupation was used. 
35% of the population were in groups 1/11,11% in IIINM, 35% in HIM and 19% in 
groups IV/V. An increasing proportion of the population were in groups IV/V with 
increasing age and decreasing proportion in groups UII with increasing age. Men were 
more likely to be in social class group I/II than women. 
Table 3.21 shows the prevalence of AMD causing visual impairment by social class 
group. People in groups I to IIIM had a similar prevalence of visual impairment due to 
AMD of approximately 2.5% to 3%. People in social class group IV/V had an 
increased risk of AMD causing visual impairment (3.9%). However, the confidence 
intervals for these estimates overlap. Table 3.22 shows a logistic regression model 
including terms for age, sex and social class group. There was little evidence of any 
association with social class. People in social class group IV/V 
had a non-significant 
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increased odds ratio (1.15,0.34 to 2.11), however, there was no overall trend with social 
class. 
3.6 REGIONAL VARIATION IN AMD CAUSING VISUAL IMPAIRMENT 
Practices taking part in the MRC Trial were divided into the following regions: South, 
Midlands, North and Scotland. 38% of participants were in the south, 28% in the 
Midlands, 24% in the north and 10% in Scotland. 
Table 3.23 shows the prevalence of AMD causing visual impairment by region. There 
was little evidence for any regional differences in the prevalence of AMD causing 
visual impairment (design-based x2 p=0.119). 
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3.7 KEY POINTS 
9 3.7% (3.2% to 4.2%) of this population aged 75 years and above had AMD causing 
visual impairment. 
9 There was a strong relationship with age: 1.2% of the 75-79 age-group were visually 
impaired due to AMD compared to 14.4% of people aged 90 years and above. 
9 Women were at greater risk of AMD causing visual impairment than men at all 
ages. 
" There were an estimated 192,000 (144,000 to 239,000) people aged 75 years and 
above visually impaired due to AMD in the UK in 2001. 
" AMD causing visual impairment was not associated with housing tenure, socio- 
economic status score nor an occupational classification of social class. 
9 There was no evidence of any regional variation in AMD causing visual 
impairment. 
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TABLES AND FIGURES 
Table 3.1 Prevalence of visual impairment, low vision and blindness 
All visual impairment Low vision Blindness 
Binocular acuity <6/18 Binocular acuity <6/18 - 3/60 Binocular acuity <3/60 
95% confidence 95% confidence 95% confidence 
N Prevalence interval Prevalence interval Prevalence interval 
All ages 
Total 14600 12.4 10.8 to 13.9 10.3 8.7 to 11.8 2.1 1.8 to2.4 
Men 5620 9.1 7.9 to 10.4 7.5 6.2 to 8.7 1.7 1.3 to2.0 
Women 8980 14.4 12.6 to16.2 12.1 10.2 to 13.9 2.3 1.9 to2.8 
Men and women 
75-79 6898 6.2 5.1 to 7.3 5.6 4.5 to 6.6 0.6 0.4 to 0.8 
80-84 4602 11.9 9.9 to 13.8 9.6 7.6 to 11.5 2.3 1.8 to 2.8 
85-89 2319 23.4 20.5 to 26.4 19.2 16.2 to 22.1 4.3 3.4 to 5.2 
90+ 781 36.9 32.5 to 41.2 30.0 25.8 to 34.1 6.9 4.8 to 9.0 
Men 
75-79 2961 4.8 3.6 to 5.9 4.2 3.1 to 5.2 0.6 0.3 to 0.9 
80-84 1695 10.0 8.4 to H. 7 7.7 6.0 to 9.4 2.3 1.5 to 3.1 
85-89 782 19.2 15.5 to 22.9 16.0 12.4 to 19.6 3.2 2.0 to 4.4 
90+ 182 28.6 21.6 to 35.5 22.0 15.6 to 28.4 6.6 3.1 to 10.1 
Women 
75-79 3937 7.3 6.0 to 8.5 6.6 5.4 to 7.9 0.6 0.3 to 1.0 
80-84 2907 12.9 10.4 to 15.5 10.6 8.1 to 13.1 2.3 1.6 to 3.0 
85-89 1537 25.6 22.3 to 28.9 20.8 17.6 to 24.0 4.8 3.6 to 6.0 
90+ 599 39.4 34.5 to 44.3 32.4 27.4 to 37.4 7.0 4.7 to 9.3 
Data from the 53 practices in the universal arm of the MRC Trial. Confidence intervals 
adjusted for the clustered design of the study 
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Table 3.2 Risk of visual impairment and blindness by age and sex 
Odds ratio 
95% confidence 
interval 
Visual impairment: binocular acuity <6/18 
Independent associations 
Age 75-79 1 
80-84 2.05 1.80 to 2.33 
85-89 4.65 3.88 to 5.56 
90+ 8.88 7.11 to l 1.07 
Men I 
Women 1.67 1.51 to 1.85 
With both factors in the model 
Age 75-79 1 
80-84 2.00 1.76 to 2.28 
85-89 4.52 3.76 to 5.42 
90+ 8.34 6.67 to 10.43 
Men 1 
Women 1.46 1.32 to 1.61 
Blindness: binocular acuity <3/60 
Independent associations 
Age 75-79 1 
80-84 3.76 2.63 to 5.37 
85-89 7.11 4.95 to 10.20 
90+ 11.84 7.88 to 17.8 
Men 1 
Women 1.39 1.09 to 1.78 
With both factors in the model 
Age 75-79 1 
80-84 3.73 2.61 to 5.32 
85-89 7.02 4.89 to 10.06 
90+ 11.51 7.64 to 17.35 
Men 
Women 1.16 0.91 to 1.49 
Data from the 53 practices in the universal arm of the MRC Trial. Odds ratios derived 
from logistic regression models taking into account cluster sample design. They 
represent the increased odds of developing visual impairment or blindness associated 
with age (compared to age-group 75-79) and being female. 
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Table 3.3 Comparing practices taking part and not taking part in causes of visual 
impairment study 
Number of Age 
people in Prevalence 
practice of visual 
taking part in Male impairment 
MRC Trial % Minimum Maximum Mean % 
Practices 294 39 
taking part 
in causes 
study 
(n=49) 
Practices 181 37 
not taking 
part in 
75.2 97.0 81.2 
75.5 96.2 81.8 
12.2 
11.6 
causes 
study 
(n=4) 
Data from the 53 practices in the universal arm of the MRC Trial. All the figures in this 
table are mean figures for practices in each of the two groups (taking part in causes of 
visual impairment study, not taking part in causes of visual impairment study). 
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Table 3.4 Reasons for no cause of visual loss 
Reason for no cause of visual loss 
Notes unavailable 
- moved GP practice (87) 
- notes not supplied by FHSA (31) 
- notes lost (17) 
- no consent from patient (2) 
N% 
137 43 
Patient never had an ophthalmic examination 134 42 
- Refused referral (26) 
- No assessment, unclear why (108) 
Cause not clear 15 5 
Form not completed 30 10 
Total with no cause of visual loss 316 100 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. 
130 
Table 3.5 Comparing people with data on cause of visual impairment with those 
with missing data on cause of visual impairment 
Age Binocular 
acuity <3/60 
Male Minimum Maximum Mean (blind) 
People with data 28 75 108 84.7 25.5 
on cause of visual 
loss (n=1292) 
People with no 28 75 102 85.5 13.0 
data on cause of 
visual loss 
(n=316)) 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. 
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Table 3.8 Other causes of visual impairment 
N Main or contributory cause 
Corneal opacity 
Retinal degeneration 
Diseases of visual cortex 
and optic pathways 
17 Main cause-7 
*With AMD -1 
*With cataract -8 
*With retinal detachment -1 
15 Main cause- 12 
*With cataract -3 
12 Main cause -5 
*With AMD -4 
* With cataract -2 
* With myopic degeneration -1 
Retinal detachment 
Visual symptoms 
without obvious cause/ 
systemic cause 
Amblyopia 
Herpes zoster 
Uveitis 
Trauma 
7 Main cause -6 
* With corneal opacity -1 
5 Main cause -4 
* With cataract -1 
5 *With AMD -2 
*With cataract -2 
* With glaucoma -1 
3 Main cause -3 
2 *With cataract -2 
2 Main cause -2 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. Visual impairment: binocular acuity 
less than 6/18 with usual spectacle correction. People achieving 6/18 or better with 
pinhole in either eye were excluded. Other causes of visual loss from hospital consultant 
questionnaire where available, from general practitioner notes otherwise. 
*Causes where more than one coexisting eye disease and main cause not clear, each of 
first two causes contribute 0.5 to final total count (see table 3.7). 
134 
Table 3.9 Cataract as a cause of visual loss 
(a) N% 
Being assessed at time of MRC Trial detailed examination 
" On waiting list 36 10.3 
" Referral in process at time of MRC Trial detailed examination 8 2.3 
Cataract identified prior to MRC Trial 
" Operation performed* 50 14.3 
" Operation not performed** 187 53.4 
Cataract newly identified after MRC Trial examination 
" Within one year 43 12.3 
" More than one year after 11 3.1 
Not enough information 15 4.3 
Total number with cataract as a cause of visual loss 350 100 
(b) 
*Probable reason for visual impairment at time of MRC Trial examination 
Immediately post-op 3 6.0 
Surgical complications / Astigmatism /PCO 14 28.0 
No obvious reason for visual loss 33 66.0 
Total number with operation performed 50 100 
(c) 
** Probable reason why operation not performed 
Refused operation 28 15.0 
Operation not indicated for health/comorbidity reasons 56 29.9 
Cataract mild previously no further follow-up 62 33.2 
Cataract mild previously, referred within one year of MRC Trial 31 16.6 
Cataract mild previously, referred more than one year after MRC Trial 10 5.3 
Total number with operation not performed 187 100 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. 
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Table 3.10 AMD 
N % 
Non-AMD cause 460 47.1 
Possible AMD 88 9.0 
Definite AMD 428 43.9 
Total number of visually impaired people with 976 100 
cause of visual loss identified 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. 
Table 3.11 Subtypes of AMD 
N% 
Type unspecified 112 26.2 
Neovascular AMD 144 33.6 
Geographic atrophy 172 40.2 
Total number of visually impaired people with 
definite AMD identified as a cause of visual 428 100 
loss 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. 
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Table 3.12 Characteristics of people with AMD as a main cause of visual loss 
AMD as a main cause of visual Other cause of visual loss 
loss (n = 516) (n=460) 
N%N% 
Age in years 
75-79 
80-84 
85-89 
90+ 
Male 
Female 
Registered blind 
Registered partially 
sighted 
Not registered 
Data missing 
Binocular visual acuity 
logMAR score 
0.5-0.675 
0.7-0.875 
0.9-1.375 
Blind 
Data missing 
74 14.3 128 27.8 
159 30.8 140 30.4 
176 34.1 141 30.7 
107 20.7 51 11.1 
138 26.7 132 28.7 
378 73.3 328 71.3 
122 23.6 54 11.7 
176 34.1 88 19.1 
202 39.2 288 62.6 
16 3.1 30 6.5 
126 24.4 221 48.0 
89 17.3 83 18.0 
71 13.8 34 7.4 
90 17.4 28 6.1 
140 27.1 94 20.4 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. 
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Table 3.13 Characteristics of people with different subtypes of AMD as a main 
cause of visual loss 
Type unspecified Neovascular disease Geographic 
(n=112) (n=144) atrophy (n=172) 
N%N%N% 
Age in years 
75-79 20 17.9 20 13.9 25 14.5 
80-84 31 27.7 54 37.5 46 26.7 
85-89 40 35.7 45 31.3 65 37.8 
90+ 21 18.7 25 17.4 36 20.9 
Male 20 17.8 44 30.6 46 26.7 
Female 92 82.1 100 69.4 126 73.3 
Registered blind 23 20.5 40 27.8 30 17.4 
Registered 34 30.4 64 44.4 62 36.1 
partially sighted 
Not registered 53 47.3 37 25.7 74 43.0 
Data missing 2 1.8 3 2.1 6 3.5 
Binocular visual 
acuity logMAR 
0.5-0.675 34 30.4 26 18.1 47 27.3 
0.7-0.875 18 16.1 20 13.9 35 20.4 
0.9-1.375 14 12.5 20 13.9 21 12.2 
Blind 17 15.2 27 18.8 29 16.9 
Data missing 29 25.9 51 35.4 40 23.3 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. 
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Table 3.14 Age-specific prevalence (%) of AMD causing visual impairment 
Prevalence excluding people 
with no information on cause of 
visual impairment from 
Minimum prevalence denominator 
% Prevalence 95% c. i. % Prevalence 95% c. i. 
All ages 
Total 13900 3.7 3.2 to 4.2 3.9 3.4 to 4.5 
Men 5357 2.6 2.1 to 3.1 2.7 2.2 to 3.2 
Women 8543 4.4 3.8 to 5.0 4.7 4.1 to 5.4 
Men and women 
75-79 6582 1.1 0.9 to 1.4 1.2 0.9 to 1.4 
80-84 4388 3.6 3.0 to 4.3 3.8 3.1 to 4.5 
85-89 2186 8.1 6.4 to 9.7 8.9 7.0 to 10.7 
90+ 744 14.4 11.6 to 17.2 17.1 13.7 to 20.5 
Men 
75-79 2831 0.9 0.5 to 1.3 0.9 0.6 to 1.3 
80-84 1623 2.9 2.2 to 3.6 3.0 2.3 to 3.8 
85-89 729 6.2 4.4 to 8.0 6.8 4.8 to 8.7 
90+ 174 11.5 6.9 to 16.1 13.2 7.8 to 18.7 
Women 
75-79 3751 1.3 0.9 to 1.7 1.3 0.9 to 1.7 
80-84 2765 4.1 3.2 to 4.9 4.3 3.3 to 5.3 
85-89 1457 9.1 7.0 to 10.9 9.9 7.7 to 12.1 
90+ 570 15.3 12.0 to 18.6 18.4 14.4 to 22.3 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. Confidence intervals adjusted for 
clustered design of study 
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Table 3.15 Risk of visual impairment due to AMD by age and sex 
Odds ratio 95% confidence 
interval 
Independent associations 
Age 75-79 1 
80-84 3.31 2.66 to 4.11 
85-89 7.70 5.95 to 9.97 
90+ 14.77 10.75 to 20.29 
Men I 
Women 1.75 1.49 to 2.06 
With both factors in the model 
Age 75-79 1 
80-84 3.24 2.60 to 4.04 
85-89 7.46 5.71 to 9.75 
90+ 13.86 10.03 to 19.15 
Men 1 
Women 1.44 1.22 to 1.69 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. Odds ratios derived from logistic 
regression models taking into account cluster sample design. They represent the 
increased odds of developing visual impairment due to AMD associated with age 
(compared to age-group 75-79) and being female. 
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Table 3.17 AMD causing visual impairment and housing tenure 
Housing tenure Number of People with AMD causing visual impairment 
people with N% 95% confidence 
data on vision intervals 
Home owner 8803 292 3.3 2.8 to 3.9 
Rented 3 796 140 3.7 2.8 to 4.6 
accommodation 
Sheltered 1202 75 6.2 4.7 to 7.8 
accommodation 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. Confidence intervals adjusted for 
clustered design of study. 99 people had missing data on housing tenure 
Table 3.18 Association between AMD causing visual impairment and housing 
tenure, controlling for age and sex. 
Housing tenure Odds ratio 95% confidence intervals 
Home owner 1 
Rented accommodation 1.06 0.80 to 1.41 
Sheltered accommodation 1.12 0.83 to 1.50 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. Derived from a logistic regression 
model with AMD causing visual impairment as the dependant variable (O=not visually 
impaired/visually impaired due to other causes, 1=AMD causing visual impairment) and 
including terms for age (four groups), sex and housing tenure. Confidence intervals 
adjusted for the clustered design of the study. 99 people had missing data on housing 
tenure 
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Table 3.19 AMD causing visual impairment and socio-economic status score 
People with AMD causing visual impairment 
Socio-economic Number of 95% confidence 
status score people N% intervals 
Score =0 7410 214 2.9 2.4 to 3.4 
Score =1 4506 181 4.0 3.1 to 4.9 
Score >2 1332 37 2.8 2.0 to 3.6 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. Confidence intervals adjusted for 
clustered design of study. 1352 people had missing data on socio-economic status score 
of whom 1251 were in sheltered accommodation 
Table 3.20 Association between AMD causing visual impairment and socio- 
economic status score, controlling for age and sex 
Socio-economic status Odds ratio 95% confidence intervals 
score 
Score =01 
Score =11.22 0.98 to 1.52 
Score >20.94 0.69 to 1.27 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. Odds ratios derived from a logistic 
regression model with AMD causing visual impairment as the dependant variable 
(O=not visually impaired/visually impaired due to other causes, 1=AMD causing visual 
impairment) and including terms for age (four groups), sex and socio-economic score. 
Confidence intervals adjusted for the clustered design of the study. 1352 people had 
missing data on socio-economic status score of whom 1251 were 
in sheltered 
accommodation 
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Table 3.21 AMD causing visual impairment and social class group 
People with AMD causing visual impairment 
*Social class Number of N% 95% confidence 
group people intervals 
1/1 1 1044 30 2.9 1.4 to 4.3 
IIINM 304 8 2.6 0 to 5.4 
HIM 958 24 2.5 1.3 to 3.7 
IV/V 514 20 3.9 2.2 to 5.6 
Data from the 11 practices in which quality of life interviews done and which also in 
universal arm of MRC Trial and causes of visual impairment study (23 practices in 
whole MRC Trial randomly selected for quality of life interviews). In these 11 
practices, 229 people had missing data on social class group. Social class group is 
derived from occupation. For widowed and married women, husband's occupation was 
used. Confidence intervals adjusted for the clustered design of the study. 
Table 3.22 Association between AMD causing visual impairment and social class 
group, controlling for age and sex 
Odds ratio 95% confidence intervals 
I/II 1 
IIINM 0.88 0.29 to 2.62 
HIM 0.86 0.42 to 1.78 
IV/V 1.15 0.63 to 2.11 
Data from the 11 practices in which quality of life interviews done and which also in 
universal arm of MRC Trial and causes of visual impairment study (23 practices in 
whole MRC Trial randomly selected for quality of life interviews). 229 people had 
missing data on social class group. Social class group is derived from occupation. For 
widowed and married women, husband's occupation was used. Odds ratios derived 
from a logistic regression model with AMD causing visual impairment as the dependant 
variable (O=not visually impaired/visually impaired due to other causes, 1=AMD 
causing visual impairment) and including terms for age (four groups), sex and social 
class group. Confidence intervals adjusted for the clustered design of the study. 
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Table 3.23 AMD causing visual impairment by region 
People with AMD causing visual impairment 
Number of N% 95% confidence 
people intervals 
South 5092 192 3.8 3.0 to 4.5 
Midlands 4066 150 3.7 2.5 to 4.8 
North 3297 116 3.5 2.7 to 4.4 
Scotland 1445 58 4.0 3.0 to 5.1 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. Confidence intervals are adjusted for 
clustered design of study 
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Figure 3.1 Location of practices participating in the MRC Trial of the Assessment 
and Management of Older People in the Community 
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Figure 3.2 Study profile 
All patients aged 75 and over in 106 
general practices 
(excluding those in long-term care or 
terminally ill) 
N= 42,278 eligible 
Randomised 
Targeted Universal 
53 general practices 53 general practices 
N= 21,037 eligible N= 21,241 eligible 
Targeted 
Selected participants had 
detailed assessment (results 
not included in this thesis) 
Universal 
All participants offered 
detailed assessment including 
visual acuity test 
N= 15,126 (71 %) given 
detailed assessment 
N= 14,600 (69%) analysed 
with data on vision 
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Figure 3.3 Comparison of different measures of visual impairment 
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Figure 3.4 Causes of visual impairment by age and sex 
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Figure 3.5 Causes of low vision and blindness 
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CHAPTER FOUR IMPACT 
4.1 Introduction 
4.2 Functional ability 
4.3 Self-reported health and physical activity 
4.4 Sickness Impact Profile and Philadelphia Geriatric Morale Scale (subsample) 
4.5 Depression and cognitive impairment 
4.6 Falls and hip fractures 
4.7 Mortality 
4.8 Key points 
Tables and figures 
4.1 INTRODUCTION 
4.1.1 Research questions 
The aim of this chapter is to investigate the association between AMD causing visual 
impairment and : 
9 functional ability 
9 health-related quality of life 
" psychological well-being 
" emotional well-being (morale) 
" morbidity 
9 mortality 
and to investigate whether the these associations vary in different age and sex groups. 
4.1.2 Terminology 
The terminology used in this chapter is as follows: the variables indicating functional 
ability, health-related quality of life etc were analysed as the outcome. The 
hypotheses 
relate to whether AMD causing visual impairment might be associated with 
functional 
ability, health-related quality of life etc... "AMD causing visual 
impairment" is 
therefore considered as the exposure in these analyses. Potential confounding factors 
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associated with both outcome and exposure were identified from review of the 
literature. 
Confidence intervals and statistical significance 
As for previous chapters, 95% confidence intervals are reported in brackets (lower to 
upper) after the effect estimates (odds ratios or hazard ratios). If the effect estimate is 
already in brackets the 95% confidence intervals are quoted after a comma. Statistical 
significance (p<0.05) is assumed whenever the confidence intervals do not cross unity. 
4.2 FUNCTIONAL ABILITY 
4.2.1 Distribution in study population 
There were three variables that reflected functional ability: difficulty reading newsprint, 
difficulty managing finances and activities of daily living (ADL). Table 4.2 shows the 
distribution of these outcomes in the study population. 
Overall, 9.9% of the study population reported a lot of difficulty reading newsprint and 
3.4% had difficulty managing their own finances. Older people experienced more 
difficulties. The proportion of people reporting a lot of difficulty reading newsprint 
increased from 5% in the 75-79 age-group to 27.7% in those 90 years and above. 
Similarly, those reporting difficulty managing their own finances increased with age 
(1.9% to 9.4%). 
Women also reported more difficulties. 7.7% of men had difficulty reading newsprint 
compared to 11.2% of women. 2.8% of men had difficulty managing finances compared 
to 3.8% of women. 
The ADL score ranged from 5 to 24 with a median value of 10 and mean of 12.1. 
Graphical plots and tests of normality indicated that the variable was highly skewed, it 
was therefore divided into five equal groups (quintiles) and the proportion of people in 
the worst quintile (i. e. experiencing most difficulties with activities of daily living) was 
analysed. 
The proportion of people in the worst quintile increased with increasing age, from 9.3% 
in the 75-79 age-group to 54.6% in the 90 and above age-group. Women were more 
likely to be in the worst quintile than men (22.0% compared to 13.7%). 
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4.2.2 Association with confounding factors 
Table 4.1 (and table F. 1 in Appendix F) shows the association between these three 
functional ability variables and potential confounding factors. Difficulty reading 
newsprint was associated with all the potential confounding variables with the exception 
of smoking and reported hip fractures. Difficulty managing finances was associated 
with all variables except smoking, reported hip fracture and body mass index. Being in 
the worst quintile for ADL score was associated with all confounding variables. 
4.2.3 Association with visual impairment and AMD, controlling confounders 
This section discusses tables 4.3 to 4.6. Each table contains results for three models. In 
all three models the outcome was the impact variable (for example, "a lot of difficulty" 
reading newsprint). Model 1 included a term for visual impairment (O=not visually 
impaired 1=visually impaired); Model 2 included a term for visual impairment by cause 
(O=not visually impaired, 1=visually impaired due to other causes, 2=visually impaired 
due to AMD); Model 3 included only visually impaired people and included a term for 
visual impairment by cause (0=visually impaired due to other causes, 1=visually 
impaired due to AMD). These three models were repeated with different confounders. 
(a) age and sex alone; (b) age, sex and all other potentially confounding factors, except 
those potentially on the causal pathway (see table 4.1); and (c) age, sex, and all other 
potentially confounding factors. The discussion of these tables is restricted to the 
models including all potential confounders, i. e. (c). Only where there are interesting 
differences between the results are these discussed in more depth. 
Reported difficulty reading newsprint 
Visually impaired people were more likely to report "a lot of difficulty" reading 
newsprint compared to those not visually impaired (odds ratio 13.34,10.56 to 16.85) 
(table 4.3). 
People visually impaired due to AMD were also more likely to report difficulties 
reading newsprint compared to people not visually impaired, with a 
large increased 
relative odds (odds ratio 48.97,34.93 to 68.65). This was 
in contrast to people visually 
impaired due to other causes who had a more modest increased odds of reporting "a lot 
of difficulty" reading newsprint compared to people not visually 
impaired (odds ratio 
7.68,5.98 to 9.87). 
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People visually impaired due to AMD were more likely to report difficulty reading 
newsprint, compared to people visually impaired due to other causes, and controlling 
for binocular acuity score in addition to other confounders (odds ratio 3.96,2.66 to 
5.90). 
Reported difficulty managing finances 
Visually impaired people were more likely to report difficulty managing their own 
finances compared to those not visually impaired (odds ratio 2.52,1.98 to 3.21) (table 
4.4). 
As for reading newsprint, there was some evidence that people visually impaired due to 
AMD were worse affected. People visually impaired due to AMD had an odds ratio of 
4.12 (2.95 to 5.76) of reporting difficulties compared to non visually impaired people. 
People visually impaired due to other causes had an odds ratio of 1.89 (1.42 to 2.52) 
compared to non visually impaired people. 
People visually impaired due to AMD were more likely to report difficulty managing 
their finances, compared to people visually impaired due to other causes, and 
controlling for binocular acuity score in addition to other confounders (odds ratio 1.66, 
1.03 to 2.67). 
Being in worst quintile for ADL score 
Visually impaired people were more likely to be in the worst quintile for ADL score 
compared to people not visually impaired (odds ratio 1.86,1.47 to 2.36) (table 4.5). 
As for reading newsprint and managing finances above, there was some evidence that 
people visually impaired due to AMD were worse affected than people visually 
impaired due to other causes. People visually impaired due to AMD had an odds ratio of 
2.72 (1.98 to 3.73) for being in the worst quintile for ADL score compared to people not 
visually impaired. People visually impaired due to other causes had an odds ratio of 
1.55 (1.16 to 2.06) compared to non visually impaired people. Comparing people 
visually impaired due to AMD directly to those visually impaired due to other causes, 
and controlling for binocular acuity score in addition to other confounders, gave an odds 
ratio of 1.65 (1.07 to 2.55). 
Repeating these analyses without the confounding factors potentially on the causal 
pathway (depression, cognitive impairment, falls and hip fractures) gave a slightly 
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different result. People with AMD were at increased risk of being in the worst quintile 
for ADL score (odds ratio 1.44,0.96 to 2.16) however this was of borderline statistical 
significance (p=0.079). 
4.2.4 Effect modification by age and sex 
Models 1 and 2 (including all confounding factors) were repeated including interaction 
terms for "visual impairment term*sex" and "visual impairment term*age". There was 
little evidence of any effect modification by age and sex. 
4.3 SELF-REPORTED HEALTH AND PHYSICAL ACTIVITY 
4.3.1 Distribution in study population 
Participants were asked to grade their health compared to people their own age. Table 
4.6 shows the distribution of this variable in the study population. Self-reported health 
was graded as excellent, very good, good, fair or poor. As only 3% fell into the poor 
category, fair and poor were grouped together. Overall, 16.1 % reported that their health 
was "fair/poor". There was no particular trend with age and a slightly higher reported 
"fair/poor" health in women (17.2% vs. 14.4%). Participants were asked how physically 
active they felt that they were. This was graded as very, fairly, not very and not at all. 
Overall, 4.8% reported being "not at all" physically active. This increased with age and 
was higher in women. 
4.3.2 Association with confounding factors 
Self-reported health was strongly associated (p<0.001) with all the confounders, i. e. 
housing tenure, smoking, alcohol consumption, body mass index, hearing impairment, 
reported stroke, diabetes, urinary incontinence, lower legs swollen in the morning, 
severe shortness of breath, three or more prescribed medicines, depression, cognitive 
impairment, falls and hip fractures (table 4.1). Self-reported physical activity was 
associated with most of the potential confounders, with the exception of body mass 
index and hearing impairment. 
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4.3.3 Association with visual impairment and AMD, controlling confounders 
Reporting "fair/poor" health 
Visually impaired people were more likely to report having "fair/poor" health compared 
to people not visually impaired, however, this effect was modest and not statistically 
significant (odds ratio 1.20,0.98 to 1.47) (table 4.7). 
In contrast to all visually impaired people, people visually impaired due to AMD were 
more likely to report "fair/poor" health than people not visually impaired (odds ratio 
1.54,1.15 to 2.06). People visually impaired due to other causes had an odds ratio of 
1.07 (0.85 to 1.36) compared to non visually impaired people. 
Comparing people visually impaired due to AMD directly to those visually impaired 
due to other causes, and controlling for binocular acuity score in addition to other 
confounders, gave an odds ratio of 1.86 (1.26 to 2.74). 
Reporting being "not at all" physically active 
Visually impaired people were more likely to report being "not at all" physically active 
compared to people not visually impaired, however, as for self-reported health, this 
effect was not statistically significant (odds ratio 1.32,0.99 to 1.76) (table 4.8). 
Similar size effects were seen in people visually impaired due to other causes and 
people visually impaired due to AMD. Comparing people visually impaired due to 
AMD directly to those visually impaired due to other causes, and controlling for 
binocular acuity score in addition to other confounders, indicated little difference 
between people visually impaired due to AMD and those visually impaired due to other 
causes. 
4.3.4 Effect modification by age and sex 
Models 1 and 2 (including all confounding factors) were repeated including interaction 
terms for "visual impairment term*sex" and "visual impairment term*age". There was 
little evidence of any effect modification by age and sex. 
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4.4 SICKNESS IMPACT PROFILE (SIP) AND PHILADELPHIA GERIATRIC 
MORALE SCALE (PGMS) 
4.4.1 Distribution in study population 
Four dimensions of the SIP were assessed in a subset of 11 randomly selected practices. 
These were: home management, mobility, body care and movement and social 
interaction. All four SIP scales were highly skewed and were therefore grouped into 
quintiles and the worst quintile analysed. In all four dimensions there was a marked 
trend with age such that older people experienced more difficulties and had a higher 
probability of being in the "worst" quintile (table 4.9). Women also reported more 
problems in all four dimensions. 
The PGMS is a series of 17 questions. One point is scored for each question answered 
"negatively", thus higher scores reflect a worse morale. In this population, the PGMS 
ranged from 0 to 17 with a median value of 4 and mean of 5.1. The variable was highly 
skewed and therefore analysed in quintiles. The proportion of people in the "worst" 
quintile increased with increasing age. At ages 75-79,20.4% were in the worst quintile, 
at ages 85 and above, 27.7%. Women had a worse morale (27.7%) than men (15.8%). 
4.4.2 Association with confounding factors 
Table 4.1 shows the association between the SIP dimensions and PGMS score with 
potential confounding factors. In general, being in the worst quintile for SIP score was 
associated with most of the potential confounding factors. 
In the case of the SIP and PGMS analyses, as described in the analysis strategy, the 
confounders had to be restricted because of the relatively small number of practices in 
which the data were collected, and hence degrees of freedom in the model. Most of the 
confounders in table 4.1 did not change the odds ratios by 10% or more. The following 
confounders were used for each model in addition to age and sex: home management, 
mobility and PGMS - housing tenure; body care and movement - three or more 
prescribed medicines and depression; social interaction - BMI and depression. 
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4.4.3 Association with visual impairment and AMD, controlling confounders 
SIP: Home management score 
Visually impaired people were more likely to be in the worst quintile for home 
management score compared with people not visually impaired (odds ratio 1.99,1.51 to 
2.63) (table 4.10). 
People visually impaired due to AMD were more likely to be in the worst quintile for 
home management score compared with people not visually impaired (odds ratio 1.85, 
1.03 to 3.34). There was little evidence of any difference between people visually 
impaired due AMD and those visually impaired due to other causes. Comparing people 
visually impaired due to AMD directly to those visually impaired due to other causes, 
and controlling for binocular acuity score in addition to other confounders, gave an odds 
ratio of 0.64 (0.23 to 1.76). 
SIP: Mobility score 
Visually impaired people were more likely to be in the worst quintile for mobility score 
compared with people not visually impaired (odds ratio 1.95,1.28 to 2.98) (table 4.11). 
People visually impaired due to AMD were more likely to be in the worst quintile for 
mobility score compared with people not visually impaired (odds ratio 1.85,1.21 to 
2.84). As for home management, there was little evidence of any difference between 
people visually impaired due AMD and those visually impaired due to other causes. 
Comparing people visually impaired due to AMD with those visually impaired due to 
other causes and controlling for binocular acuity score in addition to other confounding 
factors gave an odds ratio of 0.86 (0.43 to 1.71). 
SIP: Body care and movement score 
Visually impaired people were more likely to be in the worst quintile for body care and 
movement score compared with people not visually impaired (odds ratio 1.56,1.08 to 
2.25) (table 4.12). 
In contrast to all visually impaired people, people visually impaired due to AMD were 
not more likely to be in the worst quintile for mobility score compared with people not 
visually impaired (odds ratio 0.94,0.55 to 1.63). 
People with AMD appeared to fare better than people visually impaired due to other 
causes. Comparing people visually impaired due to AMD with those visually 
impaired 
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due to other causes and controlling for binocular acuity score in addition to other 
confounding factors gave an odds ratio of 0.42 (0.23 to 0.79). 
SIP: Social interaction score 
Visually impaired people were more likely to be in the worst quintile for social 
interaction score compared to people not visually impaired, however, this effect was not 
statistically significant (odds ratio 1.32,0.89 to 1.97) (table 4.13). 
Similar size effects were seen in people visually impaired due to other causes and 
people visually impaired due to AMD. Comparing people visually impaired due to 
AMD directly with those visually impaired due to other causes, controlling for 
binocular acuity score in addition to other confounding factors, suggested little 
difference between AMD and other causes in social interaction (odds ratio 1.02,0.42 to 
2.45). 
PGMS 
Visually impaired people were more likely to be in the worst quintile for PGMS score 
compared to people not visually impaired, however, this effect was modest and not 
statistically significant (odds ratio 1.23,0.84 to 1.81) (table 4.14). 
People visually impaired due to AMD were more likely to be in the worst quintile for 
PGMS score compared to people not visually impaired, however, as for visually 
impaired people as a whole, this effect was not statistically significant (odds ratio 1.44, 
0.86 to 2.40). There was little evidence for any differences between AMD and other 
causes in terms of their association with morale. Comparing people visually impaired 
due to AMD with those visually impaired due to other causes and controlling for 
binocular acuity score in addition to other confounding factors gave an odds ratio of 
1.01 (0.53 to 1.93). 
4.4.4 Effect modification by age and sex 
There was weak evidence that the association between visual impairment and home 
management score varied in men and women (interaction visual impairment*sex 
p=0.035) and stronger evidence that the association between visual 
impairment and the 
body care and movement score was different in men and women (interaction visual 
impairment*sex p=0.005). Repeating the analyses for men and women separately gave 
the following results. 
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In men, the odds ratio for being in the worst quintile for home management score in 
people visually impaired compared to those not visually impaired was 3.64 (2.37 to 
5.58). In women, the equivalent odds ratio was 1.46 (0.90 to 2.36). 
In men, the odds ratio for being in the worst quintile for home management score in 
people visually impaired due to AMD compared to those not visually impaired was 5.17 
(2.65 to 10.07). In women, the equivalent odds ratio was 1.12 (0.54 to 2.35). 
Similarly in the case of body care and movement score, visual impairment was 
associated with body care and movement in men but not in women. In men, the odds 
ratio for being in the worst quintile for body care and movement score in people 
visually impaired compared to those not visually impaired was 2.22 (1.64 to 2.99). In 
women, the equivalent odds ratio was 1.32 (0.88 to 2.00). 
In men, the odds ratio for being in the worst quintile for body care and movement score 
in people visually impaired due to AMD compared to those not visually impaired was 
1.74 (0.57 to 5.35). In women, the equivalent odds ratio was 1.01 (0.73 to 1.39). 
In men, the odds ratio for being in the worst quintile for body care and movement score 
in people visually impaired due to other causes compared to those not visually impaired 
was 2.42 (1.88 to 3.12). In women, the equivalent odds ratio was 1.47 (0.89 to 2.44). 
4.5 COGNITIVE IMPAIRMENT AND DEPRESSION 
4.5.1 Distribution in study population 
There were two measures of psychological well-being - cognitive ability as measured 
by the Mini Mental State Examination (MMSE) and depression as measured by the 
Geriatric Depression Scale (GDS). The MMSE was restricted to the "verbal" section 
only in order to avoid vision-dependant tasks. Both measures were converted to binary 
format using cut-points derived from the literature. The MMSE was dichotomised with 
a cutoff of less than 12 indicating poor cognitive ability. For GDS a cutpoint of six and 
above was used to indicate depression. 
Table 4.15 shows the distribution of these variables in the study population. 
Overall, 7.7% of the population was depressed as indicated by a GDS score of six or 
more. The prevalence of depression increased with increasing age from 6.5% in the 75- 
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79 age-group to 10.7% in people aged 90 years and above. Women had a marginally 
higher prevalence of depression than men (8.5% versus 6.5%). 
Overall, 5.4% of the population had cognitive impairment as defined by an MMSE 
(verbal section) of less than 12. The proportion of people with poor cognitive ability 
increased with increasing age from 2.6% in the 75-79 age-group to 19.6% in the 90 
years and above age-group. A greater proportion of women had poor cognitive ability 
than men (6.5% versus 3.5%). 
4.5.2 Association with confounding factors 
Table 4.1 shows the association of the variables indicating psychological well-being and 
potential confounding factors. Depression was strongly associated with all the potential 
confounding factors with the exception of alcohol consumption and cognitive 
impairment. Cognitive impairment was associated with fewer confounding factors. 
4.5.3 Association with visual impairment and AMD, controlling confounders 
Depression 
Visually impaired people were more likely to be depressed compared to people not 
visually impaired (odds ratio 1.46,1.22 to 1.76) (table 4.16). 
Similar size effects were seen in people visually impaired due to other causes and 
people visually impaired due to AMD. After controlling for visual acuity, there was 
little evidence for any difference between visual impairment due to AMD and visual 
impairment due to other causes - comparing people visually impaired due to AMD with 
those visually impaired due to other causes and controlling for binocular acuity score in 
addition to other confounding factors gave an odds ratio of 0.86 (0.58 to 1.27). 
Cognitive impairment 
Visually impaired people were more likely to be cognitively impaired compared with 
people not visually impaired (odds ratio 1.67,1.28 to 2.19) (table 4.17). 
People visually impaired due to AMD were more likely to be cognitively impaired 
compared to people not visually impaired, however, this effect was not statistically 
significant (odds ratio 1.36,0.87 to 2.13). 
Comparing people visually impaired due to AMD with those visually impaired due to 
other causes and controlling for binocular acuity score in addition to other confounding 
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factors gave an odds ratio of 0.59 (0.32 to 1.06). This result suggests that people with 
visual impairment due to AMD may be less likely to be cognitively impaired compared 
to people with visual impairment due to other causes, taking visual acuity into account. 
The upper confidence interval for this result crosses 1 however and therefore this 
finding is not statistically significant and could have arisen by chance. 
4.5.4 Effect modification by age and sex 
Models 1 and 2 (including all confounding factors) were repeated including interaction 
terms for "visual impairment term*sex" and "visual impairment term*age". There was 
no evidence of any effect modification by age and sex. 
4.6 FALLS AND HIP FRACTURES 
4.6.1 Distribution in study population 
There were two aspects of morbidity that were considered - falls and hip fractures. 
Table 4.18 shows the distribution of these in the study population. 
20% of the population reported having one or more falls at home in the last six months. 
12.5% had had one fall, 4.5% two falls, 2.0% three falls, and 1.9% four of more falls. 
The cut-point of two or more falls was chosen as this represented a group of people 
significantly affected by falls. 8.4% of the population reported two or more falls in the 
last six months. This proportion increased with increasing age from 5.9% in the 75-79 
age-group to 15.4% in the 90 years and above age-group. Women had a slightly higher 
risk of reporting two or more falls than men (9.0% vs. 7.5%). Overall 3.8% of the 
population reported having had a fractured hip. Women were much more likely to report 
fractured hip (5.0%) than men (1.9%). There was an increasing risk of hip fracture with 
age from 2.3% in the 75-79 age-group to 7.7% in the 90 years and above age-group. 
4.6.2 Association with confounding factors 
Table 4.1 shows the association of potential confounding factors with reported falls and 
hip fractures. 
Two or more falls at home was associated with most of the confounders, with the 
exception of smoking. Reported hip fracture was associated with fewer potential 
confounding factors. 
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4.6.3 Association with visual impairment and AMD, controlling confounders 
Falls 
Visually impaired people were more likely to report two or more falls at home in the 
last six months compared to not visually impaired people, however, this effect was 
modest and not statistically significant (odds ratio 1.18,0.95 to 1.47) (table 4.19). 
Similar size effects were observed in people visually impaired due to AMD and people 
visually impaired due to other causes. Comparing people visually impaired due to AMD 
with those visually impaired due to other causes and controlling for binocular acuity 
score in addition to other confounding factors gave an odds ratio of 0.89 (0.51 to 1.54). 
Hip fractures 
Visually impaired people were more likely to report a fractured hip compared to people 
not visually impaired, however, this effect was modest and not statistically significant 
(odds ratio 1.23,0.94 to 1.61) (table 4.20). 
As for falls there was little evidence of any difference between people visually impaired 
due to AMD and those visually impaired due to other causes. Comparing people 
visually impaired due to AMD with those visually impaired due to other causes and 
controlling for binocular acuity score in addition to other confounding factors gave an 
odds ratio of 0.86 (0.49 to 1.51). 
4.6.4 Effect modification by age and sex 
The association between visual impairment and reported hip fracture appeared to be 
different at different ages (p=0.045). Repeating the analyses in each age-group gave the 
following results: ages 75-79 the odds ratio of reporting hip fracture if visually impaired 
was 1.86 (0.97 to 3.56); ages 80-84 it was 1.22 (0.75 to 1.99); ages 85-89 it was 0.66 
(0.43 to 1.03); ages 90 years and above it was 2.21 (1.04 to 4.71). For AMD causing 
visual impairment the corresponding odds ratios were: ages 75-79,0.87 (0.11 to 7.17); 
ages 80-84 0.60 (0.21 to 1.74); ages 85-89 0.48 (0.20 to 1.15); ages 90 years and above 
3.75 (1.61 to 8.74). These figures suggest that the main difference occurs at ages 90 
years and above. At ages 75-89 the odds ratio of reporting 
hip fracture if visually 
impaired was 1.30 (0.96 to 1.76). At ages 90 years and above it was 2.21 (1.04 to 4.71). 
For AMD causing visual impairment the corresponding odds ratios were: ages 75-89 
0.78 (0.43 to 1.42); ages 90 years and above 3.75 (1.61 to 8.74). 
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4.7 MORTALITY 
4.7.1 Crude incidence rates and rate ratios 
Table 4.21 shows the incidence rates of mortality in the three groups. Non visually 
impaired people had an incidence rate of 0.072/person year at risk. There was an 
increased mortality rate in visually impaired compared to non-visually impaired people. 
People visually impaired due to AMD were nearly twice as likely to die following the 
detailed assessment, compared to people who were not visually impaired (rate ratio 
1.84,1.61 to 2.11). 
Similar size effects were observed in people visually impaired due to AMD and people 
visually impaired due to other causes. 
4.7.2 Association with confounding factors 
Mortality was strongly associated with all the potential confounding variables identified 
(table 4.1). 
4.7.3 Association with visual impairment and AMD, controlling confounders 
Three Cox proportional hazard models were constructed with deaths as the outcome and 
time since the detailed assessment as the person time at risk. December 31St was taken 
as the censoring date if still alive. Age, sex and all the potential confounding factors as 
set out in table 4.1 were included in these models. 
After controlling for all the potential confounders, visually impaired people had a 
hazard ratio of 1.32 (1.22 to 1.43) compared to people not visually impaired. People 
visually impaired due to AMD had a lower risk (hazard ratio 1.21,1.07 to 1.37). 
Comparing people visually impaired due to AMD with those visually impaired due to 
other causes, including a term for binocular acuity score in the model, gave a hazard 
ratio of 0.76 (0.63 to 0.90). This indicates that mortality in people visually impaired due 
to AMD is significantly lower than in people visually impaired due to other causes, after 
taking into account obvious confounders, including visual acuity. 
4.7.4 Effect modification by age and sex 
There was no evidence for any effect modification by age and sex. 
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4.8 KEY POINTS 
After controlling for appropriate confounding factors, compared to people not visually 
impaired, visually impaired people were more likely to: 
" report "a lot of difficulty" reading newsprint 
" report difficulty managing finances 
" be in the worst quintile for ADL score 
" be in the worst quintile for the following dimensions of the SIP: home management, 
mobility and body care and movement 
" be cognitively impaired 
" be depressed 
" die 
After controlling for appropriate confounding factors, compared to people not visually 
impaired, people visually impaired due to AMD were more likely to: 
" report "a lot of difficulty" reading newsprint 
" report difficulty managing finances 
" be in the worst quintile for ADL score 
" report "fair/poor" health 
" be in the worst quintile for the following dimensions of the SIP: home management, 
mobility 
" be depressed 
" die 
After controlling for appropriate confounding factors including binocular acuity score, 
compared to people visually impaired due to other causes, people visually impaired due 
to AMD were more likely to: 
" report "a lot of difficulty" reading newsprint 
" report difficulty managing finances 
" be in the worst quintile for ADL score 
" report "fair/poor" health 
and less likely to: 
" be in the worst quintile for SIP body care and movement dimension 
" die. 
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Table 4.2 Percentage with "a lot of difficulty" reading newsprint, difficulty 
managing finances or in worst quintile for ADL score by age and sex 
% with 
% with "outcome" in each age- "outcome" in 
group men and women 
% with 
Outcome "outcome" 75-79 80-84 85-89 90+ Men Women 
A lot of 
difficulty 9.9 5.0 10.7 16.2 27.7 7.7 11.2 
reading 
newsprint 
Difficulty 
managing own 3.4 1.9 3.4 
finances 
Activities of 
daily living - 18.9 9.3 18.8 
worst quintile 
6.0 9.4 2.8 3.8 
34.0 54.6 13.7 22.0 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. 
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Table 4.3 "A lot of difficulty" reading newsprint: logistic regression models 
assessing the associations with visual impairment, visual impairment due to other 
causes and visual impairment due to AMD 
Values in Model 1 Model 2 Model 3 
the table are 
odds ratios 
(95% c. i. ) Comparing VI 
Comparing VI Comparing VI due AMD 
Comparing VI other causes with due AMD with with VI other 
with not VI not VI not VI causes 
(a) 
Controlled 12.99 8.47 37.88 3.13 
age & sex 
(10.60 to 15.91) (6.83 to 10.50) (29.60 to 48.48) (2.39 to 4.11) 
(b) 
Controlled 
for all 
confounders 13.22 7.72 46.84 3.84 
except those (10.53 to 16.59) (6.06 to 9.83) (33.32 to 65.83) (2.63 to 5.62) 
potentially 
on causal 
pathway 
(c) 
Controlled 13.34 7.68 48.97 3.96 
age, sex, & (10.56 to 16.85) (5.98 to 9.87) (34.93 to 68.65) (2.66 to 5.90) 
all 
confounders 
VI = visual impairment 
(a) Models 1 to 3 were constructed as follows: the outcome/dependant variable was 
0=none/little difficulty reading newsprint 1=a lot of difficulty reading newsprint. 
Terms for age (75-79,80-84,85-89,90+), sex and visual impairment were 
included. Binocular visual acuity score (quintiles) was included in model 3. 
(b) As for (a) including terms for all potential confounding factors (see table 4.1) 
but not including terms for confounders potentially on causal pathway 
(c) As for (a) including terms for all potential confounding factors (see table 4.1). 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. Confidence intervals adjusted for 
clustered design of the study. 
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Table 4.4 Difficulty managing finances: logistic regression models assessing 
associations with of visual impairment, visual impairment due to other causes and 
visual impairment due to AMD 
Values in the Model 1 Model 2 Model 3 
table are odds Comparing 
ratios (95% Comparing VI Comparing VI VI due AMD 
c. i. ) Comparing VI other causes due AMD with with VI other 
with not VI with not VI not VI causes 
(a) Controlled 
age & sex 
3.01 
(2.40 to 3.78) 
2.56 4.08 1.47 
(2.02 to 3.24) (3.00 to 5.54) 
(1.04 to 
2.09) 
(b) Controlled 
for all 
confounders 
except those 
potentially on 
causal 
pathway 
2.81 
(2.27 to 3.48) 
(c) Controlled 2 . 52 age, sex, & all (1.98 to 3.21) 
confounders 
VI = visual impairment 
2.20 4.33 1.57 
(1.72 to 2.80) (3.16 to 5.93) 
(1.48 to 
1.89 4.12 
1.66 
(1.42 to 2.52) (2.95 to 5.76) 
(1.03 to 
2.67) 
(a) Models 1 to 3 were constructed as follows: the outcome/dependant variable was 
O=no difficulty 1=difficulty managing finances. Terms for age (75-79,80-84, 
85-89,90+), sex and visual impairment were included. Binocular visual acuity 
score (quintiles) was included in model 3. 
(b) As for (a) including terms for all potential confounding factors (see table 4.1) 
but not including terms for confounders potentially on causal pathway 
(c) As for (a) including terms for all potential confounding factors (see table 4.1). 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. Confidence 
intervals adjusted for 
clustered design of the study. 
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Table 4.5 Worst quintile for ADL score: logistic regression models assessing 
associations with of visual impairment, visual impairment due to other causes and 
visual impairment due to AMD 
Model 1 Model 2 Model 3 
Values in the Comparing 
table are odds Comparing VI Comparing VI VI due AMD 
ratios (95% Comparing VI other causes due AMD with with VI other 
c. i. ) with not VI with not VI not VI causes 
(a) Controlled 
2.39 
age & sex (2.01 to 2.83) 
(b) Controlled 
for all 
confounders 2.00 
except those (1.58 to 2.52) 
potentially on 
causal 
pathway 
(c) Controlled 1.86 
age, sex, & all (1.47 to 2.36) 
confounders 
VI = visual impairment 
2.31 2.57 1.09 
(1.88 to 2.84) (2.06 to 3.21) 
(0.82 to 
1.44) 
1.71 2.76 1.44 
(1.31 to 2.23) (2.01 to 3.79) 
(0.96 to 
2.16) 
1.55 2.72 1.65 
(1.16 to 2.06) (1.98 to 3.73) 
(1.07 to 
2.55) 
(a) Models 1 to 3 were constructed as follows: the outcome/dependant variable was 
0=not in worst quintile 1=in worst quintile for ADL score. Terms for age (75-79, 
80-84,85-89,90+), sex and visual impairment were included. Binocular visual 
acuity score (quintiles) was included in model 3. 
(b) As for (a) including terms for all potential confounding factors (see table 4.1) 
but not including terms for confounders potentially on causal pathway 
(c) As for (a) including terms for all potential confounding factors (see table 4.1). 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. Confidence intervals adjusted for 
clustered design of the study. 
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Table 4.6 Percentage reporting "fair/poor" health or "not at all" physically active 
by age and sex 
with"outcome" 
in men & 
% with "outcome" in each age-group women 
% with 
Outcome "outcome" 75-79 80-84 85-89 90+ Men Women 
Self-reported 
"fair/poor" 16.1 14.7 16.8 18.8 16.7 14.4 17.2 
health 
Reported being 
"not at all" 4.8 3.1 4.6 7.8 12.0 4.2 5.2 
physically 
active 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. 
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Table 4.7 "Fair/poor" self-reported health: logistic regression models assessing 
associations with of visual impairment, visual impairment due to other causes and 
visual impairment due to AMD 
Values in the 
table are odds 
ratios (95% 
c. i. ) 
Model 1 Model 2 Model 3 
(a) Controlled 
age & sex 
(b) Controlled 
for all 
confounders 
except those 
potentially on 
causal 
pathway 
Comparing VI 
with not VI 
1.73 
(1.51 to 1.98) 
1.29 
(1.07 to 1.56) 
(c) Controlled 1.20 
age, sex, & all (0.98 to 1.47) 
confounders 
VI = visual impairment 
Comparing 
Comparing VI Comparing VI VI due AMD 
other causes due AMD with with VI other 
with not VI not VI causes 
1.73 1.73 1.12 
(1.49 to 2.01) (1.38 to 2.15) (0.85 to 
1.48) 
1.17 1.63 1.67 
(0.94 to 1.45) (1.24 to 2.13) 
(1.16 to 
2.39) 
1.07 1.54 1.86 
(0.85 to 1.36) (1.15 to 2.06) 
(1.26 to 
2.74) 
(a) Models 1 to 3 were constructed as follows: the outcome/dependant variable was 
0="excellent/very good/good" health 1="fair/poor" health. Terms for age (75- 
79,80-84,85-89,90+), sex and visual impairment were included. Binocular 
visual acuity score (quintiles) was included in model 3. 
(b) As for (a) including terms for all potential confounding factors (see table 4.1) 
but not including terms for confounders potentially on causal pathway 
(c) As for (a) including terms for all potential confounding factors (see table 4.1). 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. Confidence intervals adjusted for 
clustered design of the study. 
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Table 4.8 "Not at all" physically active: logistic regression models assessing 
associations with of visual impairment, visual impairment due to other causes and 
visual impairment due to AMD 
Values in the 
table are odds 
ratios (95% 
c. i. ) 
Model 1 
Comparing VI 
with not VI 
Model 2 
Comparing VI Comparing VI 
other causes due AMD with 
with not VI not VI 
Model 3 
Comparing 
VI due AMD 
with VI other 
causes 
(a) Controlled 2.14 2.21 1.98 1.03 
age & sex (1.71 to 2.66) (1.73 to 2.81) (1.42 to 2.77) 
(0.67 to 
1.58) 
(b) Controlled 
for all 
confounders 1 52 1.51 1.55 1.16 
except those . (1.16 to 2.00) (1.10 to 2.06) (1.03 to 2.35) 
(0.68 to 
potentially on 1.95) 
causal 
pathway 
(c) Controlled 32 1 1.32 1.32 1.19 
age, sex, & all . (0.99 to 1.76) (0.95 to 1.84) (0.82 to 2.10) 
(0.68 to 
confounders 2.10) 
VI = visual impairment 
(a) Models 1 to 3 were constructed as follows: the outcome/dependant variable was 
0="very/fairly/not very" 1="not at all" physically active. Terms for age (75-79, 
80-84,85-89,90+), sex and visual impairment were included. Binocular visual 
acuity score (quintiles) was included in model 3. 
(b) As for (a) including terms for all potential confounding factors (see table 4.1) 
but not including terms for confounders potentially on causal pathway 
(c) As for (a) including terms for all potential confounding factors (see table 4.1). 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. Confidence intervals adjusted for 
clustered design of the study. 
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Table 4.9 Sickness Impact Profile and Philadelphia Geriatric Morale Scale: 
percentage of people in the worst quintile by age and sex* 
% in worst quintile in each 
age-group 
% in worst quintile 
in men and women 
% in 
worst 
quintile 75-79 80-84 85+ Men Women 
Sickness Impact Profile 
Home 20.2 10.9 21.6 40.1 17.3 22.2 
management 
Mobility 20.0 11.6 21.2 38.0 13.9 24.0 
Body care and 20.0 12.4 20.7 36.8 14.6 23.5 
movement 
Social interaction 19.5 13.7 21.0 31.0 17.1 21.1 
Philadelphia Geriatric Morale Scale 
PGMS 22.8 20.4 23.9 27.7 15.6 27.5 
Data from the 11 practices in which quality of life interviews done and which also in 
universal arm of MRC Trial and causes of visual impairment study (23 practices in 
whole MRC Trial randomly selected for quality of life interviews). 
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Table 4.10 Worst quintile for SIP home management score: logistic regression 
models assessing associations with visual impairment, visual impairment due to 
other causes and visual impairment due to AMD 
Values in the Model 1 Model 2 Model 3 
table are odds Comparing 
ratios (95% Comparing VI Comparing VI VI due AMD 
c. i. ) Comparing VI other causes due AMD with with VI other 
with not VI with not VI not VI causes 
(a) Controlled 
age & sex 
(b) Controlled 
age, sex & 
housing tenure 
2.26 
(1.74 to 2.95) 
1.99 
(1.51 to 2.63) 
2.30 
(1.71 to 3.10) 
2.05 
(1.41 to 2.99) 
2.17 0.63 
(1.34 to 3.51) (0.26 to 
1.56) 
1.85 0.63 
(1.03 to 3.34) (0.23 to 
1.76) 
VI = visual impairment 
(a) Models 1 to 3 were constructed as follows: the outcome/dependant variable was 
0=not in worst quintile 1=in worst quintile for SIP home management score. 
Terms for age (75-79,80-84,85-89,90+), sex and visual impairment were 
included. Binocular visual acuity score (quintiles) was included in model 3. 
(b) As for (a) including terms for all potential confounding factors (see section 
4.4.2) 
Data from the 11 practices in which quality of life interviews done and which also in 
universal arm of MRC Trial and causes of visual impairment study (23 practices in 
whole MRC Trial randomly selected for quality of life interviews). Confidence intervals 
adjusted for clustered design of the study. 
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Table 4.11 Worst quintile for SIP mobility score: logistic regression models 
assessing associations with visual impairment, visual impairment due to other 
causes and visual impairment due to AMD 
Values in the 
table are odds 
ratios (95% 
c. i. ) 
Model 1 
Comparing VI 
with not VI 
Model 2 
Comparing VI 
other causes 
with not VI 
Comparing VI 
due AMD with 
not VI 
Model 3 
Comparing 
VI due AMD 
with VI other 
causes 
(a) Controlled 
age & sex 
(b) Controlled 
age, sex & 
housing tenure 
2.22 
(1.52 to 3.24) 
1.95 
(1.28 to 2.98) 
2.26 
(1.51 to 3.38) 
1.99 
(1.22 to 3.25) 
2.13 0.84 
(1.34 to 3.38) 
(0.43 to 
1.64) 
1.85 0.86 
(1.21 to 2.84) 
(0.43 to 
1.71) 
VI = visual impairment 
(a) Models 1 to 3 were constructed as follows: the outcome/dependant variable was 
0=not in worst quintile 1=in worst quintile for SIP mobility score. Terms for age 
(75-79,80-84,85+), sex and visual impairment were included. Binocular visual 
acuity score (quintiles) was included in model 3. 
(b) As for (a) including terms for potential confounding factors (see section 4.4.2) 
Data from the 11 practices in which quality of life interviews done and which also in 
universal arm of MRC Trial and causes of visual impairment study (23 practices in 
whole MRC Trial randomly selected for quality of life interviews). Confidence intervals 
adjusted for clustered design of the study. 
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Table 4.12 Worst quintile for SIP body care and movement score: logistic 
regression models assessing associations with visual impairment, visual 
impairment due to other causes and visual impairment due to AMD 
Values in the 
table are odds 
ratios (95% 
c. i. ) 
Model 1 Model 2 Model 3 
(a) Controlled 
age & sex 
(b) Controlled 
age, sex, 
prescribed 
medicines & 
depression 
Comparing 
Comparing VI Comparing VI VI due AMD 
Comparing VI other causes due AMD with with VI other 
with not VI with not VI not VI causes 
1.80 2.03 1.31 0.54 
(1.33 to 2.43) (1.52 to 2.71) (0.77 to 2.23) 
(0.37 to 
0.79) 
1.56 1.89 0.94 0.42 
(1.08 to 2.25) (1.29 to 2.78) (0.55 to 1.63) 
(0.23 to 
0.79) 
VI = visual impairment 
(a) Models 1 to 3 were constructed as follows: the outcome/dependant variable was 
0=not in worst quintile 1=in worst quintile for SIP body care and movement 
score. Terms for age (75-79,80-84,85+), sex and visual impairment were 
included. Binocular visual acuity score (quintiles) was included in model 3. 
(b) As for (a) including terms for potential confounding factors (see section 4.4.2) 
Data from the 11 practices in which quality of life interviews done and which also in 
universal arm of MRC Trial and causes of visual impairment study (23 practices in 
whole MRC Trial randomly selected for quality of life interviews). Confidence intervals 
adjusted for clustered design of the study. 
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Table 4.13 Worst quintile for SIP social interaction score: logistic regression 
models assessing associations with visual impairment, visual impairment due to 
other causes and visual impairment due to AMD 
Values in the Model 1 
table are odds 
ratios (95% 
c. i. ) 
Comparing VI 
with not VI 
(a) Controlled 1.61 
age & sex (1.14 to 2.28) 
(b) Controlled 
age, sex, BMI 
& depression 
1.32 
(0.89 to 1.97) 
VI = visual impairment 
Model 2 
Comparing VI Comparing VI 
other causes due AMD with 
with not VI not VI 
1.65 
(1.15 to 2.38) 
1.51 
(0.98 to 2.35) 
1.30 
(0.83 to 2.06) 
1.37 
(0.86 to 2.18) 
Model 3 
Comparing 
VI due AMD 
with VI other 
causes 
0.98 
(0.57 to 
1.69) 
1.02 
(0.42 to 
2.45) 
(a) Models 1 to 3 were constructed as follows: the outcome/dependant variable was 
0=not in worst quintile 1=in worst quintile for SIP social interaction score. 
Terms for age (75-79,80-84,85+), sex and visual impairment were included. 
Binocular visual acuity score (quintiles) was included in model 3. 
(b) As for (a) including terms for potential confounding factors (see section 4.4.2) 
Data from the 11 practices in which quality of life interviews done and which also in 
universal arm of MRC Trial and causes of visual impairment study (23 practices in 
whole MRC Trial randomly selected for quality of life interviews). Confidence intervals 
adjusted for clustered design of the study. 
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Table 4.14 Worst quintile for PGMS: logistic regression models assessing 
associations with visual impairment, visual impairment due to other causes and 
visual impairment due to AMD 
Values in the 
table are odds 
ratios (95% 
C. i. ) 
(a) Controlled 
age & sex 
Model 1 
Comparing VI 
with not VI 
1.37 
(0.94 to 2.00) 
(b) Controlled 1.23 
age, sex & (0.84 to 1.81) housing tenure 
VI = visual impairment 
Model 2 
Comparing VI Comparing VI 
other causes due AMD with 
with not VI not VI 
1.31 
(0.90 to 1.90) 
1.56 
(0.88 to 2.75) 
1.16 
(0.75 to 1.78) 
1.44 
(0.86 to 2.40) 
Model 3 
Comparing 
VI due AMD 
with VI other 
causes 
0.96 
(0.51 to 
1.82) 
1.01 
(0.53 to 
1.93) 
(a) Models 1 to 3 were constructed as follows: the outcome/dependant variable was 
0=not in worst quintile 1=in worst quintile for PGMS. Terms for age (75-79,80- 
84,85+), sex and visual impairment were included. Binocular visual acuity 
score (quintiles) was included in model 3. 
(b) As for (a) including terms for potential confounding factors (see section 4.4.2) 
Data from the 11 practices in which quality of life interviews done and which also in 
universal arm of MRC Trial and causes of visual impairment study (23 practices in 
whole MRC Trial randomly selected for quality of life interviews). Confidence intervals 
adjusted for clustered design of the study. 
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Table 4.15 Percentage depressed (GDS 6+) or cognitively impaired (MMSE<12) by 
age and sex 
% with "outcome" in each age- 
group 
%/n with 
Outcome "outcome" 75-79 80-84 
% with 
"outcome" in men 
and women 
85-89 90+ Men Women 
Depression 7.7 6.5 7.8 10.1 10.7 6.5 8.5 
(GDS 6+) 
Cognitive 5.4 2.6 5.1 9.0 19.6 3.5 6.5 
impairment 
(MMSE<12) 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. 
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Table 4.16 Depression (GDS 6+): logistic regression models assessing associations 
with visual impairment, visual impairment due to other causes and visual 
impairment due to AMD 
Values in the 
table are odds 
ratios (95% 
c. i. ) 
Model 1 
Comparing VI 
with not VI 
Model 2 
Comparing VI 
other causes 
with not VI 
Comparing VI 
due AMD with 
not VI 
Model 3 
Comparing 
VI due AMD 
with VI other 
causes 
(a) Controlled 1.72 1.64 1.92 1.21 
age & sex (1.53 to 1.95) (1.34 to 2.01) (1.47 to 2.49) 
(0.81 to 
1.80) 
(b) Controlled 
for all 
confounders 1.47 1.48 1.45 
0.85 
except those (0.58 to 
potentially on 
(1.23 to 1.77) (1.16 to 1.89) (1.07 to 1.96) 1.25) 
causal 
pathway 
(c) Controlled 1.46 1.46 1.47 
0.86 
age, sex, & all (1.22 to 1.76) (1.14 to 1.87) (1.10 to 1.97) 
(0.58 to 
confounders 1.27) 
VI = visual impairment 
(a) Models 1 to 3 were constructed as follows: the outcome/dependant variable was 
0=not depressed (GDS <6) 1=depressed (GDS 6+). Terms for age (75-79,80-84, 
85-89,90+), sex and visual impairment were included. Binocular visual acuity 
score (quintiles) was included in model 3. 
(b) As for (a) including terms for all potential confounding factors (see table 4.1) 
but not including terms for confounders potentially on causal pathway 
(c) As for (a) including terms for all potential confounding factors (see table 4.1). 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. Confidence intervals adjusted for 
clustered design of the study. 
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Table 4.17 Cognitive impairment (MMSE <12): logistic regression models 
assessing associations with visual impairment, visual impairment due to other 
causes and visual impairment due to AMD 
Values in the Model 1 Model 2 Model 3 
table are odds Comparing 
ratios (95% Comparing VI Comparing VI VI due AMD 
c. i. ) Comparing VI other causes due AMD with with VI other 
with not VI with not VI not VI causes 
(a) Controlled 2.09 
age & sex (1.67 to 2.61) 
(b) Controlled 
for all 
confounders 1.67 
except those (1.27 to 2.18) 
potentially on 
causal 
pathway 
(c) Controlled 1.67 
age, sex, & all (1.28 to 2.19) 
confounders 
VI = visual impairment 
2.39 1.46 0.61 
(1.89 to 3.03) (0.99 to 2.17) 
(0.41 to 
0.92) 
1.82 1.34 0.58 
(1.31 to 2.51) (0.86 to 2.10) 
(0.33 to 
1.05) 
1.81 1.36 0.59 
(1.31 to 2.52) (0.87 to 2.13) 
(0.32 to 
1.06) 
(a) Models 1 to 3 were constructed as follows: the outcome/dependant variable was 
0=not cognitively impaired (MMSE 12+) 1=cognitively impaired (MMSE<12). 
Terms for age (75-79,80-84,85-89,90+), sex and visual impairment were 
included. Binocular visual acuity score (quintiles) was included in model 3. 
(b) As for (a) including terms for all potential confounding factors (see table 4.1) 
but not including terms for confounders potentially on causal pathway 
(c) As for (a) including terms for all potential confounding factors (see table 4.1). 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. Confidence intervals adjusted for 
clustered design of the study. 
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Table 4.18 Percentage reporting two or more falls at home in last six months or hip 
fracture by age and sex 
% with "outcome" 
Outcome 
% with % with "outcome" in each age- in men and 
"outcome" group women 
75-79 80-84 85-89 90+ Men Women 
Two or more 
falls at home in 8.4 5.9 9.1 12.0 15.4 7.5 9.0 
the last six 
months 
Reported hip 3.8 2.3 4.2 6.0 7.7 1.9 5.0 
fracture 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. 
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Table 4.19 Two or more falls at home in last six months: logistic regression models 
assessing associations with visual impairment, visual impairment due to other 
causes and visual impairment due to AMD 
Values in the 
table are odds 
ratios (95% 
c. i. ) 
Model 1 
Comparing VI 
with not VI 
Model 2 
Comparing VI Comparing VI 
other causes due AMD with 
with not VI not VI 
Model 3 
Comparing 
VI due AMD 
with VI other 
causes 
(a) Controlled 1.49 1.55 1.34 0.76 
age & sex (1.28 to 1.74) (1.29 to 1.86) (1.04 to 1.74) 
(0.51 to 
1.13) 
(b) Controlled 
for all 
confounders 1.23 1.23 1.21 0.88 
except those (0.51 to 
potentially on 
(0.98 to 1.53) (0.98 to 1.56) (0.81 to 1.81) 1.53) 
causal 
pathway 
(c) Controlled 1.18 1.19 1.16 0.89 
age, sex, & all (0.95 to 1.47) (0.95 to 1.50) (0.78 to 1.72) 
(0.51 to 
confounders 1.54) 
VI = visual impairment 
(a) Models 1 to 3 were constructed as follows: the outcome/dependant variable was 
0=none or one fall 1 --two or more falls at home in last six months. Terms for age 
(75-79,80-84,85-89,90+), sex and visual impairment were included. Binocular 
visual acuity score (quintiles) was included in model 3. 
(b) As for (a) including terms for all potential confounding factors (see table 4.1) 
but not including terms for confounders potentially on causal pathway 
(c) As for (a) including terms for all potential confounding factors (see table 4.1). 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. Confidence intervals adjusted for 
clustered design of the study. 
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Table 4.20 Reported hip fracture: logistic regression models assessing associations 
with visual impairment, visual impairment due to other causes and visual 
impairment due to AMD 
Values in the Model 1 Model 2 Model 3 
table are odds Comparing 
ratios (95% Comparing VI Comparing VI VI due AMD 
c. i. ) Comparing VI other causes due AMD with with VI other 
with not VI with not VI not VI causes 
(a) Controlled 1.46 
age & sex (1.14 to 1.88) 
(b) Controlled 
for all 
confounders 1.24 
except those (0.95 to 1.61) 
potentially on 
causal 
pathway 
(c) Controlled 1.23 
age, sex, & all (0.94 to 1.61) 
confounders 
VI = visual impairment 
1.47 1.45 1.00 
(1.09 to 1.98) (1.07 to 1.97) 
(0.70 to 
1.30 1.10 0.86 
(0.92 to 1.84) (0.74 to 1.65) 
(0.49 to 
1.51) 
1.30 1.10 
0.86 
(0.92 to 1.83) (0.73 to 1.65) 
(0.49 to 
1.51) 
(a) Models 1 to 3 were constructed as follows: the outcome/dependant variable was 
O=no reported hip fracture 1=reported hip fracture. Terms for age (75-79,80-84, 
85-89,90+), sex and visual impairment were included. Binocular visual acuity 
score (quintiles) was included in model 3. 
(b) As for (a) including terms for all potential confounding factors (see table 4.1) 
but not including terms for confounders potentially on causal pathway 
(c) As for (a) including terms for all potential confounding factors (see table 4.1). 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. Confidence 
intervals adjusted for 
clustered design of the study. 
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Table 4.21 Visual impairment and mortality rate 
Category Number Person- Incidence 95% c. i. Rate 95% c. i. 
of time at rate ratio 
deaths risk 
(years) 
Not visually 3863 53691 0.072 0.070 to 0.074 
impaired  
Visually 909 
impaired 
Not visually 3863 
impaired 
Visually 649 
impaired 
other causes 
Visually 260 
impaired 
AMD 
1 
6569 0.138 0.130 to 0.148 1.92 1.75 to 2.11 
53691 0.072 0.070 to 0.074 1 
4609 0.141 0.130 to 0.152 1.96 1.76 to 2.17 
1960 0.133 0.117 to 0.150 1.84 1.61 to 2.11 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. Confidence intervals adjusted for 
clustered design of the study. 
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Table 4.22 Mortality: Cox proportional hazard models assessing associations with 
visual impairment, visual impairment due to other causes and visual impairment 
due to AMD 
Values in the Model 1 Model 2 Model 3 
table are Comparing 
hazard ratios Comparing VI Comparing VI VI due AMD 
(95% c. i. ) Comparing VI other causes due AMD with with VI other 
with not VI with not VI not VI causes 
(a) Controlled 
age & sex 
1.53 
(1.43 to 1.63) 
1.63 1.32 0.72 
(1.50 to 1.76) (1.17 to 1.49) 
(ö g3 to 
(b) Controlled 
for all 
confounders 
except those 
potentially on 
causal 
pathway 
1.29 
(1.20 to 1.39) 
(c) Controlled 1.32 
age, sex, & all (1.22 to 1.43) 
confounders 
VI = visual impairment 
1.33 1.20 0.79 
(1.23 to 1.45) (1.06 to 1.36) 
(0.66 to 
0.94) 
1.37 1.21 0.76 
(1.26 to 1.49) (1.07 to 1.37) 
(0.63 to 
0.90) 
(a) Models 1 to 3 were Cox proportional hazards models with death as the outcome. 
Terms for age (75-79,80-84,85-89,90+), sex and visual impairment were 
included. Binocular visual acuity score (quintiles) was included in model 3. 
(b) As for (a) including terms for all potential confounding factors (see table 4.1) 
but not including terms for confounders potentially on causal pathway 
(c) As for (a) including terms for all potential confounding factors (see table 4.1). 
Data from the 49 practices taking part in the cause of visual impairment study out of 53 
practices in the universal arm of the MRC Trial. 32 people not traced. 
Confidence 
intervals adjusted for clustered design of the study. 
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Figure 4.1 Analysis plan for 
assessing effects of AMD 
causing visual impairment on 
functional limitations and 
perceived health 
Other factors: Age, 
sex, socioeconomic 
status, social 
support, smoking, 
alcohol, BMI 
Other diseases or 
impairments: 
Stroke, diabetes, 
swelling of legs, 
shortness of breath, 
prescribed medicines 
Potential confounding factors 
Confounding factors ? on causal pathway 
Exposure i. e. AMD causing visual impairment 
"Disease" i. e. impact outcome 
Functional limitations 
" Difficulty reading 
newsprint 
" Difficulty 
managing finances 
" ADL score 
AMD 
causin 
visual 
impairment 
Perceived health 
" Self-reported 
health 
" Self-reported 
physical activity 
Other diseases or 
impairments 
Depression, cognitive 
impairment, hip 
fractures and falls 
Steps in analysis 
(1) Association between potential confounding factor and AMID 
causing visual impairment: if design-based x, 2 <0.05 included as a confounding factor 
in (2) 
1 (2) Effect of confounding factor on outcome: logistic model, outcome 
as dependent variable, terms for age, sex and confounder, if Wald test <0.05 included 
as a confounding factor in (3). 
(3) Effect of AMD causing visual impairment on outcome, controlling 
confounders identified above: logistic model, outcome as dependent variable, terms 
for age, sex, confounders and AMD causing visual impairment 
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assessing effects of AMID 
causing visual impairment on 
SIP and PGMS 
Other factors: Age, 
sex, socioeconomic 
status, social 
support, smoking, 
alcohol, BMI 
Other diseases or 
impairments: 
Stroke, diabetes, 
swelling of legs, 
shortness of breath, 
prescribed medicines 
Other diseases or 
impairments 
Depression, cognitive 
impairment, hip 
fractures and falls 
Steps in analysis 
Potential confounding factors 
I Confounding factors ? on causal pathway 
I 
Exposure i. e. ANID causing visual impairment 
"Disease" i. e. impact outcome 
Sickness Impact 
Profile 
AMID 
causin 
visual 
impairment 
* Philadelphia 
Geriatric Morale Scale 
'Iq 11, (1) Association 
between potential confounding factor and AMD 
causing visual impairment: if design-based x2 <0.05 included as a confounding factor 
in (2) 
10 (2) Effect of confounding factor on outcome: logistic model, outcome PPI 
as dependent variable, terms for age, sex and confounder, if Wald test <0.05 included 
as a confounding factor in (3). 
PP, (3) Effect of AMD causing visual impairment on outcome, controlling 
confounders identified above: logistic model, outcome as dependent variable, terms 
for age, sex, confounders and AMD causing visual impairment 
* For PGMS depression not considered as a confounder due to conceptual overlap. 
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Figure 4.3 Analysis plan for 
assessing effects of AMD 
causing visual impairment on 
depression and cognitive 
impairment 
Other factors: Age, 
sex, socioeconomic 
status, social 
support, smoking, 
alcohol, BMI 
Other diseases or 
impairments: 
Stroke, diabetes, 
swelling of legs, 
shortness of breath, 
prescribed medicines 
Other diseases or 
impairments 
hip fractures and falls 
Steps in analysis 
Potential confounding factors 
Confounding factors ? on causal pathway 
Exposure i. e. AMD causing visual impairment 
"Disease" i. e. impact outcome 
Cognitive impairment 
AMID 
causin 
visual 
impairment 
Depression 
(1) Association between potential confounding factor and AMD 
causing visual impairment: if design-based x2 <0.05 included as a confounding factor 
in (2) 
(2) Effect of confounding factor on outcome: logistic model, outcome 
as dependent variable, terms for age, sex and confounder, if Wald test <0.05 included 
as a confounding factor in (3). 
kh- (3) Effect of AMID causing visual impairment on outcome, controlling 
confounders identified above: logistic model, outcome as dependent variable, terms 
for age, sex, confounders and AMID causing visual impairment 
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Figure 4.4 Analysis plan for 
assessing effects of AMD 
causing visual impairment on 
falls and hipfractures 
Other factors: Age, 
sex, socioeconomic 
status, social 
support, smoking, 
alcohol, BMI 
Other diseases or 
impairments: 
Stroke, diabetes, 
swelling of legs, 
shortness of breath, 
prescribed medicines 
/ Other diseases or 
impairments 
Depression, cognitive 
impairment 
Steps in analysis 
Potential confounding factors 
Confounding factors ? on causal pathway 
Exposure i. e. AMD causing visual impairment 
"Disease" i. e. impact outcome 
Falls 
Two or more falls 
reported at home in 
last six months 
AMD 
causin 
visual 
impairment 
Reported hip fracture 
(1) Association between potential confounding factor and AMID 
causing visual impairment: if design-based x2 <0.05 included as a confounding factor 
in (2) 
---1 (2) Effect of confounding factor on outcome: logistic model, outcome 
as dependent variable, terms for age, sex and confounder, if Wald test <0.05 included 
as a confounding factor in (3). 
hh, OP, (3) Effect of AMID causing visual impairment on outcome, controlling 
confounders identified above: logistic model, outcome as dependent variable, terms 
for age, sex, confounders and AMID causing visual impairment 
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5.1 INTRODUCTION 
5.1.1 Research questions 
The aim of this chapter is to investigate the aetiology of visually impairing AMD in 
people aged 75 years and above in the UK, that is, to test the following hypotheses: 
" that smoking cigarettes and drinking alcohol are associated with an increased 
risk of visually impairing AMD; 
" that people with evidence of cardiovascular disease are at increased risk of 
developing visually impairing AMD; 
" that factors indicating increased oestrogen exposure in women are protective for 
developing visually impairing AMD. 
5.1.2 Terminology 
The terminology used in this chapter is as follows. The outcome under study was 
case/control status with cases being people with AMD causing visual impairment and 
controls being people with good vision (binocular acuity of 6/6 or better). The risk 
factors studied were termed exposures (e. g. smoking). All exposures were also 
considered as possible confounding factors for other exposures 
i. e. as variables 
associated with both exposure and outcome that might influence the observed 
association. Other confounding factors were identified by review of the 
literature. 
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Confidence intervals and statistical significance 
As for chapter four, 95% confidence intervals are reported in brackets (lower to upper) 
after the effect estimates (odds ratio). If the effect estimate is already in brackets the 
95% confidence intervals are quoted after a comma. Statistical significance (p<0.05) is 
assumed whenever the confidence intervals do not cross unity. 
5.1.3 A note about choice of control group 
In the case-control study described in this chapter, I have a population-based group of 
people with severe AMD and I want to compare them to a population-based group of 
people without AMD. The aim behind selecting the control group for the case-control 
study is to minimise the proportion of controls who had AMD. 
If this had been a cross-sectional eye survey where everybody was examined for signs of 
AMD, then the control group would clearly be everyone in the survey who did not have 
AMD. However, I was unable to examine the controls. I therefore decided to select a 
control group of people with good vision who would be less likely to have ARM or 
AMD. I felt that it was important in the analyses of aetiological risk factors because I 
wanted to assess potential causes of AMD. This decision was taken before I did any 
analyses. In case-control studies it is common to define cases and controls at each end 
of a spectrum. 
It must be noted that this study design is different to the previous chapters. In chapter 
three, I considered the prevalence of AMD causing visual impairment. When 
calculating a prevalence figure p, the comparison group is, by definition 1-p. In chapter 
four, I was investigating the functional impact of AMD, therefore the existence of 
asymptomatic signs of AMD in people not visually impaired was not of concern. 
5.2 DISTRIBUTION OF EXPOSURES AND CONFOUNDING FACTORS IN THE 
STUDY POPULATION 
Table 5.3 shows the distribution of all risk factors in the study population. 
9.7% of the population were current smokers. Smoking decreased with increasing age 
(p<0.001) and was higher in men (12.2%) than women (7.7%) (p<0.001). 79.2% of the 
population reported that they had taken an alcoholic drink in the last year. This 
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proportion decreased with increasing age (P<0.001) and was lower in women (74.4%) 
than in men (85.4%) (p<0.001) 
A majority of the population had systolic blood pressure over 140mmHg (62.8%), 
however, reported high blood pressure was lower at 33.5%. Reported high blood 
pressure decreased with increasing age (p=0.001) and was higher in women (p<0.001) 
whereas systolic blood pressure did not change with age (p=0.292). 
5.7% of the population reported that they had been told that they had diabetes. This 
proportion was slightly higher in men (6.7%) than women (5.0%) and there was no 
clear pattern with age. 
5.4% of the population had a body mass index (BMI) of less than 20 and 16.2% had a 
BMI greater than 30. The proportion underweight increased with increasing age 
(p<0.001) and was higher in women (p<0.001). 
69.9% of the population owned their own homes, 23.7% lived in rented accommodation 
and 6.4% lived in sheltered accommodation. The proportion in sheltered 
accommodation increased with increasing age from 4.3% at ages 75-79 to 23.2% at ages 
90+. 
30.4% of the population reported being very physically active and 3.0% reported being 
not at all physically active. Physical activity declined with increasing age (p<0.001). 
Women were more likely to report lower levels of physical activity (p=0.001). 
5.3 UNIVARIATE ANALYSES 
Table 5.4 shows the associations between AMD causing visual impairment and the risk 
factors studied, after controlling for age and sex. 
Smoking was associated with AMD causing visual impairment. Current smokers were 
twice as likely to be a case compared to non-smokers (odds ratio 2.28,1.61 to 3.24). Ex- 
smokers were at intermediate risk (odds ratio 1.11,0.87 to 1.43). 
Alcohol consumption in the past year was not significantly associated with AMD 
causing visual impairment (odds ratio 0.86,0.57 to 1.29). People 
drinking more than 20 
units per week had a non-significant increased odds of AMD causing visual 
impairment 
(odds ratio 1.72,0.77 to 3.85). 
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Of the cardiovascular disease variables, reported stroke was associated with being a 
case (odds ratio 1.82,1.28 to 2.57). There was no statistically significant association 
between high blood pressure, systolic blood pressure >I 40mmHg and angina and AMD 
causing visual impairment and a marginally significant association with reported heart 
attack (odds ratio 1.35,0.98 to 1.84 p=0.063). 
Reported diabetes was associated with AMD causing visual impairment (odds ratio 
1.56,1.05 to 2.32). 
People who were relatively thin with a BMI of less than 20 were also at increased risk 
of having AMD causing visual impairment. The three groups 20-<25,25-<30 and 30+ 
had similar risks. These three groups were combined for future analysis and used as the 
referent group. Comparing people with BMI of <20 to those with a BMI of 20 or more 
gave an odds ratio of 1.60 (1.07 to 2.40). 
People in sheltered housing had a greater risk of being a case compared to those in their 
own homes (odds ratio 1.62,1.04 to 2.54). 
Reported physical activity was strongly associated with being a case. People who 
reported that they were "not at all" physically active had a greatly increased risk of 
having AMD causing visual impairment with an odds ratio of 6.90 (3.73 to 12.77) 
compared to people who were very physically active. 
5.4 MULTIVARIATE ANALYSES 
5.4.1 Final model 
A logistic regression model was constructed including all the variables significant on 
the univariate screen. It had the following terms: age (75-79,80-84,85-89,90+), sex 
(male, female), smoking (never smoked, ex-smoker, current smoker), reported stroke 
(no, yes), reported diabetes (no, yes), body mass index (20 or more, less than 20), 
housing tenure (owner occupier, rented housing, sheltered housing) and reported 
physical activity (very, fairly, not very, not at all). AMD causing visual impairment 
was the dependant variable (0=control 1=case). Table 5.5 shows the results of that 
model. 
The most important risk factor for development of AMD causing visual impairment was 
age. People who were 90 or more had 50 times the risk of 
having the condition 
compared to people aged 75-79 (odds ratio 54.49,29.88 to 99.36). 
Women were also at 
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increased risk with an odds ratio of 1.76 (1.39 to 2.22). The other factor most strongly 
associated with being a case was physical activity. People reporting that they were "not 
at all" physically active were nearly five times more likely to have AMD causing visual 
impairment compared to those who reported that they were "very" physically active 
(odds ratio 4.96,2.50 to 9.85). 
The only other exposure that appeared to be important was smoking. Current smokers 
were at an 80% increased odds of developing AMD causing visual impairment (odds 
ratio 1.79,1.16 to 2.75). 
As reported stroke, reported diabetes, body mass index and housing tenure did not 
improve the fit of the model (adjusted Wald test p=0.1029) they were dropped from the 
model. Table 5.6 shows the final model. 
5.4.2 Smoking 
Only smoking was left in the final model and therefore it was investigated in more 
detail as set out in the analysis strategy (see section 5.1.4). 
Firstly, interaction terms for age and smoking were entered into the model. Looking at 
the odds ratios suggested that the effect of smoking was different in people aged 75 to 
79 compared to those aged 80 years and above. The interaction terms for age (two 
groups 75-79,80+)*smoking contributed significantly to the fit of the model (p=0.027). 
A further two models were fitted, one for people aged 75-79 and including terms for age 
(75,76,77,78,79), sex and physical activity (four groups), and one for people aged 80 
years and above and including terms for age (80-84,85-89,90+), sex and physical 
activity (four groups). Table 5.7 shows the results of those models for smoking. 
Smoking was a significant risk factor for developing AMD causing visual impairment 
in people aged 75 to 79, however, its effect in people aged 80 years and above was less 
strong. In the older age-groups, current smokers were at a two-fold risk however ex- 
smokers had the same risk as never smokers (odds ratio 0.96,0.70 to 2.92). 
The duration and dose of exposure to cigarette smoking was evaluated by pack years. 
This variable is a combination of daily cigarettes smoked (one pack = 20 cigarettes) and 
number of years smoked. Thus it combines dose and duration of smoking. Table 5.8 
shows the association between pack-years and risk of AMD causing visual impairment. 
In people aged 75-79, there was an increasing risk of AMD causing visual impairment 
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with increased number of pack years of exposure. In people aged 80 and above, there 
was no obvious relationship between pack-years and risk of AMD causing visual 
impairment. 
Table 5.9 shows the relationship between years since stopping smoking and AMD 
causing visual impairment. In people aged 75-79, there was an increased risk of AMD 
causing visual impairment with decreased time since stopping smoking. People who had 
stopped smoking 40 or more years ago, although the odds ratio was raised, it was not 
statistically significant (odds ratio 1.37,0.39 to 4.81). In people aged 80 years and 
above, there was some evidence of a trend with increased risk of AMD causing visual 
impairment with decreased time since stopping smoking. 
5.5 REPRODUCTIVE FACTORS IN WOMEN 
Table 5.10 shows the distribution of the various reproductive factors in women in the 
MRC Trial. The mean age of starting menstruation was 13.6 years. Older women had a 
marginally later age of menstruation. The mean number of years of menstruation was 
34.7 years. This decreased slightly with increasing age. The percentage of women with 
early menopause, i. e. menopause less than 40 years of age was 5.7%. This was highest 
in the 75-79 age-group (6.3%). The proportion of women with menopause at less than 
45 years of age due to surgery was 6.1 %. This was highest in the 75-79 age-group 
(6.6%) and lowest in the 90 and above age-group (4.0%). 
Table 5.11 shows the association between various measures of reproductive status and 
AMD causing visual impairment, controlled for age, physical activity and smoking. 
There was little evidence that reproductive indicators of relatively low lifetime levels of 
oestrogen were associated with an increased risk of being visually impaired due to 
AMD. 
Including number of years of menstruation as a continuous variable in a logistic 
regression gave an odds ratio of 0.99 (0.96 to 1.03). Women having their menopause at 
40 years or younger had a non-significant, increased risk of being a case (odds ratio 
1.87,0.95 to 2.71). This study did not confirm the findings of Vingerling et al in 
Rotterdam that menopause before 45 years of age due to surgery was a strong risk factor 
for AMD (odds ratio 1.06,0.61 to 1.85). 
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5.6 KEY POINTS 
Smoking and alcohol consumption 
There was a strong association between smoking status and risk of being visually 
impaired due to AMD. This effect was particularly strong in people aged 75-79 years of 
age. In these people there was a dose-response relationship between pack years of 
smoking and risk of AMD causing visual impairment. People giving up smoking less 
than 40 years ago were at increased risk. 
There was no statistically significant association between alcohol consumption and 
AMD causing visual impairment. 
Cardiovascular disease profile 
Cases were more likely to report that they had had a stroke, heart attack or diabetes. 
Cases were also more likely to be relatively thin (BMI <20). 
After controlling for confounding factors, none of the risk factors indicating 
cardiovascular disease or a cardiovascular disease risk profile were associated with an 
AMD causing visual impairment. 
People who reported that they were "not at all" physically active were more likely to 
have AMD causing visual impairment 
Reproductive factors in women 
There was little indication that women with relatively low lifetime oestrogen levels 
were at increased risk of developing visually impairing AMD. The study was 
underpowered to investigate some of these exposures, such as early menopause. 
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TABLES AND FIGURES 
Table 5.1 Cases and controls by age and sex 
Male 
Controls 
Female Total Male 
Cases 
Female Total 
75-79 1344 1504 2848 26 48 74 
80-84 511 633 1144 47 112 159 
85-89 123 187 310 45 131 176 
90+ 21 41 62 20 87 107 
Total 1999 2365 4364 138 378 516 
"Cases" are people with AMD causing visual impairment. "Controls" are people with 
6/6 vision or better (binocular acuity). Data from the 49 practices taking part in the 
cause of visual impairment study out of 53 practices in the universal arm of the MRC 
Trial. 
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Table 5.2 Power (%) of study of 500 cases and 4,500 controls to detect various odds 
ratios 
Risk factor Prevalence in 
control 
group* 1.2 1.5 
Odds ratios 
2 3 5 
Smoking Current smoker 9% 15.1 59.3 97.1 >99 >99 
Ex-smoker 53% 32.2 92.6 >99 >99 >99 
Alcohol Drink in last 80% 19.2 69.8 99 >99 >99 
consumption year 
Drank 10 or 10% 16.1 63.0 98.0 >99 >99 
more units last 
week 
Cardiovascular Systolic blood 63% 29.2 89.3 >99 >99 >99 
disease pressure 
> 140mmHg 
Reported stroke 6% 11.5 44.8 90.4 >99 >99 
Reported heart 10% 16.1 63.0 98.0 >99 >99 
attack 
Reported 34% 31.5 92.1 >99 >99 >99 
hypertension 
Definite angina 7% 12.7 50.6 93.7 >99 >99 
Reported 6% 11.5 44.8 90.4 >99 >99 
diabetes 
Reproductive Menopause <45 3% 7.5 27.1 68.8 98.1 >99 
factors years due to 
surgery 
Power calculated assuming a design effect of 1.5 and therefore an effective sample size 
of 500/1.5 = 333 cases 
*Control group - people with binocular acuity 6/6 or better 
in MRC Trial. 
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Table 5.3 Distribution of risk factors in the study population 
% with risk factor 
% with % with risk factor in each age- in men and 
risk group wo men 
factor 
All 75-79 80-84 85-89 90+ Men Women 
ages 
Risk factor N=4880 N=2922 N=1303 N=486 N=169 N=2137 N=2743 
Never smoked 38.2 35.2 39.5 46.5 57.2 20.0 52.2 
Ex-Smoker 52.1 54.2 51.9 45.5 36.7 67.8 40.2 
Current smoker 9.7 10.6 8.5 8.0 6.2 12.2 7.7 
% taken alcoholic 79.2 81.7 78.9 68.7 67.9 4 85 74 4 drink in last year . . 
Reported high 33.5 34.9 34.0 27.3 22.4 28.2 37.6 blood pressure 
Reported stroke 6.7 6.1 7.3 10.1 8.4 7.6 6.4 
Reported heart 10.0 9.6 10.2 11.5 10.8 13.1 7.5 
attack 
Systolic blood 
pressure 62.8 62.4 64.8 60.6 61.0 59.8 65.2 
> 140mmHg 
Angina 6.6 7.3 6.5 3.4 3.6 6.9 6.4 
Reported diabetes 5.7 5.4 6.0 7.0 5.4 6.7 5.0 
Body mass index 5.4 4.4 5.6 9.0 12.8 3.5 6.9 
<20 
20-<25 35.4 33.4 37.7 41.5 38.4 33.5 36.9 
25-<30 43.1 44.6 41.6 39.9 34.6 48.6 38.7 
30+ 16.2 17.7 15.1 9.7 14.3 14.4 17.6 
Housing tenure 69.9 72.8 68.5 61.3 54.9 74.0 66.8 
Owner occupier 
Rented housing 23.7 22.8 24.5 26.9 22.0 22.2 24.8 
Sheltered housing 6.4 4.3 7.0 11.9 23.2 3.9 8.4 
Reported physical 30.4 33.9 28.2 19.6 15.9 31.7 29.3 
activity Very 
Fairly 52.8 53.3 53.1 52.7 42.7 54.2 51.7 
Not very 13.9 10.9 15.6 21.5 31.1 11.9 15.4 
Not at all 3.0 1.9 3.2 6.2 10.4 2.3 3.5 
Data from 4364 controls and 516 cases in the 49 practices taking part in the cause of 
visual impairment study out of 53 practices in the universal arm of the MRC Trial. 
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Table 5.4 Univariate analyses 
95% confidence 
Risk factor N Odds ratio interval Wald test 
Never smoked 1815 1 
Ex-Smoker 2480 1.11 0.87 to 1.43 0.389 
Current smoker 458 2.28 1.61 to 3.24 <0.001 
% taken alcoholic drink in 3830 0.86 0.57 to 1.29 0.446 
last year 
Number of units drunk in last 2543 1 
week None 
1/9 
10/19 
20 or more 
1889 0.83 
305 0.62 
143 1.72 
0.62 to 1.10 0.182 
0.29 to 1.30 0.202 
0.77 to 3.85 0.180 
Reported high blood pressure 1629 0.99 0.78 to 1.26 0.947 
Reported stroke 335 1.82 1.28 to 2.57 0.001 
Reported heart attack 483 1.35 0.98 to 1.84 0.063 
Systolic blood pressure 
> 140mmHg 
3046 1.09 0.93 to 1.29 0.268 
Angina 318 1.04 0.63 to 1.74 0.866 
Reported diabetes 281 1.56 1.05 to 2.32 0.030 
Body mass index 
<20 249 1 
20-<25 1640 0.63 0.41 to 0.91 0.037 
25-<30 1995 0.60 0.40 to 0.91 0.017 
30+ 748 0.67 0.39 to 1.14 0.135 
Body mass index <20 249 1.60 1.07 to 2.40 0.022 
Socio-economic status 3389 1 
Owner 
Rented housing 1147 1.34 0.99 to 1.81 0.058 
Sheltered housing 311 1.62 1.04 to 2.54 0.034 
Reported physical activity 1472 1 
Very 
Fairly 2564 2.20 1.57 to 3.08 <0.001 
Not very 670 4.94 3.56 to 6.84 <0.001 
Not at all 145 6.90 3.73 to 12.77 <0.001 
Odds ratios are derived from logistic regression models including terms for age (75- 
79,80-84,85-89 and 90+), sex and each risk factor separately. Confidence intervals 
adjusted for clustered design of the study. Data from 4364 controls and 
516 cases in the 
49 practices taking part in the cause of visual impairment study out of 53 practices in 
the universal arm of the MRC Trial. 
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Table 5.5 Multivariate analyses 
Risk factor Odds ratio 95% confidence interval Wald test 
Age 75-79 1 
80-84 5.08 3.93 to 6.55 <0.001 
85-89 17.38 11.92 to 25.33 <0.001 
90+ 54.49 29.88 to 99.36 <0.001 
Men 1 
Women 1.76 1.39 to 2.22 <0.001 
Never smoker 1 
Ex-Smoker 1.07 0.82 to 1.40 0.604 
Current smoker 1.79 1.16 to 2.75 0.009 
No reported stroke 1 
Reported stroke 1.37 0.92 to 2.05 0.118 
No reported diabetes 1 
Reported diabetes 1.31 0.84 to 2.03 0.228 
Body mass index 20 or more 1 
Body mass index <20 1.39 0.91 to 2.13 0.125 
Housing tenure 1 
Owner occupier 
Rented housing 1.24 0.90 to 1.71 0.183 
Sheltered housing 1.25 0.81 to 1.93 0.315 
Very physically active 1 
Fairly physically active 1.99 1.46 to 2.71 <0.001 
Not very physically active 4.06 2.89 to 5.70 <0.001 
Not at all physically active 4.96 2.50 to 9.85 <0.001 
Odds ratios derived from a logistic regression model including terms for all risk factors 
together. Confidence intervals adjusted for clustered design of the study. Data from 
4364 controls and 516 cases in the 49 practices taking part in the cause of visual 
impairment study out of 53 practices in the universal arm of the MRC Trial. 
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Table 5.6 Final model 
Risk factor Odds ratio 95% confidence interval Wald test 
Age 75-79 1 
80-84 5.01 4.02 to 6.24 <0.001 
85-89 17.86 12.72 to 25.1 <0.001 
90+ 54.62 33.0 to 90.28 <0.001 
Men 1 
Women 1.84 1.44 to 2.35 <0.001 
Never smoker 1 
Ex-Smoker 1.10 0.84 to 1.45 0.489 
Current smoker 2.97 1.32 to 2.95 0.001 
Very physically active 1 
Fairly physically active 2.12 1.52 to 2.96 <0.001 
Not very physically active 4.48 3.24 to 6.20 <0.001 
Not at all physically active 6.28 3.43 to 11.51 <0.001 
Derived from a logistic regression model including terms for all risk factors included on 
the table. Confidence intervals adjusted for clustered design of the study. Data from 
4364 controls and 516 cases in the 49 practices taking part in the cause of visual 
impairment study out of 53 practices in the universal arm of the MRC Trial. 
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Table 5.7 Smoking and AMD causing visual impairment, stratified by age 
Risk factor Odds 95% Wald test 
ratio confidence interval 
People aged 75-79 
Never smoker 1 
Ex-Smoker 2.34 1.30 to 4.22 0.006 
Current smoker 3.41 1.36 to 8.54 0.010 
People aged 80 and above 
Never smoker 1 
Ex-Smoker 0.96 0.70 to 2.92 0.771 
Current smoker 1.85 1.17 to 3.20 0.010 
People aged 75-79: Odds ratios derived from a logistic regression model including 
terms for age (75,76,77,78,79), sex and physical activity (very, fairly, not very, not at all 
physically active). People aged 80 years and above: Odds ratios derived from a logistic 
regression model including terms for age (80-84,85-89,90+), sex and physical activity 
(very, fairly, not very, not at all physically active). Confidence intervals adjusted for 
clustered design of the study. Data from 4364 controls and 516 cases in the 49 practices 
taking part in the cause of visual impairment study out of 53 practices in the universal 
arm of the MRC Trial. 
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Table 5.8 Smoking (pack years) and AMD causing visual impairment, stratified by 
age 
95% 
Odds 
confidence 
Risk factor ratio interval Wald test 
People aged 75-79 
Never smoked 1 
Less than 20 pack years 2.23 1.09 to 4.58 0.030 
20 to less than 40 pack years 3.06 1.48 to 6.36 0.003 
40 to less than 60 pack years 2.15 0.64 to 7.22 0.209 
60 or more pack years 3.73 1.62 to 8.61 0.003 
People aged 80 and above 
Never smoked 1 
Less than 20 pack years 1.01 0.69 to 1.49 0.956 
20 to less than 40 pack years 0.99 0.65 to 1.49 0.956 
40 to less than 60 pack years 1.10 0.65 to 1.85 0.715 
60 or more pack years 0.74 0.33 to 1.64 0.447 
People aged 75-79: Odds ratios derived from a logistic regression model including 
terms for age (75,76,77,78,79), sex and physical activity (very, fairly, not very, not at all 
physically active). People aged 80 years and above: Odds ratios derived from a logistic 
regression model including terms for age (80-84,85-89,90+), sex and physical activity 
(very, fairly, not very, not at all physically active). Confidence intervals adjusted for 
clustered design of the study. Data from 4364 controls and 516 cases 
in the 49 practices 
taking part in the cause of visual impairment study out of 53 practices in the universal 
arm of the MRC Trial. 
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Table 5.9 Years since stopping smoking and AMD causing visual impairment, 
stratified by age 
95% 
Odds confidence 
Risk factor ratio interval Wald test 
People aged 75-79 
Never smoked 1 
Stopped 40 or more years ago 1.37 0.39 to 4.81 0.613 
Stopped 20 to 39 years ago 2.49 1.14 to 5.41 0.023 
Stopped less than 20 years ago 2.71 1.36 to 5.40 0.006 
Current smoker 3.42 1.37 to 8.51 0.009 
People aged 80 and above 
Never smoked 1 
Stopped 40 or more years ago 0.88 0.59 to 1.30 0.500 
Stopped 20 to 39 years ago 0.75 0.50 to 1.13 0.160 
Stopped less than 20 years ago 1.49 0.99 to 2.24 0.055 
Current smoker 1.85 1.17 to 2.92 0.010 
People aged 75-79: Odds ratios derived from a logistic regression model including 
terms for age (75,76,77,78,79), sex and physical activity (very, fairly, not very, not at all 
physically active). People aged 80 years and above: Odds ratios derived from a logistic 
regression model including terms for age (80-84,85-89,90+), sex and physical activity 
(very, fairly, not very, not at all physically active). Confidence intervals adjusted for 
clustered design of the study. Data from 4364 controls and 516 cases in the 49 practices 
taking part in the cause of visual impairment study out of 53 practices in the universal 
arm of the MRC Trial. 
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Table 5.10 Distribution of reproductive factors in women 
% with risk factor in each age-group 
% with 
risk factor 
All ages 75-79 80-84 85-89 90+ 
Risk factor N=2449 N=1429 N=656 N=274 N=90 
Mean age (SD) 13.6 13.5 13.7 13.6 14.2 
menstruation started (1.5) (1.5) (1.5) (1.4) (1.4) 
Mean (SD) years of 34.7 34.8 34.7 34.6 33.7 
menstruation (5.4) (5.5) (5.2) (5.3) (5.4) 
% with early menopause 
i. e. menopause at less 5.7 6.3 4.8 5.3 5.4 
than 40 years of age 
% with menopause less 
than 45 years due to 6.1 6.6 5.8 5.0 4.0 
surgery 
Data from 2365 controls and 378 cases in the 49 practices taking part in the cause of 
visual impairment study out of 53 practices in the universal arm of the MRC Trial. 
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Table 5.11 Reproductive factors in women and AMD causing visual impairment 
Risk factor Odds ratio 
95% confidence 
interval Wald test 
Number of years of menstruation 0.99 0.96 to 1.03 0.705 
Years of menstruation 
Lowest quartile 1 
2"d quartile 0.69 0.43 to 1.10 0.120 
3rd quartile 0.93 0.58 to 1.49 0.759 
Highest quartile 1.03 0.66 to 1.60 0.895 
Menopause before 40 years of age 1.87 0.95 to 2.71 0.074 
Menopause before 45 years of age 1.06 0.61 to 1.85 0.835 
due to surgery 
Odds ratios derived from logistic regression models all of which included terms for age 
(75-79,80-84,85-89 and 90+), physical activity (very, fairly, not very, not at all 
physically active) and smoking (never, ex, current smoker). Confidence intervals 
adjusted for clustered design of the study. Data from 2365 controls and 378 cases in the 
49 practices taking part in the cause of visual impairment study out of 53 practices in 
the universal arm of the MRC Trial. 
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CHAPTER Six DISCUSSION 
6.1 Strengths and weaknesses 
6.2 Prevalence of visual impairment 
6.3 Causes of visual impairment 
6.4 Prevalence of AMD causing visual impairment 
6.5 Functional ability 
6.6 Self-reported health and physical activity 
6.7 Sickness Impact Profile and Philadelphia Geriatric Morale Scale 
6.8 Depression and cognitive impairment 
6.9 Falls and hip fractures 
6.10 Mortality 
6.11 Smoking 
6.12 Other risk factors 
6.13 Unanswered questions and future research 
6.14 Policy implications 
Tables 
The overall aim of this thesis was to investigate the prevalence and impact of AMD 
causing visual impairment in people aged 75 years and above in the UK. A secondary, 
albeit more limited, objective was to investigate a small number of potential risk factors 
for AMD. The study was an add-on study to the large MRC Trial of the Assessment and 
Management of Older People in the Community. 
In this chapter I will consider the strengths and weaknesses of the study, discuss the 
main findings and compare these to other studies. This will be followed by discussion of 
the implications for future research and policy. 
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6.1 STRENGTHS AND WEAKNESSES 
6.1.1 Strengths 
" The MRC Trial was a nationwide, representative population-based study providing a 
large sample of people aged 75 years and above 
Combining all previous published population-based studies together shows that, 
worldwide, prior to the MRC Trial, less than 7,000 people aged 75 years and above 
have been assessed for visual impairment (see chapter one table 1.5). In the current 
study, visual acuity tests were done on nearly 15,000 people aged 75 years and above. 
Obtaining large numbers of population-based cases of visual impairment makes this a 
unique study in eye epidemiology in the UK, increasing its precision. The national 
representativeness of the sample increases the generalisability of the results. Many 
previous studies have been conducted in a single cluster, a problem that is avoided in 
this study. Population-based studies, particularly in older people, are very expensive 
requiring much nurse time and home visits. Nationwide studies are even more so. It was 
a costly exercise collecting data at the MRC Trial detailed assessment, including visual 
acuity screening. The resources required for the add-on study ascertaining the causes of 
visual impairment were a fraction of the total costs of the MRC Trial. 
" It was straightforward to identify suitable comparison groups 
This study offered a large population-based case-group (n=516) of people visually 
impaired due to AMD. This meant that it was relatively straightforward to identify a 
group of population-based controls. For the case-control study of risk factors, these 
were people with good vision (6/6 or better) who took part in the MRC Trial. For the 
cross-sectional analyses of impact, these were people visually impaired due to other 
causes, and people not visually impaired. This is the first time that investigation of the 
association between AMD and functioning and quality of life has included a population- 
based group of controls. 
" Independent collection of linked data 
In order to avoid bias, identification of cases or outcome should 
be independent of 
exposure. Non-random misclassification of AMD was unlikely as all medical records 
were reviewed by practice nurses who were unaware of the study 
hypotheses and did 
not have access to data on exposure. Some of the nurses had undertaken the 
detailed 
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assessments six or months before, however, this was a very long complicated 
examination and questionnaire. It is unlikely that the nurses would have been able to 
remember all responses for each of the several hundred patients assessed. Data on 
quality of life was collected by independent fieldworkers. 
6.1.2 Weaknesses 
" Visual acuity was measured using a simple, portable chart 
The MRC Trial aimed to test multi-dimensional assessment in the general practice 
setting. Simple, portable interventions that could be used by nurses were chosen. The 
visual acuity test, therefore, was a simple one that nurses could use easily and take with 
them on home visits. The Glasgow acuity chart follows the principles of the Bailey- 
Lovie chart which has now become the gold standard method for measuring visual 
acuity in research studies(Bailey and Lovie 1976). The Glasgow chart has 
approximately equally legible letters on each row and the separation of the letters within 
rows is uniform so that contour interaction is controlled. Each row is presented 
separately. The visual task at each level of the chart is therefore the same irrespective of 
acuity or test distance. The chart employs a logarithmic progression of sizes. The 
logMAR visual acuity notation (see Appendix B), which corresponds to the logarithm of 
the reciprocal of the Snellen notation, is now recognized as the most logical measure of 
visual acuity. 95% of vision measurements made with the Glasgow Acuity Chart differ 
by less than 0.07 log unit compared to the Bailey-Lovie chart(McGraw et al. 2000). 
The method of testing acuity followed recommended guidelines(Ferris, III and Bailey 
1996) with the exception of the lack of standardisation of illumination. It has been 
recommended that high contrast charts and illumination of between 807 to 1345 lux is 
used(Ferris and Sperduto 1982). The Glasgow acuity chart is easy to use and, being 
portable, could be taken into people's home. Nurses were trained in the use of the chart, 
including supervised practice with the method. During the training session, they were 
given details on how to make sure that ensure good lighting conditions during the visual 
screening test. The charts are high contrast and in general, most surgeries will have had 
fluorescent lighting, this illumination will have been achieved. However, vision was 
measured in 53 general practice surgeries, spread throughout the country, and on home 
visits. Standardisation of the lighting conditions was therefore not possible. This may 
have introduced increased between-practice variation(Silver et al. 1978). 
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For logistic reasons each nurse only had one chart. If they were suspicious that a 
participant may have memorised the letters they were to ask the participant to read the 
letters from right to left (Appendix B Measuring visual acuity). However, as this test 
was only done on one occasion, it is likely that the impact of learning effects will be 
small. 
"A pinhole occluder was used to correct for refractive error 
The results are for presenting vision, that is, visual acuity as used in every day life by 
the people taking part in the MRC Trial. This measure of visual impairment is the most 
relevant for public health purposes. It is often usual in eye surveys to present visual 
impairment after correction for refractive error. There were limited data on refractive 
error in the population through the use of the pinhole test. 
The pinhole test is not as good an assessment as subjective refraction but has been 
assessed to be adequate in validation studies(Ederer et al. 1986). It was not easily used 
in this population with nearly 40% of visually impaired people not having a pinhole test. 
This fact must be borne in mind when comparing the results of this study to other 
population-based studies (see table 6.1). Studies using refraction to correct for refractive 
error consistently estimate a lower prevalence of visual impairment. 
" Visual impairment was assessed using distance visual acuity only 
Other studies have shown that visual field loss can contribute considerably to the overall 
burden of visual impairment and blindness with nearly three times as many people 
visually impaired because of visual field loss than visual acuity loss(Taylor et al. 1997). 
In the current study, people were included who had good central visual acuity but who 
were registered blind or partially sighted because of visual field loss. It is likely, 
however, that we have underestimated the level of visual impairment because we did 
not measure visual fields. AMD affects primarily the central vision so the number of 
people visually impaired due to AMD who were not detected in the study will be not as 
great as for eye diseases that affect primarily the visual field, for example, glaucoma. 
" Data on cause of visual impairment was obtained from medical record review and 
contact with hospital ophthalmologists 
The size and geographical spread of practices, combined with the age of the 
participants, meant that it was not possible to arrange for a standardised ophthalmic 
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examination of everyone identified as visually impaired during the trial. Causes of 
visual loss were identified using a combination of medical record review in the general 
practice and hospital ophthalmologist questionnaire. There was good agreement at the 
hospital and general practice level. It is likely that, for the simple categories of cause 
presented, this method of assessment has worked well. 
There is a particular difficulty with assessing cause of visual loss from the medical 
notes. The coding is dependent on the thoroughness with which the health care staff 
recorded the eye conditions. Essentially we have no idea of the extent to which data are 
missing. However, comparing the information from the hospital and general practice 
suggested that in fact the hospital ophthalmologist who knew the patient involved was 
less likely to record so many conditions. Omission is not so likely to have been a 
problem and it is more likely that conditions not severe enough to cause visual loss have 
been recorded. 
Although this method of case ascertainment for AMD must be considered less robust 
than cross-sectional survey using standardised methods, it is important to remember that 
this study deals with a particularly functionally impaired group of people. There will 
undoubtedly be some misclassification (as there is in all epidemiological studies). 
However, I would argue that, on the whole, this study has "captured" a representative 
group of people with late stage AMD severe enough to cause visual impairment. There 
is always a tradeoff between very precise classification of disease (which requires time 
and resources, particularly for AMD) and statistical precision (which requires large 
numbers of participants). The size and representativeness of this study means that it 
provides important information about the prevalence and impact of AMD causing visual 
impairment in the UK. The fact that the risk factor analyses confirm the findings from 
previous studies adds to the credibility of the findings presented here. 
In the USA several important studies have used a similar method of case ascertainment 
to the current study. In the Nurses' Health Study and Physicians' Health Study, a 
diagnosis of AMD was self-reported by the participants and followed by questionnaire 
to their ophthalmologist(Seddon et al. 1996; Cho et at. 2000; Christen et at. 1996; Ajani 
et at. 1999). These studies were very large and ophthalmic examination of all 
participants, as in the MRC Trial, would have been prohibitively expensive and 
unnecessary. As it was, these two studies have 
demonstrated convincing dose-related 
relationships between smoking and AMD. 
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Random misclassification of AMD will mean that the effect estimates are in fact 
underestimates of the true effects. Non-random misclassification is unlikely as the 
ascertainment was independent of exposure measurement. 
" People with macular degeneration and vision >6/18 were not counted in this study 
As the MRC Trial was a pragmatic assessment of simple assessment methods in general 
practice, the cutoff for referral was less than 6/18. As eye examinations were not 
undertaken on all the participants, information on eye disease was restricted to people 
who failed the visual acuity test. This selects out a particularly functionally visually 
impaired group, however, information was not available on people with AMD whose 
visual function was not so affected. For the prevalence estimates, these results will be 
an underestimate of the impact of AMD as many people will be visually impaired to 
lesser levels. A visual acuity of less than 6/12 but greater than 6/18 will have many 
disadvantages, for example, being unable to drive. 
" Some people in the control or comparison groups will have AMD. 
When identifying cases for a case-control study, high specificity is important, i. e. the 
case definition should make it unlikely that people without AMD were included in the 
case group(Copeland et al. 1977). All cases had a written diagnosis of AMD and 
hospital and general practice sources of data agreed well. A high sensitivity in case 
detection is less important. As the control group was large with over 4,000 people, some 
cases may be included in the control group with little impact on study results. 
There is little published information on visual acuity and AMD. Owen et al performed a 
systematic review pooling data on the prevalence of visual impairment (acuity 6/18 or 
worse) due to AMD and prevalence of geographic atrophy and neovascular disease 
separately(Owen et al. 2002). The data were drawn from six population-based studies in 
North America, Australia and Europe. The difference between prevalence of visual 
impairment due to AMD and prevalence of geographic atrophy or neovascular AMD 
gives a rough indicator of the prevalence of AMD not causing visual 
impairment. 
Applying the estimates to the control group population structure suggests that, at the 
most, 3% of people not visually impaired could have late stage AMD. In the case- 
control study, even smaller numbers will have AMD because the control group only 
contained people with good vision (6/6 or better). Klein et al showed 
in the Beaver Dam 
Eye Study that visual acuity and late stage AMD are strongly correlated such that on 
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average, a diagnosis of late stage AMD is associated with a loss of vision of 30 letters 
acuity (sufficient to drop from 6/5 to 6/1 8)(Klein et al. 1991 b). Therefore, the 
proportion of the control group in the case-control study with late stage AMD is likely 
to be very small. 
The prevalence of early ARM in the control group will be higher. This proportion will 
be minimised by including only people with good vision as early ARM is also 
associated with a small decrease in vision. The presence of early ARM in the control 
group will have the effect of biasing the estimates of effect towards null. 
" The case definition included macular degeneration and vision loss 
The fact that the group of people with AMD have, by definition, visual impairment as 
well, means that these two parameters are very much linked. This means that the results 
apply to the most important group of people with AMD, i. e. those who have the disease 
to such an extent that they have suffered significant visual loss. However, when 
considering, in particular, the analyses of the impact of AMD, there is a conundrum. It 
is of interest to know how much of the impact of the disease is due to the visual 
impairment and how much due to AMD itself. Within the visually impaired group I was 
able to control for visual acuity in order to investigate whether the poor prognosis of 
AMD had any effects over and above those of visual impairment. For most of the 
results, with the notable exception of tasks requiring reading, AMD did not appear to 
have any extra impact over and above its effect on vision. It is perhaps unsurprising that 
most, if not all, of the impact of AMD comes through its effect on vision. 
" Not all potential confounders were measured 
In an ideal world, it would have been good to have information on genetics, dietary and 
blood levels of antioxidant micronutrient intake and an assessment of lifetime light 
exposure. In particular, it would be interesting to see whether the impact of, for 
example, smoking differs in different genetic groups. It is likely that AMD is a group of 
diseases with a common phenotype, however, the study of the genetics of AMD is not 
well established(Gorin et al. 1999; Yates and Moore 2000). Previous studies on 
smoking have not indicated any major confounding effects of antioxidants or light 
exposure, although these could be argued theoretically(Eye Disease Case-Control Study 
Group 1992). 
" Prevalent rather than incident cases of AMD 
218 
The analyses presented in the thesis related to the baseline analyses of the MRC Trial, 
i. e. the data were cross-sectional. This means that prevalent rather than incident cases of 
AMD were identified. This is the most usual aetiological study design in AMD research 
and can be justified on the basis that AMD is a chronic, non-fatal disease(Rothman 
1986). 
9 Exposure and outcome were assessed concurrently 
One of the weaknesses of cross-sectional studies is the concurrent assessment of 
exposure and outcome. Ensuring that these are collected independently has been 
addressed above. In this case, historical data, for example, number of years smoked, is 
more powerful than purely cross-sectional data, for example, current blood pressure. It 
is important to be aware of the possibility of reverse causation, i. e. an exposure 
occurring after the incidence of the disease. More emphasis has been placed on 
historical exposures, such as smoking, than concurrent measures such as obesity. 
" People in nursing homes were excluded from the study 
People in residential or sheltered accommodation were included in the MRC Trial, 
however, people in nursing homes, i. e. accommodation where residents receive nursing 
care, were not. 
9.5% of the population aged 75 years and above in the UK are in nursing homes(Office 
for National Statistics 2002). Other studies have shown a high prevalence of visual 
impairment in nursing homes(Tielsch et al. 1995; Mitchell et al. 1997; VanNewkirk et 
al. 2000b). For example, in people aged 85 years and above taking part in the NDNS 
study, 30% of those living in the community were visually impaired (<6/18) compared 
to 47% of those living in residential nursing homes, i. e. a prevalence ratio of 1.6(van der 
Pols et al. 2000). If we assume a similar increased prevalence of visual impairment in 
the nursing home population (multiplying 10% by 1.6 to get 16%), and that 10% of the 
population was excluded on the basis of being in nursing homes, the overall estimate of 
prevalence increases from 10% to 10.6%. It is likely that excluding the nursing home 
population will not have affected the prevalence estimates substantially. 
" There were missing data for some people 
71% of eligible people in the 53 practices in the universal arm of the study were given a 
detailed assessment (see chapter three figure 3.2). Table 1.2 (chapter one) shows the 
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response rate in other comparable studies. These range from 46% to 95%, with a 
median of value of 75%. 
People taking part in the study were of a similar age (on average one year younger) than 
those who did not, however, women were less likely to take part. People who did not 
have a vision test were older, more likely to be women and more likely to be cognitively 
impaired. As older people and women have higher rates of visual impairment and 
visual impairment due to AMD, the effect of this is to make the estimates of prevalence 
presented in this thesis conservative, i. e. minimum estimates. 
There was a group of visually impaired people for whom I could not find out the cause 
of visual impairment. These people had a similar age and sex distribution compared to 
people for whom cause was available. They had better visual acuity, i. e. less severe 
visual loss. As AMD was associated with more severe visual loss, I chose not to make 
any assumptions about people for whom cause of visual loss was missing. I calculated 
the prevalence rates for AMD causing visual impairment, assuming that none of these 
people had AMD. This, again, is a conservative assumption and leads to minimum 
estimates of the prevalence of AMD causing visual impairment. 
There is no reason to suppose that the missing data will have affected the associations 
examined, either in terms of examining the impact of AMD causing visual impairment, 
or the potential risk factors. It is likely that the associations observed apply in the non- 
participants as well. Bias could occur if, for example, smokers with AMD causing 
visual impairment were more likely to participate or non-smokers without AMD 
causing visual impairment were less likely to participate. This does not seem very 
likely. Similarly in the analyses of impact of AMD causing visual impairment, people 
with functional difficulties and AMD would have to be more likely to participate or 
people with no functional difficulties and no AMD less likely to participate. Again this 
seems unlikely. 
" Lack of information on ethnic group 
Causes of visual impairment are likely to differ in different ethnic groups in Britain. The 
prevalence of AMD may well vary. The age-structure of 
immigrant communities is 
younger than the native British population. The MRC Trial aimed to select a population 
representative of the UK population, however, the proportion of people 
in ethnic 
minorities in the over 75s population is small and 
did not permit independent analysis. 
220 
6.2 PREVALENCE OF VISUAL IMPAIRMENT 
6.2.1 Principal Findings 
Visual impairment (binocular acuity less than 6/18) is common in this age-group. 12% 
of people in the study were visually impaired. The risk of visual impairment increased 
steeply in these older age-groups. 37% of people aged 90 years and above were visually 
impaired. There was a higher risk of visual impairment in women. 
Using mid-2001 population estimates for the UK* there are approximately 609,000 
people aged 75 years and above living in the community with visual impairment (95% 
confidence interval 475,000 to 745,000) of who 157,000 are aged 90 years or above. As 
women experienced higher levels of visual impairment and also make up a larger 
proportion of the elderly, the majority of the burden of visual impairment in this age- 
group is borne by women. Out of the estimated 609,000 people visually impaired 
453,000 (74%) are women. 
6.2.2 Comparison with other studies 
The most recent study of visual acuity in the British population was a sample of 1,362 
participants aged 65 years and above taking part in the National Diet and Nutrition 
Survey (NDNS) which estimated the prevalence of visual impairment (<6/18) to be 
12% (van der Pols et al. 2000). This is comparable to the estimate of 12.4% from this 
study. The NDNS sample, however, included people resident in nursing homes who had 
a higher prevalence of visual impairment. Reidy et al in a study of 1,547 people aged 
65 years and above in north London found that 30% of their sample had bilateral visual 
acuity worse than 6/12 (Reidy et al. 1998). This is similar to the current study where 
29.2% (28.5% to 29.9%) of people 75 years and above had a binocular acuity worse 
than 6/12. 
Studies of vision in the British population tend to report higher levels of visual 
impairment than studies in equivalent populations in other part of Europe, North 
America and Australia. Part of this can be attributed to different methods, particularly 
the emphasis on best corrected acuity and use of subjective refraction in studies in other 
countries. However in the Salisbury Eye Evaluation project approximately 9% of white 
* http: //www. gad. gov. uk/population/1998/pop5yearuk98-08. html, accessed 14`h August 2001 
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participants aged 75 to 84 years had presenting acuity worse than 6/12 in the better eye 
(Rubin et al. 1997). This compares with 15% of people aged 75 to 84 in the MRC Trial 
having a binocular acuity worse than 6/12. These differences may reflect differences in 
study methods and or in use of services, especially cataract services. 
There was a significant increased risk of visual impairment in women which agrees with 
the results of a recent meta-analysis showing an odds ratio for women of 1.63 for 
industrialised countries (Abou-Gareeb et al. 2001). It is not clear whether this excess in 
women represent differences in the incidence of conditions causing vision impairment 
or differences in access and use of services. 
6.2.3 Comments 
This study is the largest nationwide study undertaken to date and, for that reason, 
provides more precise estimates of the size of the problem. The prevalence of visual 
impairment presented here is clearly a minimum or conservative measure. The numbers 
of people with less severe, but still significant, visual impairment are considerably 
higher. 
6.3 CAUSES OF VISUAL IMPAIRMENT 
6.3.1 Principal findings 
One in four people were visually impaired due to refractive error. There was a strong 
relationship with visual acuity - cataract causing more moderate visual impairment 
whereas AMD resulted in poorer vision. This effect was independent of age. 
AMD was the most important cause of visual loss in people aged 75 years and above, 
being either the major or an important contributory cause in 48% of the sample. There 
was a strong age effect, whereby people aged 90 years or above were proportionately 
more affected. 
6.3.2 Comparison with other studies 
Previous studies into the causes of visual impairment in this age-group either have not 
been representative of the general population(Evans 1995). or have had a small numbers 
of people identified with visual impairment. Table 6.2 compares these results with other 
published studies from similar populations in North America, Australia and Europe. 
The number of people with low vision (n=727) and blindness (n=249) with cause of 
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visual loss identified in the MRC Trial was substantially larger than for other 
comparable studies (range 10 to 42 blind people and 21 to 134 people with low vision). 
The results of the MRC Trial compare well with other studies and show that the pattern 
of cause of visual loss differs according to the level of visual loss. AMD is 
proportionately a more important cause of blindness than of low vision; conversely 
cataract is generally, although not always, found to be a more important cause of low 
vision than AMD. 
Other studies have shown a strong age effect as well, whereby people aged 90 years and 
above were proportionately more affected by AMD(Klaver et al. 1998). 
6.3.3 Comments 
The MRC Trial provided the opportunity to identify a large group of visually impaired 
older people and ascertain the cause of visual loss. This study highlights the importance 
of refractive error, AMD and cataract as the main causes of visual loss in older people. 
AMD is particularly important in the very elderly, and cataract appears to be a more 
important cause of visual loss in women. It is likely that this study underestimates the 
impact of refractive error as not everyone could use the pinhole occluder. 
6.4 PREVALENCE OF AMD CAUSING VISUAL IMPAIRMENT 
6.4.1 Principal findings 
The prevalence of AMD causing visual impairment was estimated at 3.7% (3.2% to 
4.2%) in people aged 75 years and above. This prevalence increased with age. The 
prevalence was 14.4% (11.6% to 17.2%) at 90 years and above. There was a higher risk 
of AMD causing visual impairment in women. 
There were estimated to be approximately 192,000 people aged 75 years and above in 
the UK living in the community with visual impairment due to AMD (95% confidence 
interval 144,000 to 239,000) of whom 60,000 are aged 90 years or above. As for visual 
impairment, the majority of the burden of visual impairment in this age-group is borne 
by women. Out of the estimated 192,000 people visually impaired due to AMD, 
146,000 (76%) are women. 
The prevalence of AMD causing visual impairment did not vary by socio-economic 
group or region. 
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6.4.2 Comparison with other studies 
In a recent review pooling data from several international studies of AMD the 
prevalence of visual impairment due to AMD was estimated as: 75-79 1.55%, 80-84 
3.58%, 85-89 8.07% and 90+ 15.3% (Owen et al. 2002). These results compare well 
with the estimates of prevalence from the MRC Trial: 1.2%, 3.6%, 6.6% and 14.1 %. 
Previous estimates of the prevalence of visual impairment due to AMD have been much 
higher, for example, the RNIB website estimates that there are 750,460 people visually 
impaired people aged 75 years and above of whom half, i. e. approximately 375,000 will 
have AMD. * These figures were based on the RNIB Survey(Bruce et al. 1991). As has 
been pointed out elsewhere (Owen et al. 2002), this report extrapolated from a highly 
selected interviewed group and did not provide confidence intervals around the 
estimates. 
The current study found a statistically significant increased risk of AMD causing visual 
impairment in women. Pooled analysis of previous population-based studies have not 
indicated such a strong risk (Smith et al. 1997). However, examination of figure 1.4 
(chapter one) shows that there is the possibility of an age-effect such that there is a 
greater increased risk for women at older ages. As the MRC Trial was a substantially 
older population than most previous population-based studies this could be the 
explanation. 
6.4.3 Comments 
The prevalence estimates presented here are minimum estimates. However, they agree 
well with the estimates expected on the basis of applying a pooled analysis of the major 
population-based prevalence studies of AMD to the UK population and are substantially 
lower than the estimates that are currently commonly used. 
http: //www. rnib. org. uk/wesupply/fctsheet/authuk. htm [Accessed December 2002] 
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6.5 FUNCTIONAL ABILITY 
6.5.1 Principal findings 
People visually impaired due to AMD were more likely to report that they had a lot of 
difficulty reading newsprint, difficulty managing finances, were more likely to be in the 
worst quintile on the ADL scale compared to people not visually impaired. They 
appeared to be at an extra disadvantage compared to people visually impaired due to 
other causes, even after adjusting for visual acuity. 
6.5.2 Comparison with other studies 
Previous population-based studies have considered the association between visual 
impairment and functional ability(Marx et al. 1992; Carabellese et al. 1993; Salive et al. 
1994; West et al. 1997; Valbuena et al. 1999). Studies of AMD have been confined to 
single case groups of people with AMD attending for health care or to take part in a 
trial(Williams et al. 1998; Mangione et al. 1999). These studies have had no control 
group and so have been limited to comparisons with other patient groups. 
Several studies have demonstrated that visual impairment is associated with decreased 
functional ability, generally as measured by the ADL scale(Marx et al. 1992; 
Carabellese et al. 1993; Salive et al. 1994; West et al. 1997). This finding is confirmed 
in the current study. Studies of AMD specifically, have found that patients with AMD 
were more likely to have problems with activities of daily living compared to other 
national samples(Williams et al. 1998). Mangione et al found that more severe AMD 
was associated with more difficulties with Activities of Daily Vision, however, this 
could be attributed to increased vision loss(Mangione et al. 1999). In the current study 
people with AMD were more likely to be in the worst quintile for ADL score than 
people visually impaired due to other causes, even after controlling 
for binocular acuity 
score. 
6.5.3 Comments 
This is the first population-based study of its kind whereby people with AMD causing 
visual impairment have been compared to people not visually 
impaired and people 
visually impaired due to other causes. 
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People aged 75 years and above have many other problems that affect their daily life. 
The number of disabling health problems increases with age. People with AMD have 
two additional problems: firstly, and most importantly, is the loss of vision; secondly, 
the effect of having AMD, either the impact of the diagnosis or the specific visual 
handicap that the disease brings. 
6.6 SELF-REPORTED HEALTH AND PHYSICAL ACTIVITY 
6.6.1 Principal findings 
People with AMD were more likely to report "fair/poor" health compared to people not 
visually impaired. They appeared to rate their health worse than people visually 
impaired due to other causes, even after controlling for visual acuity. People with AMD 
had a non-significant increased odds of reporting being "not at all" physically active 
compared to people not visually impaired. 
6.6.2 Comparison with other studies 
One other study has examined the relationship of a single item measure of self-rated 
health with visual impairment(Wang et al. 2000). In the Blue Mountains Eye Study, 
decreased vision was found to have an independent impact on global health ranking by 
person younger than 80 years of age but not by older persons. Williams found that 16% 
of a sample of 86 people with AMD reported "fair or poor" health in contrast to 23% of 
people with AMD causing visual impairment in the current study(Williams et al. 1998). 
This may well be attributable to the fact that this group of people with AMD were older 
(average age 86 years) compared to the people in the American study (average age 79 
years). 
6.6.3 Comments 
This study of older people repeats Wang et al observations in the Blue Mountains Eye 
Study that visual impairment did not have a statistically significant impact on self- 
reported health. However, the confidence intervals in the current study ranged 
from near 
1 (0.98) to 1.47 and therefore are consistent with a moderate impact of visual 
impairment on self-reported health. The measures of effect in this study differed in 
statistical significance (but not much in size) depending on whether 
depression, 
cognitive impairment, falls and hip fractures were 
included as confounding factors. 
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Self-reported or perceived health is a complicated measure. Some authors have pointed 
out the difficulties in its interpretation(Bowling 1997). Poor mental health can distort 
perceptions of health but poor physical health can also lead to poor mental health. Why 
do people with AMD apparently report worse health than other people of similar age 
and with similar levels of visual acuity? This may reflect their perception that they have 
an incurable cause of visual loss that may get worse over time. 
6.7 SICKNESS IMPACT PROFILE AND PHILADELPHIA GERIATRIC MORALE 
SCALE 
6.7.1 Principal findings 
Four dimensions of the Sickness Impact Profile (SIP) were studied in the current study: 
home management, mobility, body care and movement and social interaction. Home 
management, mobility and body care and movement were significantly associated with 
visual impairment. There was little evidence of any extra impact of AMD. It was 
interesting to note that for home management and body care and movement, men 
appeared to be worse affected by visual impairment and AMD than women. 
There was a non-significant increased risk of being in the worst quintile for social 
interaction and PGMS in visually impaired people compared to non-visually impaired 
people. There was little difference between AMD and other causes. 
People with visual impairment due to AMD were less likely to suffer problems on the 
body care and movement dimension of the SIP. 
6.7.2 Comparison with other studies 
The Sickness Impact Profile has been used in hospital-based studies (for example 
(Desai et al. 1996)) but few population-based studies. The SEE project reported that 
they examined the social interaction scales from the SIP. They found that visual 
impairment was one of the most important predictors of reporting no social activities or 
no religious activities. However, the results were a little confusing because they 
categorised social activities as <1 per month, 1-3 per month and >1 times per week. 
However, the SIP responses are of the yes/no variety. In contrast to the SEE project, the 
current study did not find a statistically significant association with the social 
interaction dimension of the SIP however the confidence intervals range from 0.89 to 
227 
1.97 and are therefore consistent with nearly a two-fold odds of experiencing difficulties 
with social interaction. 
In a small study comparing 30 cases of AMD with 30 age and sex-matched controls 
people with AMD had lower life satisfaction, as measured by the Life Satisfaction 
Index Wellbeing (Davis et al. 1995). However the difference was small (3 points on the 
scale) and although statistically significant may not have represented an important 
difference. 
6.7.3 Comments 
The analyses of SIP and PGMS were more problematic because these measures were 
only collected in a subset of 11 practices. This meant that it was difficult to include all 
potential confounding factors in the model at the same time. The analysis strategy used 
was to identify the most important confounders by selecting those that affected the odds 
ratio by 10% or more (in contrast to the other analyses which included confounders that 
were significantly associated with exposure and outcome). Although there were few 
confounders that affected the odds ratio substantially, for the analyses examining the 
relationship between visual impairment, AMD and SIP, the possibility of residual 
confounding is more of a problem. 
People with AMD had less problems with the body care and movement dimension of 
SIP (see Appendix E). A number of these questions relate to more intrinsic features of 
bodily functioning, for example, "I move my hands or fingers with some difficulty or 
limitation ". It may be that some of the people visually impaired due to other causes 
were suffering from systemic illness, such as stroke, that would affect their body care 
and movement. It is perhaps unsurprising that this visual impairment due to AMD had 
less effect on this dimension of quality of life. 
6.8 DEPRESSION AND COGNITIVE IMPAIRMENT 
6.8.1 Principal findings 
After controlling for appropriate confounding factors and compared to people not 
visually impaired, visually impaired people had an approximately 50% increased chance 
of depression and 70% increased chance of cognitive impairment. There was little 
evidence of any differences between people visually impaired due to AMD and those 
visually impaired due to other causes. 
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6.8.2 Comparison with other studies 
Carabellese found that visual impairment was associated with an increased risk for 
depression (Carabellese et al. 1993). A couple of studies have examined relatively small 
cohorts of people with AMD and reported the rates of depression (Rovner et al. 2002; 
Brody et al. 2001). Both studies found that approximately 33% were depressed. In the 
absence of a control group, this figure is a little difficult to interpret, however, Brody et 
al compared it to other studies of community-dwelling elderly people and found it to be 
double the rate expected (Brody et al. 2001). This contrasts to the current study where 
15% of people with AMD causing visual impairment were depressed. However, this 
was approximately double the rate found in people not visually impaired (7%). The 
difference in rates of depression is probably due to the measures used. The definition of 
depression in the study by Brody et al was based on the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV). Depressed subjects had a mean GDS score of 
5.86. This suggests that some of the participants in the MRC Trial who had GDS scores 
of less than six may have been classified as depressed by the alternative measure. 
6.8.3 Comments 
An association between visual impairment and depression does not necessarily mean 
that there is a causal link. It may be that there is a confounding factor that we have not 
considered. Another possibility is that depressed people are not so good at doing visual 
acuity tests. There is little evidence that this is the case, although some studies have 
suggested that people with clinical depression are more likely to perceive ambient light 
as being dimmer than usual (Friberg and Borrero 2000), and experience increased rates 
of disturbed colour vision (Heim and Morgner 1997). The mechanisms by which visual 
impairment may lead to depression may relate to social isolation, adjustment to loss of 
vision, difficulties with daily activities, lack of exercise. It has also been noted that 
people with severe loss of vision may experience sleep problems (Tabandeh et al. 
1998). 
The diagnosis of AMD is one of a chronic, progressive disease leading to "blindness". 
There is little in the way of treatment that can slow down progression and none that can 
restore vision. The hypothesis that such a diagnosis may 
lead to increased levels of 
depression, compared to other diagnoses such as cataract, has not been borne out in this 
study. Some studies have found that the longer the duration of vision 
loss occurs the 
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less it is associated with emotional distress(Williams et al. 1998; Ip et al. 2000). It may 
be that in this older population a certain amount of adjustment to the diagnosis has 
occurred. 
Severely cognitively impaired people are likely to have difficulties doing the visual 
acuity test. In our sample, 23.3% of cognitively impaired people did not do a vision test 
compared to 2.4% of not impaired people. People with a clinical diagnosis of dementia 
have been found to have higher rates of visual impairment (Uhlmann et al. 1991). and 
people visually impaired more likely to develop delirium (Inouye et al. 1993). 
The MMSE is divided up into two sections -a verbal section with a maximum score of 
21, and a performance section (involving, for example, copying a drawing) with a 
maximum score of 9. The following cut-points have generally been accepted: 24-30 no 
cognitive impairment, 18-23 mild cognitive impairment, 0-17 severe cognitive 
impairment. The MMSE shows high levels of sensitivity for detecting severe cognitive 
impairment (Tombaugh and McIntyre 1992). 
The corresponding cut-point for severe cognitive impairment, when using only the 
verbal section is less than 12. Analyses using data from the verbal section only were 
used in order to minimise the effect of vision on the performance of the test, 
independent of cognition. However, it is very likely that visual impairment makes it 
more difficult to do the MMSE, which is partly based on memory. Previous studies 
have demonstrated that people with visual impairment can achieve low scores on the 
MMSE despite having no clinical signs of dementia (Jagger et al. 1992). Memory and 
learning improve significantly when vision is restored after cataract surgery (Fagerstrom 
1992). 
6.9 FALLS AND HIP FRACTURES 
6.9.1 Principal findings 
Visually impaired people had a modest non-significant increased risk of reporting two 
or more falls at home in the last six months compared with people not visually impaired 
and a similar non-significant increased risk of reporting 
hip fracture compared with 
people not visually impaired. No difference between AMD and other causes of visual 
loss was observed. There was some evidence that the effect of visual 
impairment on hip 
fractures was different at different ages. In people aged 90 years and above, visual 
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impairment due to AMD was associated with nearly a four-fold increased chance of 
reporting hip fracture. 
6.9.2 Comparison with other studies 
There are a number of studies suggesting that people with impaired vision are more 
likely to fall(Klein et al. 1998a; Ivers et al. 1998; Jack et al. 1995). In the Beaver Dam 
Eye Study, 10.5% of people with a current binocular acuity of less than 20/25 reported a 
history of falls in the last year compared to 5.2% of people with vision of 20/20 or 
better (Klein et al. 1998a). This is very similar to the results of the current study where 
13% of visually impaired people reported two or more falls in the last six months 
compared to 8% of people not visually impaired. Little further information was given in 
the Beaver Dam Study report, for example, no adjustment was made for confounding by 
age, sex or other factors. 
In the Blue Mountains Eye Study, there was an increased risk of two or more falls in the 
past year associated with visual impairment, after adjustment for a variety of 
confounding factors (Ivers et al. 1998). The increased risk was of a similar order of 
magnitude to the current study. The Blue Mountains Eye Study examined the role of 
eye disease and falls. They found that AMD was not significantly associated with 
falling -a finding repeated in this study. 
In contrast to the current study, a number of other studies have found a significant 
relationship between hip fractures and visual impairment. In the prospective 
osteoporotic fractures study, risk of hip fractures was associated with poor depth 
perception and poor contrast sensitivity (Cummings et al. 1995). In the retrospective 
Auckland Hip Fracture Study, binocular acuity less than 20/60 was significantly 
associated with increased risk of hip fractures after adjustment for various risk factors. 
The authors attributed 40% of fractures to poor visual acuity or stereopsis. In the 
Framingham Study, people with poor vision were more than twice as likely to have a 
hip fracture compared to those without (Felson et al. 1989). A similar risk was found in 
the EPIDOS prospective study (Dargent-Molina et al. 1996). Similarly, in the cross- 
sectional Beaver Dam Eye Study, 5.2% of people with vision 
20/25 or worse reported 
hip fracture compared to 1.4% of people with vision 20/20 or better (Klein et al. 1998a). 
231 
6.9.3 Comments 
There are many other illnesses and health problems that will co-exist due to the fact that 
people with AMD are, in general, older. However, the impact of AMD causing visual 
impairment on morbidity, i. e. a presumed causal link, is unlikely in most except for 
depression (considered above) and hip fracture. 
In this study visual impairment was associated with a statistically non-significant 20% 
increased chance of falls and hip fractures. Only the 90 years and above age-group was 
visual impairment a significant risk factor for reported hip fracture. This estimate is 
substantially lower than that seen in other studies. It may in part be explained by the fact 
that more confounders were considered in this study. However, the odds ratio 
controlling only age and sex was 1.49 (1.28 to 1.74) for falls and 1.46 (1.14 to 1.88) for 
hip fractures. 
6.10 MORTALITY 
6.10.1 Principal findings 
After controlling for all the potential confounders, visually impaired people had an 
increased risk of death compared to people not visually impaired. People visually 
impaired due to AMD had a lower risk compared to people visually impaired due to 
other causes. There did not appear to be any effect modification by age or sex. 
6.10.2 Comparison with other studies 
Previous studies have found that visual impairment is strongly associated with mortality 
(Klein et al. 1995a; Laforge et al. 1992; Lee et al. 2002; McCarty et al. 2001b; McCarty 
et al. 2001 b; Reidy et al. 2002; Taylor et al. 2000; Thompson et al. 1989; Wang et al. 
2001). In two of these studies, women and not men have been at increased risk(Lee et 
al. 2002; Reidy et al. 2002). 
Few studies have examined AMD directly but, in contrast to cataract, 
it does not appear 
to be linked to an increased risk of mortality (Klein et al. 1995a). This was confirmed 
by the current study whereby visual impairment was strongly associated with mortality 
but the majority of this risk was related to vision impairment 
due to other causes and not 
AMD. 
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6.10.3. Comments 
Other studies have found differences between men and women a finding that was not 
repeated in this study. It was not possible to assess the extent to which the association 
between mortality and visual impairment is due to accidents in visually impaired older 
people. However, controlling for falls had little effect on the relationship. Accidents 
account for only a small proportion of deaths in the elderly and it is likely that this is not 
the major explanation for the increased risk of mortality. 
I did not distinguish the different causes of visual loss in the "other causes" group, 
however, cataract as a cause of visual loss is likely to predominate in that group and 
may well be the explanation for the excess mortality in that group. 
6.11 SMOKING 
6.11.1 Principal findings 
Current smokers had a two-fold increased risk of being visually impaired due to AMD 
compared to non-smokers. This effect was particularly strong in people aged 75-79 
years of age. In these people there was a three-fold increased risk and a dose-response 
relationship between pack years of smoking and risk of AMD causing visual 
impairment. People who stopped smoking more than 40 years ago had a similar risk to 
non-smokers. Based on these findings, approximately 28% of cases of AMD in this 
study population were attributable to smoking, either currently or in the past 
(attributable risk %_ ((OR-1)/OR)*proportion exposed amongst cases)(Rothman 
1986). 
6.11.2 Comparison with other studies 
Levels of smoking in the MRC Trial cohort were similar to those reported in the Health 
Survey for England 1997*. Approximately 12% of men and 8% of women reported 
being a current smoker in the MRC Trial cohort, compared to 12% of men and 11 % of 
women aged 75 years and above in the Health Survey for England. 
The results of this study are similar to other studies on smoking and AMD. The results 
of other studies on smoking are in table 1.11 in chapter one. The current study is the 
http:: `wýý-ýý"doü":: o\`. uk'stats: `Iistable. hmi. Accessed June 17th 2003. 
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largest number of population-based cases of late-stage AMD identified to date. The size 
of effect is compatible with the other studies; most estimated a two-fold or three-fold 
risk. 
A dose-response relationship has been seen in the prospective studies(Seddon et al. 
1996; Christen et al. 1996), and the cross-sectional Rotterdam study(Vingerling et al. 
1996). In the Physicians' Health Study, people who had stopped smoking 20 or more 
years before the start of the study had a borderline increased risk of AMD with vision 
loss. Similar results were seen in the Rotterdam Study. However, in these studies the 
number of cases was lower. Time since stopping smoking was grouped into broader 
categories than the current study. 
In the Nurses Health Study 29% of cases of AMD were attributable to smoking(Seddon 
et al. 1996). This value is very similar to the results of the current study (28%). 
6.11.3 Comments 
This nested case-control study forms one of the largest case-control studies of AMD in 
the British population and one of the largest reported to date. It examined the role of 
smoking, alcohol consumption, cardiovascular disease and reproductive factors in 
women. The role of genetic factors, antioxidant micronutrients and light exposure were 
not studied. The results fit in remarkably well with results seen in other studies with 
different designs, ages studied and methods of ascertainment of AMD. Of the risk 
factors examined, the only one to emerge as being important is smoking, which is 
estimated to account for approximately one in three cases in this population of people 
aged 75 years and above living in Britain. 
Possible explanations for the modification of the effect of smoking by age include that 
the measurement of disease or exposure may be more unreliable in the older age-groups. 
An alternative explanation is that, as smoking is an important cause of mortality, 
smokers surviving beyond the age of 80 years have more vigorous defense mechanisms 
to deal with the harmful effects of smoking. These mechanisms may also apply to 
AMD. Vingerling et al in the Rotterdam Study reported a similar effect modification by 
age(Vingerling et al. 1996), however this was later revised (Klaver et al. 1997). 
The current study was limited by not having information on antioxidant intake. One 
alternative explanation is that smokers eat less fruit and vegetables and thereby increase 
their risk of AMD. However, in the Eye Disease Case-Control Study Group, plasma 
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levels of antioxidant micronutrients were adjusted for and a similar effect size reported 
(Eye Disease Case-Control Study Group 1992). 
6.12 OTHER RISK FACTORS 
6.12.1 Principal findings 
Alcohol consumption 
There was little indication that alcohol consumption was protective. People who 
reported that they had taken an alcoholic drink in the last year had a small (less than 
20%) non-significant increased risk of visual impairment due to AMD. The majority of 
the "drinkers" had consumed less than 10 units in the previous week. There was a non- 
significant increased risk of visual impairment due to AMD in people who had drunk 20 
or more units in the last week (equivalent to 160g ethanol) and reduced risks in people 
with moderate consumption compared to non-drinkers. 
Cardiovascular disease 
People with AMD were more likely to report that they had had a stroke, heart attack or 
diabetes. In the case of heart attack and diabetes this association was of marginal 
significance only. After controlling for other confounding factors, the association with 
reported stroke was attenuated and no longer statistically significant. 
Reproductive factors in women 
There was little indication that women with reproductive factors indicating relatively 
low lifetime oestrogen levels were at increased risk of developing visually impairing 
AMD. 
6.12.2 Comparison with other studies 
Alcohol consumption 
Alcohol consumption in the MRC Trial was similar to that reported in the Health 
Survey for England 1997*. In the MRC Trial 84% of men and 70% of women reported 
having had a drink in the past year. This compares to 85% of men aged 75 years and 
h!! p tats_hstahlehtin. Accessed June 17th 2003. 
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above and 75% of women in the Health Survey for England who reported drinking in 
the previous week. 
In the Blue Mountains Study, total alcohol intake was not associated with ARM(Smith 
and Mitchell 1996). In NHANES-I moderate wine consumption was associated with a 
decreased risk of AMD(Obisesan et al. 1998). However, this association was of 
marginal statistical significance (odds ratio 0.86,0.74 to 0.996). In the Beaver Dam 
Study, men drinking 78g/week of alcohol or more from beer had a higher five-year age- 
adjusted incidence of early ARM(Moss et al. 1998). In the prospective Physicians 
Health Study, there was a small non-significant reduced risk for low to moderate levels 
of alcohol intake(Ajani et al. 1999). In the combined analysis of the Nurses' Health 
Study and the Health Professionals Follow-up Study, there was a suggestion of a 
moderate increased risk of the disease in women who drank 30g/day or more (relative 
risk 1.5,1.0 to 2.4)(Cho et al. 2000). 
Cardiovascular disease 
In the Health Survey for England 1998*, 73% of men and 78% of women aged 75 years 
and above had systolic blood pressure of 140mmHg or more or had a diastolic pressure 
of 90mmHg or over or were taking antihypertensive medication. This compares to 60% 
of men and 68% of women in the MRC Trial cohort who had high systolic or diastolic 
blood pressure (but not including those who were taking antihypertensive medication). 
There has been inconsistent evidence for the relationship between cardiovascular 
disease and AMD with several studies finding an association(Chaine et al. 1998; 
Hyman et al. 2001; Goldberg et al. 1988a) and others not(Klein et al. 1993a; Smith et 
al. 1998b; Delcourt et al. 2001). 
Oestrogens 
The Eye Disease Case-Control Study Group was the first study to report on 
oestrogens(Eye Disease Case-Control Study Group 1992). Women taking oestrogen 
replacement were at a reduced risk of neovascular AMD compared to women who had 
never taken replacement therapy. However, it is known that women who take 
hormone 
* htt archive. officiai-documents. co. itk/docun1ennt/dahist1rve\98! hse-03.1htm#:. 2. Accessed June 
17th 2003 
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replacement therapy are very different to those who do not and these differences may 
not have been adequately controlled for in the analysis. In the Rotterdam Study, women 
with early menopause after removal of one or both ovaries had an increased risk of 
macular degeneration compared to women who had their menopause at 45 years or 
later(Vingerling et al. 1995c). These results were not confirmed by the Beaver Dam 
Study(Klein et al. 1994a), or the Blue Mountains study(Smith et al. 1997) nor in the 
current study. Menopause before 45 years of age due to surgery was not a risk factor for 
AMD. 
6.12.3 Comments 
This study of over 500 cases of severe AMD had a reasonable power (over 80%) to 
investigate odds ratios of two or more (see chapter five table 5.2). An effect of smoking 
was observed. However, it may well be that the effect of alcohol on AMD is more 
modest. Previous studies have found non-significant increased risk or odds in the region 
of 30%. If the real effect is of that order, it will be quite difficult to detect reliably in 
observational studies. Firstly, the studies will need to accrue large numbers of cases of 
AMD, preferably prospectively. Secondly, even if a statistically significant risk of that 
order is observed, given that the increased risk is modest it will be difficult to be 
confident that it could not have been due to the effect of an unidentified confounder. 
The measures of oestrogen used in this study were fairly crude. They consisted of 
measuring the years of menstruation or time since the menopause. It may be that these 
are not good measures of relative oestrogen exposure. In this particular cohort, it is 
unlikely that use of hormone replacement therapy will have been common. In the Health 
Survey for England 1997*, less than 3% of women aged 75 years and above reported 
ever using HRT. The difficulties with assessing the effects of exogenous oestrogen have 
been discussed. One of the ways forward in this area is to add an assessment of AMD in 
trials of hormone replacement therapy. This was to be one of the secondary outcomes of 
the MRC sponsored WISDOM trial. However, the trial has recently been abandoned. 
* htt1-. %'ýj_w : dý>.. h. ? v_ul: 'stats hstable_htm.. Accessed June 17th 2003. 
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6.13 UNANSWERED QUESTIONS AND FUTURE RESEARCH 
" Periodic assessment of the prevalence of visual impairment and AMD 
The prevalence of visual impairment may change with changing circumstances. It 
would be useful to have regular (say five- or ten-yearly) assessment of the prevalence of 
visual impairment in the UK. This could take the form of adding on collection of data 
on visual acuity to other nationwide studies (as is done with NHANES in the USA). 
This study indicates a substantial burden of AMD causing visual impairment in this age- 
group which rises exponentially with increasing age. As for visual impairment, it would 
be useful to have regular assessment of the prevalence of AMD causing visual 
impairment in the UK. This could take the form of adding on collection of data on 
AMD to other nationwide studies. 
Regular national assessment of the prevalence of this condition would make it possible 
to conduct ecological studies. For example, as the prevalence of smoking in the 
population changes over time, it would be interesting to examine whether corresponding 
changes in the prevalence of AMD could be observed. 
A criticism of the current study is that AMD was assessed from medical record review 
rather than fundus photographs. Future prevalence studies, if adequately funded, could 
incorporate such data collection, even if only on a sample. 
" Assessment of the prevalence of visual impairment and AMD in ethnic minorities 
As the age-structures of these populations change, visual impairment and eye disease is 
likely to become more of a problem. Surveys in specific geographical locations will be 
required. 
" Why do women have a higher risk of visual impairment than men? 
Women aged 75 years and above have a higher risk of visual impairment than men. The 
reasons for this should be investigated in more detail. Is this due to lack of access to 
services or differences in incidence of eye disease causing visual impairment? 
" Barriers to eye health care in older people 
The majority of people with cataract or refractive error could have their sight restored 
with appropriate treatment. Further research as to why people 
do not get glasses or a 
cataract operation is needed. What are the barriers to access to optometric and cataract 
surgery services in this age-group? 
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" Further research on impact of AMD 
This is the first time that the association between AMD and functional ability has been 
investigated in a population-based study with an appropriate control group. The 
observation that people with AMD are particularly disabled with respect to tasks 
requiring reading, in comparison to people with other causes of visual loss, has not been 
seen before, to my knowledge. Similarly, for the relationship between AMD and self- 
reported health and physical activity. This is the first time AMD has been studied in this 
context and this finding could usefully be studied again. If the finding is repeated, i. e. 
that people with AMD report worse health than people with visual loss due to other 
causes, in depth qualitative studies as to the determinants of this difference should be 
done. 
For SIP, as for self-rated health, this is the first time AMD has been studied in this 
context and compared to an appropriate control group. Future studies could include 
vision related measures of quality of life such as the NEI-VFQ(Mangione et al. 2001). 
and other dimensions of SIP. 
" What is the basis of the link between cognitive impairment and AMD causing visual 
impairment? 
Are people with cognitive impairment not so good at doing visual acuity tests? Or does 
visual loss predispose towards either cognitive impairment, or difficulty doing the 
MMSE, independent of cognitive impairment. It is difficult to distinguish these 
hypotheses in a cross-sectional study. One option would be to assess the performance 
on the MMSE in people prior to cataract surgery. This could then be compared to their 
performance when vision is restored. The assumption would be that cognition would not 
have improved in a relatively short period and, any improvement in the MMSE test 
could be attributed to the change in vision. 
" Counselling support for depression. 
The link between visual impairment and depression, from this study and others, appears 
to be fairly well established. Future studies need to address what should be done about 
this problem. Counselling support for people with AMD needs to 
be developed. One 
small study has shown that it is possible to develop a self-management program with 
positive benefits on quality of life(Brody et al. 2002). 
Research at the primary care level 
as to how best to provide such support is needed. 
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" Why does visual impairment lead to an increased risk of death? 
Is visual impairment harmful, per se, for example, leading to reduced nutrition or self- 
care, or is visual impairment a marker for failing health? 
" Do changing rates of smoking in the population result in changing incidence rates of 
AMD? 
Smoking is an example of an exposure where it is not possible to do a randomised 
controlled trial. An ecological study design to assess the impact of removing smoking as 
an exposure would be to examine whether changing rates of smoking over time are 
related to changing prevalence rates of AMD. 
6.14 POLICY IMPLICATIONS 
0 Projected burden of AMD causing visual impairment in the UK for planning low 
vision services and hospital eye services 
This study has shown that the burden of visual impairment due to AMD is considerable 
in people aged 75 years and above. Nearly 200,000 people aged 75 years and above are 
visually impaired due to AMD in the UK. This figure will rise as the population ages 
over the next few decades. Given the current prevalence of AMD, in the year 2051 the 
numbers of people affected in the 75 years and above age-group will be over twice as 
high. * Policy makers need to be aware of the prevalence of this condition when planning 
the need for low vision services and hospital eye services for AMD. Although the 
burden is substantial it is lower than some previous estimates. 
A recent study of low vision services for vision rehabilitation in the UK showed that the 
distribution of low vision services was geographically uneven(Culham et al. 2002). 
Compared to the probable number of people with a visual impairment in the UK there 
were inadequacies in service provision. The authors concluded that a review of current 
services is needed. 
Research into the effectiveness of low vision aids is limited but systematic reviews are 
underway(Virgili and Rubin 2002). More research is needed into which vision aids are 
* Calculated by applying prevalence rates to projected population in 2051 obtained from 
http:! %vti+'w" d, -oti'"<< [Accessed December 2002] 
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effective in this age-group and the best way in which they should be delivered. The 
differing needs of the very elderly should be considered separately. 
New treatments for AMD are being developed and researched(Evans 2002). The 
implications of these for costs in the NHS need to be established against projected 
numbers with the disease in the UK. 
0 Should we be screening for AMD? 
Currently there is little effective treatment for most people with AMD(Fine et al. 2000). 
A proportion of people with neovascular disease at its early stages may benefit from 
laser photocoagulation or photodynamic therapy. In the MRC Trial, visual acuity 
screening and referral for visual impairment was included in order to assess whether 
there was any benefit from such screening. The results of a nested trial of visual acuity 
screening suggests that there was not any benefit(Smeeth et al. 2002a). Possible reasons 
include a low referral rate by the general practitioners. Given that pragmatic screening 
in the community for visual impairment, much of which is caused by cataract which has 
a safe and effective cure, screening for AMD, which does not have such treatment is 
unlikely to be beneficial. However, education campaigns for AMD promoting 
awareness of visual symptoms such as distortion may increase the number of people 
coming forward with earlier stages of the disease for treatment. 
" Visual impairment is extremely common in the very old, AMD is the most 
important cause of visual impairment 
It is common to summarise the health experience of people over 65 or over 75 years of 
age. These summary figures hide a dramatically increased risk of visual impairment and 
blindness in people aged over 90 years. 
The needs of very old people are likely to be quite different to the (nowadays) relatively 
active 75 year old person. The role of low vision aids and access to hospital eye services 
in this age-group may need to be addressed differently to the younger ages. More 
research into the effectiveness of low vision aids in the very elderly is needed. 
" Much visual impairment in people aged 75 years and above could 
be alleviated by a 
pair of spectacles 
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Policy makers need to consider the role of the high street optician and mechanisms for 
providing cheap and reliable spectacles to groups of the population that may not be able 
to afford high street spectacles. 
" Cataract causes much avoidable visual impairment in this age-group. 
More investment in cataract surgery to reduce waiting list times along with research into 
the barriers to cataract surgery in this age-group is needed. 
" The level of smoking in the population should be reduced and young people 
discouraged from taking up smoking 
AMD is another reason why governments should act to reduce the level of smoking and 
should be included in public health campaigns aimed at reducing smoking. One in every 
three cases of AMD could be prevented if nobody smoked. This would have huge social 
and financial implications. 
" Visual impairment predominately affects women. This has implications for delivery 
of services. 
" More research into the causes and cure of AMD. 
This study, along with others, has demonstrated the detrimental impact of visual 
impairment on quality of life, mental health, falls and mortality. Given the impact of 
visual impairment, research into the causes and cure of AMD must be maintained and 
developed. Clearly the role of genetics in the aetiology of AMD holds much promise; 
similarly, the possible role of a diet rich in antioxidant micronutrients has not been fully 
explored. A variety of treatments for AMD are currently being explored and trials of 
these need to be expedited. 
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Table 6.1 Comparison with other population-based studies on prevalence of visual 
impairment and blindness 
Prevalence of visual acuity less than 6/18 
65 plus 75 plus 85 plus 
Correction of 
Country Study refractive error N%N%N% 
UK MRC Trial Presenting 14600 12.4 3100 23.5 
(current binocular 
study) acuity <6/18 
UK 
**UK 
UK 
**USA 
Wormald et al Pinhole <6/18 207 7.7 106 14.2 
Reidy et al Presenting 
binocular 
acuity <6/12 
1547 30.2 
Van der Pols 
et al 
SEE project 
Pinhole <6/18 13 62 12.0 
Presenting 
binocular 
acuity <6/12 
Nether- Rotterdam Refraction 
lands Study 
*USA Baltimore Eye Refraction 
Study 
2520 6.9 905 11.7 
4214 2.2 1806 4.7 408 11.8 
1751 2.6 836 4.8 206 13.1 
USA Beaver Dam Refraction 2073 2.7 795 6 
Eye Study 
Australia Blue Refraction 1990 2.1 783 5.0 132 13.6 
Mountain Eye 
Study 
*Australia Melbourne Refraction 1467 2.8 605 6.2 161 18.8 
Visual 
Impairment 
Project 
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Table 6.2 Comparison with other population-based studies on the causes of visual 
loss 
% with 
Definition Number 
of visual visually 
Study Year Age impairment impaired AMD Cataract Glaucoma Diabetes Other 
Blindness 
MRC Trial 1995- 75+ 
98 
Baltimore 1988- 65+ 
Eye Study 89 
Beaver Dam 1988- 40+ 
Eye Study 90 
SEE >65 
Melbourne 40+ 
VIP 
Blue 65- 
Mountains 84 
Eye Study 
*Rotterdam 1990- 75+ 
Study 93 
<3/60 249 66 7 12 3 11 
<=6/60 42 38 17 14 2 29 
<=6/60 21 57 5 0 10 28 
<6/60 15 40 13 33 0 13 
<=6/60 24 88 4 0 0 8 
<=6/60 10 70 0 10 0 20 
<3/60 50 70 8 6 0 16 
Low vision 
MRC Trial 1995- 75+ <6/18 - 728 41 39 8 3 9 
98 3/60 
Baltimore 1988- 65+ <6/12 - 134 25 44 3 0 28 
Eye Study 89 >6/60 
SEE 40+ <6/18 - 31 23 10 16 10 42 
>=6/60 
Melbourne >65 <6/18 - 21 38 33 10 
5 14 
VIP >6/60 
Blue 65- <6/12 - 50 32 42 
2 8 16 
Mountains 84 >6/60 
Eye Study 
*Rotterdam 1990- 75+ <6/18 - 170 28 57 
2 0 14 
Study 93 3/60 
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APPENDICES 
APPENDIX A MRC TRIAL STUDY TEAM 
The MRC Trial is a large community-based randomised trial taking place in England, 
Wales and Scotland (Britain). Participating practices belong to the MRC General 
Practice Research Framework (GPRF) which is a network of practices interested in 
research co-ordinated by the MRC Epidemiology Unit at Northwick Park Hospital. 
Investigators: Professor Astrid Fletcher, London School of Hygiene and Tropical 
Medicine, Dr Dee Jones, University of Wales College of Medicine, Professor Chris 
Bulpitt, Imperial College School of Medicine, Dr Alistair Tulloch, University of Oxford 
Principal Investigator: Professor Astrid Fletcher 
Centres: Practices from the Medical Research Council General Practice Research 
Framework (MRC GPRF), Director Dr Madge Vickers 
Collaborators on economic analyses: Professor Mike Drummond (University of York), 
Linda Davies (University of Manchester) 
Sponsor: Medical Research Council, Department of Health, Scottish Office 
Trial Steering Committee: Professor Sir John Grimley Evans (Chair from Jan 2001), Dr 
Carol Brayne, Professor Andy Haines (Chair 1994-2000), Professor Karen Luker, Dr 
Madge Vickers 
London School of Hygiene and Tropical Medicine : Elizabeth Breeze, Edmond Ng, Gill 
Price, Liam Smeeth, Susannah Scott, Susan Stirling, Rakhi Kabiwala, Jabibi Mazar 
Imperial College of Medicine: Maria Nunes, Ruth Peters, 
University of Wales College of Medicine: Amina Latif, Elaine Stringer 
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APPENDIX B: MEASURING VISUAL ACUITY 
Instructions on measuring visual acuity from the manual of 
operations for the MRC Trial of the assessment and 
management of older people in the community 
Do the test under well-lit conditions but avoid strong 
overhead lights which may dazzle the patient. Light should 
shine on the chart but not into the patient's eyes. Keep 
the lighting conditions constant. 
Measure visions at 3 metres. Use the string provided to 
measure distance. It is very important that the test is 
done at 3 metres - considerable effort should be made to 
find suitably lit 3 metre space in the practice. If this 
really is not possible, you may do the test at 1 metre but 
this will have to be agreed with your trainer before you do 
so because doing the visual acuity test at 1 metre is not a 
very accurate test for people who have good vision. For 
home visits more flexibility may be required. 
Tick the box on the form to indicate at which distance the 
test was done. 
Start by testing both eyes, then each eye separately. When 
testing one eye the patient must be asked to cover the 
other eye with the palm of their hand, or with the 
"'occluder" part of the pinhole, depending on what is 
easiest for them. Alternatively a patch may be used. 
The patient should wear the glasses they normally use for 
driving or watching television. If they normally do not 
wear spectacles but use them for specific activities 
requiring distance vision they should put these spectacles 
on for the entire visual acuity test. We want to measure 
visual deficit arising because patients do not have 
spectacles rather than because they choose not wear the 
spectacles which they have been prescribed. Hold the 
booklet vertically. If it is held at an angle reflections 
will make the letters difficulty to see. 
Ask the participant to read the letter on screening cards 
(cards 1- 3). The patient should be encouraged to respond 
until they get a letter wrong. 
The last successful response 
is used to determine the starting point 
for the measurement 
of line acuity. The appropriate card 
is selected and the 
patient should attempt to 
identify each of the 4 letters 
presented. If the patient 
is able to identify correctly 3 
or more letters on a line then 
the next card in the series 
should be presented. If they 
identify 3 or more letters, go 
on to the next card. If they can read at 
least one letter 
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on this card, the number of letters they identify correctly 
should be used to score the vision. If they cannot read any 
of this line, go back to the previous line and ask them to 
re-read it. Score this line even if they can still read 3 
or 4 letters - you know they cannot read the next line. 
The patient should be encouraged to read every letter on 
the line. Do not let them stop if they say they cannot see 
it. A phrase such as "It doesn't matter if you get it wrong 
but have a try" may be used to persuade them to finish the 
line. 
If you think the participant may be memorizing the letters, 
you may ask them to read a line from right to left. 
The vision is scored according to the number of letters 
read on the last line on which at least 1 letter can be 
read. The score should be read off from the score card on 
the back of the card. For example, if they read 3 letters 
on line 1 (HVYU) then their score is 0.825. A larger score 
indicates a worse vision. 
If a participant is unable to read Line 1 (the biggest 
letters) at 3 metres, reduce the test distance to 1 metres 
(again using the string provided). Take the vision as 
before, score for "l metre". If they are still unable to 
read Line 1 this means that they have a visual acuity 
defined as "blind" by WHO (<3/60); the appropriate box in 
the questionnaire should be ticked, and patient referred to 
the ophthalmic team if not investigated in the last year. 
If the score is 0.5 or greater then retest using the 
pinhole. Pinhole vision will only be taken for each eye 
separately. Take the vision at 3 metres to start with, even 
if the patient was down to 1 metre distance for initial 
testing. If the patient has problems holding the pinhole 
they may balance it on their nose - using the "occluder" 
part to cover the other eye; this is why it is the shape it 
is. 
If the score improves with pinhole to less than 0.5 then 
the participant should be referred to the optician, because 
when the vision improves with pinhole 
it indicates that the 
vision may be improved with spectacles. 
Anyone whose vision score is 0.5 or more using the pinhole 
should be referred to the ophthalmic team 
if not 
investigated in the last year. 
Do not be alarmed if vision gets worse with pinhole - this 
sometimes happens. Use the non-pinhole vision score 
for 
your referral criteria in that situation. 
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Appendix B: MRC Elderly Study regional trainers checklist for visual acuity 
1. Is the Glasgow Acuity Chart in good condition? 
2. Is the test being conducted in appropriate conditions? 
3. Is the room well lit? 
4. Are strong overhead lights avoided? 
5. Is the distance measured correctly (3 metres/l metre)? 
6. Is the patient wearing appropriate glasses (glasses used 
for seeing better in the distance)? 
7. Does the nurse conduct the test satisfactorily? 
8. Is the chart held vertically? 
9. Are the screening cards used properly? 
10. Does the nurse stop at the correct line? 
11. Does the nurse use the appropriate encouragement? 
12. Is the score recorded correctly? 
13. Is the pinhole used at the right cut-off? 
14. Does the nurse understand the referral criteria? 
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Appendix B: Snellen acuity and logMAR score 
LogMAR means logarithm of the minimal angle of resolution. Snellen notation refers to 
the angle detected such that the reciprocal of the Snellen fraction represents the number 
of minutes. Thus logMAR and Snellen are related by the following equation. 
LogMAR = log (1 /Snellen fraction) 
The following table shows equivalent values for the two scales 
Snellen LogMAR 
6/6 0 
6/12 0.301 
6/18 0.477 
6/60 1 
3/60 1.30 
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APPENDIX C DATA COLLECTION FORMS 
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MRC ELDERLY STUDY: 
IDENTIFYING CAUSE OF VISUAL IMPAIRMENT 
ID NUMBER r7] QýýF-] Fý 
Date of detailed examination: // 
Please go through the notes and identify ALL the letters which refer to eye problems or 
deal with referrals to or from any eye specialist - optician, ophthalmologist or eye hospital. 
Please look through all the notes, not just since the start of the MRC Elderly Study. We are 
interested in all eye problems, not just those identified during the study. 
Total number of letters (correspondence) identified in the medical notes: m 
Please allocate a number to the letters in chronological order. Letter number 1 being the 
first letter identified in the notes. If there are more than 7 letters please use extra sheets 
being sure to fill in the id number for each. For each letter please complete the following 
information: 
LETTER NUMBER 1 Date of letter // 
PURPOSE OF LETTER: eg, report from ophthalmologist, referral to optician 
DIAGNOSIS: Please write down any terms which you think refer to the diagnosis even if 
you are not sure what they mean. Please record any vision measurements. 
TREATMENT: Please write down any terms which you think refer to treatment even if 
you are not sure what they mean 
If you have any problems completing this form please contact 
Jennifer Evans on 0171 566 2819 
2-A 14 
Hospital form 
<PATIENT DETAILS ON FRONT SHEET WHICH WAS DETACHED BEFORE 
RETURNING THE FOLLOWING FORM> 
Patient Id Number <generated automatically> 
This patient was given a visual acuity examination as part of the MRC Elderly Trial on 
<date generated automatically>. At that time they were visually impaired i. e. they had a 
central acuity of less than 6/18 in the better eye or reported that they were on the Blind 
or Partial Sight Register. We would be grateful if you could let us know what was the 
main cause of visual loss for this person on the <date generated automatically>, 
whether or not they have since died. If there is more than one cause of visual loss please 
indicate which cause, in your opinion, contributes most to the visual loss by writing 1,2 
or 3 as appropriate in the "cause rating" circle. 
Please tick the relevant box (es). 
Cause Both Right Left Cause 
rating 
Age-related macular degeneration 
Exudative disease ("wet") (new vessels) (PED).. 
Geographic atrophy ("dry") (no new vessels) ...... 
Other, specify 
Cataract 
Age-related ................................ Congenital ................................. 
Other, specify 
Glaucoma 
Primary open-angle .......................... 
Primary closed-angle ....................... . 
Other, specify. 
Diabetic eye disease 
Diabetic retinopathy ...................... 
Other, specify 
Myopic degeneration ..................... 
Other, specify 
EER8 0000 0000 If there is a different cause in each eye please indicate here 
by circling R or L which eye lost vision last ................................. 
R /L 
Best corrected vision at hospital examination nearest to 
date of MRC Elderly Trial 
Examination on <date generated automatically> RL 
Name of person completing form: 
Position in hospital: 
Signature: Date // 
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APPENDIX D CODING OF CAUSE OF VISUAL LOSS 
Code Description 
10'AMD unspecified 
11 AMD exudative disease 
18 Possible AMD 
19', Other AMD 
20 Cataract unspecified 
21 Age-related cataract 
Congenital cataract 
29 Cataract other 
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coding of cause lookup table 
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APPENDIX E SICKNESS IMPACT PROFILE AND PHILADELPHIA GERIATRIC 
MORALE SCALE 
The following questions comprise the four dimensions of the Sickness Impact Profile 
used and the Philadelphia Geriatric Morale Scale 
Home management 
I only do housework or work around the house for short periods of time or I rest often 
I do less of the daily household chores than I used to do 
I do not do any of the daily household chores that I used to do 
I do not do any of the maintenance or repair work that I used to do in my home or 
garden 
I do not do any of the shopping that I used to do 
I do not do any of the cleaning that I used to do 
I have difficulty using my hands, for example, turning tapes, using kitchen gadgets, 
sewing or doing repairs 
I do not do any of the clothes washing that I used to do 
I do not do heavy work around the house 
I have given up taking care of personal or household business affairs, for example, 
paying bills, banking or doing household accounts 
Mobility 
I only get about in one building 
I stay in one room 
I stay in bed more 
I stay in bed most of the time 
I do not use public transport now 
I stay at home most of the time 
I only go out if there is a lavatory nearby 
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I do not go into town 
I only stay away from home for short periods 
I do not get about in the dark or in places that are not lit unless I have someone to help 
Body care and movement 
I make difficult movements with help, for example, getting in or out of the bath or a 
care 
I do not get in and out of bed or chairs without the help of a person or mechanical aid 
I only stand for short periods of time 
I do not keep my balance 
I move my hands or fingers with some difficulty or limitation 
I only stand up with someone's help 
I kneel, stoop or bend down only by holding onto something 
I am in a restricted position all the time 
I am very clumsy 
I get in and out of bed or chairs by grasping something for support or by using a stick or 
walking frame 
I stay lying down most of the time 
I change position frequently 
I hold onto something to move myself around in bed 
I do not bath myself completely, for example, I need help with bathing 
I do not bath myself at all, but am bathed by someone else 
I use a bedpan with help 
I have trouble putting on my shoes, socks or stockings 
I do no have control of my bladder 
I do not fasten my clothing, for example, I require assistance with buttons, zips or 
shoelaces 
I spend most of the time partly dressed or 
in nightclothes 
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I do not have control of my bowels 
I dress myself, but do so very slowly 
I only get dressed with someone's help 
Social interaction 
I go out to visit people less often 
I do not go out to visit people at all 
I show less interest in other people's problems, for example, I don't listen when they tell 
me about their problems. I don't offer to help 
I am often irritable with those around me, for example, I snap at people or criticise 
easily 
I show less affection 
I take part in fewer social activities that I used to 
I am cutting down the length of visits with friends 
I avoid having visitors 
My sexual activity is decreased 
I often express concern over what might be happening to my health 
I talk less with other people 
I make many demands on other people, for example, I insist that they do things for me 
or tell me how to do things 
I stay alone much of the time 
I am disagreeable with my family, for example, I act spitefully or stubbornly 
I have frequent outburst of anger at my family, for example, I hit them, scream or throw 
things at them 
I isolate myself as much as I can from the rest of my family 
I pay less attention to the children 
I refuse contact with my family, for example, I turn away from them 
I do not look after my children or family as well as I used to do 
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I do not joke with members of my family as much as I used to do 
Philadelphia Geriatric Morale Scale 
Do things keep getting worse as you get older? 
Do you have as much energy as you did last year? 
Do you fell lonely much? 
Do you see enough of your friends or relatives? 
Do little things bother you more this year? 
As you get older do you feel less useful? 
Do you sometimes worry so much you can't sleep? 
As you get older are things better than expected? 
Do you sometimes feel that life isn't worth living? 
Are you as happy now as you were when you were younger? 
Do you have a lot to be sad about? 
Are afraid of a lot of things? 
Do you get angry more than you used to? 
Is life hard for your most of the time? 
Are you satisfied with your life today? 
Do you take things to heart? 
Do you get upset easily? 
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APPENDIX F SUPPLEMENTARY ANALYSES FOR CHAPTER FOUR 
Table F. 1 Association between variables indicating functional limitations and 
potential confounding factors, controlling age and sex 
A lot of Difficulty ADL score - 
difficulty managing worst quintile 
reading finances 
newsprint 
Housing tenure <0.001 0.014 <0.001 
Smoking 0.173 0.465 0.006 
Alcohol consumption 0.003 0.048 <0.001 
Body mass index 0.015 0.054 0.003 
Hearing impairment 0.012 0.003 0.005 
Reported stroke <0.001 <0.001 <0.001 
Diabetes 0.004 0.183 <0.001 
Urinary incontinence <0.001 <0.001 <0.001 
Lower legs swollen in <0.001 0.003 <0.001 
morning 
Severe shortness of <0.001 <0.001 <0.001 
breath 
Three or more <0.001 0.001 <0.001 
prescribed medicines 
Depression <0.001 <0.001 <0.001 
Cognitive impairment <0.011 <0.001 <0.001 
Two or more falls <0.001 0.001 <0.001 
Reported hip fracture 0.709 0.498 <0.001 
Separate logistic regression models were constructed for each impact variable and each 
potential confounder and included terms 
for age (75-79,80-84,85-89 and 90+) and sex. 
The values in this table are p-values derived 
from the adjusted Wald test. 
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Table F. 2 Association between variables indicating perceived health and potential 
confounding factors, controlling age and sex 
Self-reported Self-reported 
"fair/poor" health "not at all" 
physically 
active 
Housing tenure <0.001 <0.001 
Smoking <0.001 <0.001 
Alcohol consumption <0.001 0.009 
Body mass index <0.001 0.074 
Hearing impairment <0.001 0.139 
Reported stroke <0.001 <0.001 
Diabetes <0.001 <0.001 
Urinary incontinence <0.001 <0.001 
Lower legs swollen in morning <0.001 <0.001 
Severe shortness of breath <0.001 <0.001 
Three or more prescribed medicines <0.001 <0.001 
Depression <0.001 <0.001 
Cognitive impairment 0.004 <0.001 
Two or more falls <0.001 <0.001 
Reported hip fracture <0.001 <0.001 
Separate logistic regression models were constructed for each impact variable and each 
potential confounder and included terms for age (75-79,80-84,85-89 and 90+) and sex. 
The values in this table are p-values derived from the adjusted Wald test. 
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Table F. 3 Association between being in the worst quintile for Sickness Impact 
Profile variables and Philadelphia Geriatric Morale Scale and potential 
confounding factors, controlling age and sex 
Home Mobility Body care Social PGMS 
management and interaction 
movement 
Housing tenure <0.001 <0.001 <0.001 0.062 0.017 
Smoking 0.005 0.025 0.004 0.015 0.003 
Alcohol 0.004 0.005 0.003 0.010 0.932 
consumption 
Body mass index 0.029 0.080 0.210 0.023 0.952 
Hearing 0.367 0.077 0.334 0.002 0.008 
impairment 
Reported stroke <0.001 <0.001 <0.001 0.001 0.017 
Diabetes 0.001 0.023 0.020 0.114 0.182 
Urinary <0.001 <0.001 <0.001 0.001 <0.001 
incontinence 
Lower legs <0.001 <0.001 <0.001 <0.001 0.005 
swollen in 
morning 
Severe shortness <0.001 <0.001 <0.001 0.001 <0.001 
of breath 
3 or more <0.001 <0.001 <0.001 <0.001 <0.001 
prescribed 
medicines 
Depression <0.001 <0.001 <0.001 <0.001 N/A 
Cognitive 0.034 0.001 0.102 0.016 0.580 
impairment 
Falls 0.006 <0.001 <0.001 <0.001 0.001 
Hip fractures 0.036 0.003 0.005 0.483 0.925 
11 11 Separate logistic regression models were constructed for each impact variab le and each 
potential confounder and included terms 
for age (75-79,80-84,8 5+) and sex . The values 
in this table are p-val ues derived from the adjuste d Wald test. 
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Table F. 4 Association between cognitive impairment and depression and potential 
confounding factors, controlling age and sex 
Cognitive impairment Depression (GDS six 
(MMSE less than 12) or more) 
Housing tenure <0.001 <0.001 
Smoking 0.001 <0.001 
Alcohol consumption <0.001 0.052 
Body mass index <0.001 0.005 
Hearing impairment <0.001 <0.001 
Reported stroke <0.001 <0.001 
Diabetes 0.681 0.003 
Urinary incontinence <0.001 <0.001 
Lower legs swollen in morning 0.560 <0.001 
Severe shortness of breath 0.184 <0.001 
Three or more prescribed medicines 0.927 <0.001 
Two or more falls 0.044 <0.001 
Reported hip fracture 0.498 0.043 
Separate logistic regression models were constructed for each impact variable and each 
potential confounder and included terms for age (75-79,80-84,85-89 and 90+) and sex. 
The values in this table are p-values derived from the adjusted Wal d test. 
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Table F. 5 Association between falls and hip fractures and potential confounding 
factors, controlling age and sex 
Two or more falls at home in last Reported hip fracture 
six months 
Housing tenure <0.001 0.124 
Smoking 0.577 0.029 
Alcohol consumption <0.001 0.822 
Body mass index 0.037 0.003 
Hearing impairment <0.001 0.037 
Reported stroke <0.001 0.203 
Diabetes <0.001 0.586 
Urinary incontinence <0.001 0.193 
Lower legs swollen in <0.001 0.005 
morning 
Severe shortness of breath <0.001 0.124 
3 or more prescribed <0.001 0.002 
medicines 
Depression <0.001 0.039 
Cognitive impairment 0.045 0.477 
Separate logistic regression models were constructed for each impact variable and each 
potential confounder and included t erms for age (75-79,80-84,85-89 and 90+) and sex. 
The values in this table are p-values derived from the adjusted Wald test. 
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Table F. 6 Association between mortality and potential confounding factors, 
controlling age and sex 
Mortality rate 
Housing tenure <0.001 
Smoking <0.001 
Alcohol consumption <0.001 
Body mass index <0.001 
Hearing impairment <0.001 
Reported stroke <0.001 
Diabetes <0.001 
Urinary incontinence <0.001 
Lower legs swollen in morning <0.001 
Severe shortness of breath <0.001 
3 or more prescribed medicines <0.001 
Depression <0.001 
Cognitive impairment <0.001 
Falls <0.001 
Hip fractures <0.001 
These figures are derived from a series of Cox regression models. Each model included 
terms for age (75-79,80-84,85-89,90+) and sex and each potential confounder. The 
values in this table are p-values derived from the model. 
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